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ABSTRACT
Repka, Christopher P. Oxidative Stress Alterations Following an Exercise Intervention
in Cancer Survivors. Published Doctor of Philosophy dissertation, University of
Northern Colorado, 2014.
Exercise interventions in cancer patients have been demonstrated to reduce
cancer-treatment related side effects. Despite this, the underlying mechanisms associated
with the protective aspects of exercise are generally uncharacterized, but treatmentassociated oxidative stress is thought to play a role. The purpose of this study was to
determine the effect of an exercise intervention on fatigue, cardiorespiratory fitness
(CRF), muscular strength, and blood markers of DNA and protein oxidation compared to
a non-exercising, cancer control group. METHODOLOGY: An initial fasting blood
draw and assessments of muscular strength and CRF were administered to fifteen cancer
patients within six weeks of completing radiation or chemotherapy treatment. Eight
cancer patients participated in a 10-week exercise intervention (EX) while seven
continued standard care (CON). Following the intervention, subjects completed another
fasted blood draw and a reassessment of fatigue, strength and CRF. Changes in plasma
protein carbonyls, 8-OHdG, and antioxidant status were compared between the exercise
and control groups. Baseline markers of oxidative stress were compared between healthy
individuals (NC) and cancer patients. A correlation analysis of changes in fitness
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parameters and oxidative stress in cancer patients was conducted. RESULTS: Baseline
total antioxidant capacity was significantly lower, and plasma protein carbonyls
significantly higher in cancer patients compared to NC (p < 0.05). Mean total fatigue
scores decreased significantly from 5.0 ± 2.2 to 2.6 ± 1.5 (p < 0.05) in EX, whereas
changes in CON (4.7 ± 2.5 to 3.2 ± 2.4) were not significant. All fatigue subscales
significantly decreased in EX, while only cognitive fatigue increased significantly in
CON (p < 0.05). Antioxidant capacity increased and protein carbonyls decreased in EX
(p < 0.01) but not CON. Improvements in composite arm (41%) and leg strength (34%),
isometric handgrip strength (11%), and VO2peak (16%) all significantly improved in the
EX group (p < 0.05), while none of these parameters significantly changed in CON. No
significant changes over time were found in 8-OHdG, but a group by time interaction
effect was detected (p < 0.05). Baseline antioxidant capacity significantly correlated (p <
0.05) with total, affective, sensory, and cognitive fatigue. Increases in antioxidant
capacity were correlated (p < 0.05) with reductions in affective, sensory, and cognitive
fatigue. Although 8-OHdG was not correlated with any fatigue parameter at baseline,
changes in total and affective fatigue exhibited significant correlations with changes in 8OHdG over time. CONCLUSIONS: A whole-body exercise intervention is an
effective method of increasing muscular strength, CRF and antioxidant capacity, while
reducing markers of protein oxidation. An exercise intervention was an effective method
of reducing fatigue in cancer patients following cessation of treatment, whereas standard
care resulted in non-significant reductions in fatigue. Oxidative stress may be implicated
in cancer-related fatigue, while improved antioxidant capacity following an exercise
intervention may play a role in mitigating fatigue.

iv

ACKNOWLEDGEMENTS
The completion of this dissertation would not have been possible without the
support, guidance, and assistance of several individuals. I am deeply saddened that my
late doctoral mentor, Dr. Carole Schneider was not able to see the completion of this
project. I would like to thank Dr. Reid Hayward for stepping into the role of advisor, and
my entire committee, Drs. David Hydock, Trent Lalonde, and Alana Cline, for
contributing to the completion of this project. The entire RMCRI crew, including Jessica
Brown, Dan Shackleford, Brent Peterson, and Elaine Rydberg, were instrumental in
easing my transition back to the cancer center, both in terms of logistics and friendship.
Thanks go to Colin Quinn for helping with difficult blood draws, and Dr. Patrick Burns
for assistance with blood assays. Kyle Riley was a huge help to me during assessment
and training, allowing me enough hours in the day to complete my work. Mark Puhr’s
exceptional hospitality allowed me to have a home away from home while living in
Greeley, which was vital to my well-being. I would like to acknowledge Marlon Bazon
at PVH and Theresa Henley at NCMC for identifying many of my subjects. Most
significantly, the final push to finish this dissertation would not have been logistically or
financially possible without the support of my parents, Charles and Karen Repka, and my
wonderful wife, Amanda. Thank you for believing in me and pushing me when I needed
it.
v

TABLE OF CONTENTS
CHAPTER

I.

INTRODUCTION ................................................................................................... 1
Statement of Purpose .............................................................................................. 9
Research Hypotheses ............................................................................................ 10
Significance of Study ............................................................................................ 10
Assumptions.......................................................................................................... 11
Limitations ............................................................................................................ 12
Definitions of Terms ............................................................................................. 12

II.

REVIEW OF LITERATURE................................................................................ 14
Introduction ........................................................................................................... 14
Overview of Cancer .............................................................................................. 15
Cancer Treatment .................................................................................................. 23
Reactive Oxygen Species and Oxidative Stress.................................................... 30
Cancer and Oxidative Stress ................................................................................. 52
Cancer Treatment Side Effects ............................................................................. 57
Cancer Treatment-Related Side Effects and Oxidative Stress .............................. 64
Exercise Before, During, and Following Cancer Treatment................................. 69
Counteracting Cancer Treatment-Associated Oxidative Stress With Exercise .... 74
Summary ............................................................................................................... 78

III.

METHODOLOGY ................................................................................................ 80
Experimental Design ............................................................................................. 81
Subjects ................................................................................................................. 82
Data Collection Procedures................................................................................... 84
Exercise Intervention ............................................................................................ 92
Evaluation of Oxidative Stress.............................................................................. 94
Biochemical Assays .............................................................................................. 95
Statistical Analysis ................................................................................................ 97

vi

IV.

CANCER RELATED FATIGUE AND MARKERS OF OXIDATIVE
STRESS IN CANCER PATIENTS FOLLOWING AN EXERCISE
INTERVENTION ................................................................................................ 99
Abstract ................................................................................................................. 99
Introduction ......................................................................................................... 100
Methodology ....................................................................................................... 105
Results ................................................................................................................. 112
Conclusions ......................................................................................................... 120

V.

OXIDATIVE STRESS, MUSCULAR STRENGTH, AND
CARDIORESPIRATORY ALTERATIONS FOLLOWING AN
EXERCISE INTERVENTION IN CANCER SURVIVORS ............................. 126
Abstract ............................................................................................................... 126
Introduction ......................................................................................................... 127
Methodology ....................................................................................................... 132
Results ................................................................................................................. 141
Conclusions ......................................................................................................... 150

REFERENCES ............................................................................................................... 155
APPENDIX A - PIPER FATIGUE INDEX .................................................................. 189
APPENDIX B - INFORMED CONSENT .................................................................... 193
APPENDIX C - INSTITUTIONAL REVIEW BOARD APPROVAL......................... 196
APPENDIX D - SUBJECT UPDATE QUESTIONS .................................................... 198
APPENDIX E - EXIT SURVEY FOR CONTROL SUBJECTS ................................. 200
APPENDIX F - STANDARD CURVES FOR BIOCHEMICAL ANALYSES .......... 202

vii

LIST OF TABLES
TABLE
1

General Staging of the TNM System .................................................................... 23

2

ROS Dose and Potential Health Effects................................................................ 41

3

Chemotherapy drugs known to induce significant oxidative stress ...................... 65

4

Enzyme activity following 9 weeks of exercise training ...................................... 77

5

RMCRI Treadmill Protocol .................................................................................. 86

6

Borg Scale: Rating of Perceived Exertion ............................................................ 87

7

Suggested initial resistance (% of Body Weight) ................................................. 89

8

Recommended Exercise Intensity ......................................................................... 93

9

Subject Characteristics ........................................................................................ 113

10

Baseline Fatigue Scores ...................................................................................... 114

11

Changes in Fatigue Scores .................................................................................. 114

12

Baseline Oxidative Stress Parameters ................................................................. 117

13

Changes in Oxidative Stress Parameters............................................................. 118

14

Correlations Between Oxidative Stress and Fatigue Parameters at Baseline ..... 120

15

Correlations Between Changes in Oxidative Stress and Fatigue Parameters ..... 120

16

RMCRI Treadmill Protocol ................................................................................ 136

viii

17

Suggested initial resistance (% of Body Weight) ............................................... 137

18

Subject Characteristics ........................................................................................ 142

19

Baseline Oxidative Stress Parameters in Cancer and Non-Cancer Groups ........ 142

20

Changes in Oxidative Stress Parameters in Exercise and Control groups .......... 144

21

Muscular Strength and Cardiorespiratory Fitness Changes ................................ 145

22

Changes in Individual Muscular Strength Parameters ........................................ 146

23

Correlations Between Oxidative Stress and Fitness Parameters at Baseline ...... 149

24

Correlations Between Changes in Oxidative Stress and Fitness Parameters ...... 149

ix

LIST OF FIGURES
FIGURE
1

The Cell Cylce ...................................................................................................... 17

2

Initiation and Promotion ....................................................................................... 20

3

The Level of Free Radicals at Various Stages of Carcinogenic Process .............. 56

4

Doxorubicin-Induced Generation of ROS/RNS in the Heart ............................... 61

5

Experimental Design ............................................................................................. 82

6

Flow of Cancer Patients through the Study ........................................................ 107

7

Total Fatigue Scores for All Groups and Time Points ........................................ 115

8

Behavioral Fatigue Scores for All Groups and Time Points............................... 115

9

Affective Fatigue Scores for All Groups and Time Points ................................. 116

10

Sensory Fatigue Scores for All Groups and Time Points ................................... 116

11

Cognitive Fatigue Scores for All Groups and Time Points ................................ 117

12

Trolox Equivalent Antioxidant Capacity for All Groups and Time Points ........ 118

13

8-OHdG Plasma Concentration for All Groups and Time Points....................... 119

14

Flow of Cancer Patients through the Study ........................................................ 134

15

Plasma Protein Carbonyl Concentration for All Groups and Time Points ......... 143

16

Trolox Equivalent Antioxidant Capacity for All Groups and Time Points ........ 143

x

17

Handgrip Strength for All Groups and Time Points ........................................... 146

18

Composite Arm Strength for All Groups and Time Points................................. 147

19

Composite Leg Strength for All Groups and Time Points .................................. 147

20

VO2peak Values for All Groups and Time Points .............................................. 148

21

Time to Exhaustion During Treadmill Test for All Groups and Time Points .... 148

xi

1

CHAPTER I
INTRODUCTION
Cancer is a group of diseases characterized by uncontrolled growth and regulation
of cells. The etiology of cancer is associated with both environmental (chemicals,
radiation, smoking, diet, and infectious organisms) and inherent factors (inherited genetic
mutations, hormones, and immune conditions). The development of cancer depends on
an interaction between these factors, and requires the circumvention of various cellular
checkpoints. When a cell receives a “hit,” a carcinogen alters a cell’s DNA, affecting its
function and growth.

Normally, the cellular reproductive processes are halted or

terminated at the checkpoints to prevent cancer development or progression, but in the
presence of a promoter, the genetically altered cell may proliferate and metastasize,
resulting in cancer.
Although nearly 600,000 people are expected to die of cancer in the US this year,
overall cancer mortality has drastically decreased in the previous several decades, due to
improved detection and treatment methods (American Cancer Society, 2014). The
National Cancer Institute estimates that 13.7 million Americans with a history of cancer
were alive in 2012 and about 1,665,540 new cancer cases are expected to be diagnosed in
2014. In 2010, there were 171.76 cancer related deaths per 100,000 compared to a
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214.95 per 100,000 rate in 1990, illustrating improved efficacy of cancer treatment
methods (Howlader, 2012). Although this is an encouraging trend, the adverse side
effects of surgery, radiation, chemotherapy, and other treatment modalities are associated
with severe physiological side effects that may last for years. Typical side effects include
muscle weakness, reduced cardiorespiratory fitness, peripheral neuropathy,
immunosuppression, and general fatigue, resulting in an overall decrease in quality of
life. While these conditions are multicausal and multifactorial, oxidative stress is thought
to play a pivotal role in many pathological processes associated with cancer and its
treatments (Fang, Seki, & Maeda, 2009; Robbins & Zhao, 2004; Zhao & Robbins, 2009).
Oxidative stress is a state in which reactive oxygen species (ROS) are produced at
a rate that exceeds cellular adaptive and repair capacities, namely enzymatic and nonenzymatic antioxidants. Also known as free radicals, ROS can cause damage to tissues
by stealing electrons from nearby molecules, creating new free radicals and propagating a
chain reaction. This process causes damage to lipid membranes within any cell, in a
process called lipid peroxidation. ROS can also damage other cellular components,
including proteins and nucleic acids, resulting in skeletal and cardiac muscle dysfunction,
and potentially DNA modification, respectively. The development and progression of
many cancers are associated with oxidative stress-induced DNA modification, but cancer
cells themselves can produce increased levels of ROS, perpetuating dysfunction and
cancer growth (Valko, Rhodes, Moncol, Izakovic, & Mazur, 2006; Yeh et al., 2006),
Interestingly, many modes of cancer treatment depend on extremely high doses of ROS
as a mechanism of cancer killing, including radiation, many chemotherapy regimens, and
novel strategies such as pro-oxidant therapy and photodynamic therapy. Unfortunately,
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oxidative stress typically affects healthy tissue in addition to malignant tissue, resulting in
both acute and chronic side effects.
The most commonly produced ROS are superoxide and hydroxyl radicals. Most
free radical production in healthy individuals occurs in the mitochondria, due to a
“leakage” of electrons from 1-2% of the oxygen in the electron transport chain (Boveris
& Chance, 1973). This can form a superoxide radical (O2•-), as the unstable intermediate
semiquinone anion can directly transfer electrons to molecular oxygen instead of
reducing to ubiquinone (Turrens, 1997). Although once considered merely a byproduct
of oxidative phosphorylation, several alternate sources of ROS production have since
been identified.

Among these, the inducible enzymatic production of various ROS

indicates that they play important roles in cellular function. NAD(P)H oxidase catalyzes
the production of superoxide in phagocytes, which use free radicals to destroy pathogens,
in what is known as a respiratory burst. Another enzyme, xanthine reductase, is
expressed in two forms: xanthine reductase, which creates the antioxidant uric acid, and
xanthine oxidase, a pro-oxidant enzyme (Vorbach, Harrison, & Capecchi, 2003). These
enzymes are tightly regulated to ensure an appropriate cellular level of ROS, and to
maintain redox balance, illustrating the importance of ROS creation in healthy
individuals.
While oxidative stress can be damaging to every cell and system within the body,
ROS are necessary for proper cellular functioning. Nitric oxide (NO) is a free radical,
but has long been recognized as an important mediator of vasodilation. In recent years,
other ROS, including superoxide (Buetler, Krauskopf, & Ruegg, 2004), have been
recognized as important cellular signaling molecules. Reactive oxygen species have been
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shown to play signaling roles in muscular contraction, adaptive responses to stress,
including heat shock proteins and cytokines, and activation of the MAP-K pathway and
p53 tumor suppressor protein (Emerling et al., 2005; Jackson, 2009a; Liu, Chen, & St
Clair, 2008; Valko et al., 2007; Zhang & Gutterman, 2007). Additionally, ROS are
thought to be involved in the chronic adaptive response to exercise (Powers, Duarte,
Kavazis, & Talbert, 2009).
Because ROS production is a normal physiological process, an antioxidant
defense system is in place to counteract normally produced free radicals. Antioxidants
are molecules that inhibit free radical reactions, typically acting as a reducing agent by
donating an electron and ceasing the oxidative chain reaction. Enzymatic antioxidants
include superoxide dismutases, catalases, and glutathione peroxidases, and common
endogenous non-enzymatic antioxidants include glutathione, albumin, ferritin, uric acid,
bilirubin and pyruvate. Common dietary non-enzymatic antioxidants include vitamin C
and vitamin E. Any disruption in antioxidant capacity of healthy cells can alter redox
balance and health status. Cancer cells typically have reduced antioxidant enzyme
activity, but in certain types of cancers and metastatic growth, antioxidant enzyme
activity is augmented, conveying multidrug resistance to these cells (Oberley, 2002).
Due to the extremely transient nature of ROS, it is difficult to perform chemical
analyses of ROS themselves. Rather, downstream products of oxidative stress in blood
and tissues may be analyzed via biochemical analysis. Malondialdehyde (MDA), a stable
end product of lipid peroxidation, is likely the most common marker of oxidative stress.
Other markers of lipid peroxidation include 4-hydroxynonenal (4-HNE) and F2
isoprostanes such as 8-iso-prostaglandin F2α (8-isoprostane). 8-Hydroxy-
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2’deoxyguanosine (8-OHdG), a fairly ubiquitous byproduct of oxidative DNA damage, is
the primary biomarker for DNA oxidation. Carbonyl derivatives of proline, lysine,
arginine and threonine are the most common oxidation product of protein. Additionally,
the ratio of reduced glutathione to oxidized glutathione (GSH:GSSG) is a commonly used
determinant of oxidative stress (Serru et al., 2001).
In addition to generalized damage to body tissues, and the association between
chronic oxidative stress and cancer, numerous chronic pathophysiological conditions may
be linked to oxidative stress, including diabetes, hypertension, vascular disease, cachexia,
neural dysfunction, chronic heart failure, and ischemia-reperfusion injury. Cancer
chemotherapy and radiation therapy are known to elicit many of these pathologies as side
effects, most notably cardiac dysfunction. Oxidative stress has been hypothesized to
initiate or aggravate these medical conditions (Y. Chen, Jungsuwadee, Vore, Butterfield,
& St Clair, 2007; Robbins & Zhao, 2004; J. Wang & Yi, 2008).
Some of the most effective cancer treatments also are the most damaging to
normal tissue. Doxorubicin, for instance, is a highly effective antineoplastic agent used
for various cancers, yet causes a dose-dependent cardiotoxicity associated with oxidative
stress (Chaiswing et al., 2004; Kanter, Hamlin, Unverferth, Davis, & Merola, 1985).
While the primary antineoplastic mechanisms of DOX are inhibition of topoisomerase II
and intercalation in DNA (Chen, Jungsuwadee, Butterfield, & St Clair, 2007), resulting in
inhibition of DNA replication and RNA transcription, the induction of ROS may
contribute to antitumor activity (Taatjes, Fenick, Gaudiano, & Koch, 1998). Doxorubicin
cardiotoxicity causes morphological damage within the myocardium, often apparent
when left ventricular ejection fraction (LVEF) falls below 45%, and may result in
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congestive heart failure (Ng, Better, & Green, 2006). Several authors have identified
oxidative stress as a primary mechanism of DOX cardiotoxicity (Y. Chen et al., 2007;
Simunek et al., 2009). Other common chemotherapy drugs, including tamoxifen,
etoposide, 5-fluorouracil, alkylating agents and platinum coordinating complexes are
known to induce significant oxidative stress. Radiation, by nature, is characterized by
ROS production and exerts its physiological effects, both beneficial and harmful, via this
mechanism. Even surgery is capable of producing enough ROS as a side effect to
facilitate increased growth of metastatic tumors (Hyoudou, Nishikawa, Kobayashi,
Umeyama, et al., 2006).
The challenge for oncologists and the entire cancer care team is to maximize
effectiveness of treatment while minimizing side effects. Reduction of oxidative stress in
healthy tissues is a method which may reduce or eliminate many of the cancer treatmentassociated side effects. Antioxidant therapy, while an attractive strategy, is currently not
advocated by the American Cancer Society (D'Andrea, 2005) due to the potential for
reduced treatment efficacy and relatively poor reduction of side effects with dietary
antioxidant supplementation (Lawenda et al., 2008; Myers et al., 1983; Unverferth et al.,
1983). Additionally, endogenous antioxidant enzymes are coordinately regulated, so that
glutathione peroxidases and catalases are upregulated in concert with SOD to match the
current level of ROS production (McCord, 2008). Exogenous administration of any one
of these alone could result in aberrant redox regulation.
An increasingly popular rehabilitation method in cancer patients is prescriptive,
whole-body exercise. Exercise has been shown to minimize many side effects of cancer
treatment. Exercise during treatment is known to increase tolerance for high doses of
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chemotherapy (Chicco, Schneider, & Hayward, 2006) and can reduce the damaging side
effect of hormonal therapy (Hydock, Lien, Schneider, & Hayward, 2007). Furthermore,
exercise following treatment may reduce the chance for cancer recurrence (Courneya,
2003). Exercise following surgery has been shown to be beneficial in increasing the
natural killer (NK) cell cytotoxic activity (NKCA), (Na, Kim, Kim, Ha, & Sup Yoon,
2000) suggesting that exercise may play a role in cancer treatment, rather than simply
rehabilitation.
Resistance and aerobic exercise during and following treatment have been found
to be beneficial as a means to reduce self reported fatigue (Mock et al., 2001; Schneider,
Hsieh, Sprod, Carter, & Hayward, 2007c; Schwartz, 2007), which is the most prevalent
symptom in cancer survivors. Prescriptive exercise programs have successfully
improved muscular strength (Courneya et al., 2007) and muscular endurance (Schneider,
Hsieh, Sprod, Carter, & Hayward, 2007a) in cancer survivors. A similar effect on
cardiorespiratory endurance has been noted in cancer survivors (Schneider et al., 2007c).
Improvements in functional capacity in cancer patients are associated with increased selfreported quality of life (L. W. Jones et al., 2008; Schneider et al., 2007a; Thorsen et al.,
2005).
While acute, high intensity exercise bouts generate ROS, it is well documented
that exercise training increases antioxidant enzyme capacity in animals and healthy
individuals (Finaud, Lac, & Filaire, 2006; Ji, 2002). The concept of hormesis describes
the positive adaptation to a mild stressor, whereas a larger dosage of the same stressor
would be damaging or fatal. The response to ROS is exemplary of hormesis; lower doses
of ROS, such as during an acute exercise bout, trigger an adaptive response in which the
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antioxidant enzymes are upregulated. High doses, like those caused by radiation and
chemotherapy, can cause severe side effects. Although a single bout of exercise can
transiently activate mitochondrial (manganese) superoxide dismutase (MnSOD) gene
transcription, substantial MnSOD upregulation may require more chronic stimulation,
such as a prescriptive exercise intervention (Hollander et al., 1999). The effectiveness of
exercise may be due, in part, to the reduction of oxidative stress in normal cells, and
therefore protection of healthy tissues without a protective effect within cancer cells. It
appears that the antioxidant enzyme upregulation in response to exercise is
compartmentalized, as unilateral resistance training stimulated an enzymatic response
only in the trained leg (Parise, Phillips, Kaczor, & Tarnopolsky, 2005). This suggests that
healthy, exercising tissue can be protected, without increased antioxidant defense within
cancer cells.
While oxidative stress is recognized as a contributing factor in cancer and
treatment-related decrements in health, there is little research addressing the effect of
exercise on both functional parameters and markers of oxidative stress or antioxidant
enzymes. A notable study from 1985 investigating the effect of exercise on
cardiotoxicity and antioxidant enzymes in rats remains one of the most sophisticated
studies supporting exercise as a strategy to reduce treatment-induce oxidative stress and
subsequent side effects (Kanter et al., 1985). Swim training significantly reduced
cardiotoxicity of doxorubicin and increased blood values for three antioxidant enzymes
(glutathione peroxidase, superoxide dismutase, catalase), indicating a protective effect of
exercise via improved antioxidant defense. To date, no similar study has been conducted
in a human population of cancer survivors. It is therefore reasonable to examine the
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effect of a prescriptive exercise intervention on oxidative stress markers in cancer
survivors following treatment known to induce severe oxidative stress.
Statement of Purpose
The primary purpose of this study is to determine the effects of a 10-week
prescribed aerobic and resistance exercise intervention on plasma markers of oxidative
stress and antioxidant enzyme capacity in cancer survivors versus a non-exercising,
cancer control group. Markers of oxidative stress to be measured are 8-OHdG, and
reactive carbonyl derivatives. Trolox-equivalent antioxidant capacity (TEAC) will be
measured as a universal marker of antioxidant capacity in the blood. Additionally,
selected physiological variables, including peak VO2, muscular strength, and fatigue will
be compared between groups. The relationship between oxidative stress and baseline
physiological variables will be determined. Similarly, the relationship between the
change in oxidative stress and changes in physiological variables will be determined.
Baseline oxidative stress and antioxidant enzyme capacity in cancer patients will be
compared to a group of healthy individuals.
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Research Hypotheses
H1

There will be a significant decrease in blood markers of oxidative stress in
exercising subjects compared to standard care following the 10-week
intervention.

H2

There will be a significant improvement in total antioxidant capacity in
exercising subjects compared to standard care following the 10-week
intervention.

H3

There will be a significant improvement in cardiopulmonary function in
exercising subjects compared to standard care following the 10-week
intervention.

H4

There will be a significant improvement in muscular strength in exercising
subjects compared to standard care following the 10-week intervention.

H5

There will be a significant improvement in self-reported fatigue in
exercising subjects compared to standard care following the 10-week
intervention.

H6

There will be significantly greater baseline levels of oxidative stress
markers in cancer survivors than in healthy, age and gender-matched
controls.

H7

At baseline, oxidative stress will exhibit a negative correlation with
cardiopulmonary function and muscular strength, and a positive
correlation with fatigue. In contrast, antioxidant capacity will exhibit a
positive correlation with cardiopulmonary function and strength, and a
negative correlation with fatigue

H8

Changes in oxidative stress will exhibit a negative correlation with
changes in cardiopulmonary function and muscular strength, and a
positive correlation with fatigue. Changes in antioxidant capacity will
exhibit a positive correlation with changes in cardiopulmonary function
and strength, and a negative correlation with fatigue.
Significance of the Study

All cancer treatments inevitably have side effects, and beyond altering quality of
life, they often limit the aggressiveness of treatment. Radiation, chemotherapy, and even
surgery result in production of (ROS) and ultimately oxidative stress. Cancer cells
themselves are capable of producing pathological levels of ROS. Cancer patients suffer
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from fatigue, cachexia, decrements in cardiorespiratory fitness, and neurological
disorders, all which may be associated with increased oxidative stress. Additionally,
increased oxidative stress from radiation treatment is associated with the development of
second cancers (Bostrom & Soloway, 2007). Unfortunately, there has been little success
in antioxidant supplementation as a means to reduce treatment-associated side effects
without affecting treatment efficacy (Lawenda et al., 2008). Prescriptive exercise, on the
other hand, has been shown to increase muscular endurance and strength and
cardiorespiratory fitness, while reducing fatigue. Additionally, in animal models,
exercise has been shown to reduce treatment-associated side effects, increase antioxidant
enzyme activity, and decrease markers of oxidative stress (Ascensao et al., 2005a;
Wonders & Reigle, 2009). While exercise training has been shown to increase
antioxidant capacity in healthy individuals and some pathological conditions, such as
Parkinson’s disease (Bloomer et al., 2008; Finaud et al., 2006) and diabetes (Ristow et
al., 2009), to date, no study has examined the effect of a prescriptive exercise intervention
on markers of oxidative stress and antioxidant capacity in cancer survivors. Additionally,
there is little data on the degree of chronic oxidative stress in cancer survivors post
treatment.
Assumptions
This study is based upon the assumption that all subjects accurately report their
previous exercise, smoking, and antioxidant supplementation habits. It is assumed that
blood draws were taken while the subjects were fasted, and had not engaged in strenuous
activity for the previous 72 hours. Subjects in the standard care group are assumed to
have maintained baseline physical activity.
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Limitations
All subjects were recruited in Greeley, Colorado and surrounding towns, and
therefore the results may not be generalizable to the entire US population. Due to the
self-selected nature of participation in this study, it is possible that psychological factors
beyond the scope of this study independently affected fatigue values at baseline or fatigue
changes over time. Diets were not controlled and food logs were not utilized to evaluate
subjects’ consumption of antioxidant-containing foods, therefore it is possible that whole
foods containing variable antioxidant compositions affected plasma antioxidant capacity
or oxidative stress at either baseline or follow-up. Because there were a variety of cancer
types and treatments among the subjects in this study, it is possible that undetected
prolonged physiological effects of treatment and cancer type may play a role in patient
response to time out of treatment in the control group, or response to exercise in the
intervention group. Finally, although exercise interventions were similar,
individualization of exercise regimens for each cancer patient based upon specific needs
may have affected the biochemical and fatigue responses to exercise and could
potentially limit the generalizability of this study.
Definition of Terms
Antioxidant. A molecule that inhibits free radical reactions, typically by acting as a
reducing agent by donating an electron and ceasing the oxidative chain reaction.
Enzymatic antioxidants include superoxide dismutases, catalases, and glutathione.
peroxidases. Non-enzymatic antioxidants include glutathione, ascorbic acid (vitamin C),
α-tocopherol (vitamin E), flavonoids, and carotenoids (Baskin & Salem, 1997).
Cachexia. A syndrome of progressive weight loss, anorexia, and persistent erosion of
host body cell mass, often in response to a malignant growth (Laviano, Meguid, Preziosa,
& Rossi Fanelli, 2007).
Cancer. Cancer is a group of diseases characterized by abnormal, uncontrolled growth
and regulation of cells that will lead to tissue failure (American Cancer Society, 2014).
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Cancer Related Fatigue. An overwhelming, whole-body tiredness, unrelated to activity
or exertion, that makes a person feel drained and produces a strong desire to lie down and
sleep (Schneider, Dennehy, & Carter, 2003).
Carcinogen. A chemical, biological, or physical agent capable of permanently, directly,
and irreversibly changing the molecular structure of a cell. With prolonged or continuous
exposure, this predisposes the cell to transformation, and ultimately cancer development
(Langhorne, Fulton, & Otto, 2007).
Chemotherapy. Treatment with at least one drug (Langhorne et al., 2007) employed as
the primary means of anti-cancer therapy, to limit the spread of localized tumors,
particularly in late stage cancers, or as adjuvant therapy to shrink tumors prior to
radiation or surgery and destroy microscopic metastases following tumor removal (Chu
& DeVita 2005).
Lipid Peroxidation. Oxidative degradation of lipids whereby free radicals "steal"
electrons from the lipids in cell membranes, resulting in cellular damage (Baskin &
Salem, 1997).
Hormesis. A beneficial physiological response or adaptation to a mildly damaging
stimulus (Ji, Maria-Carmen, & Jose, 2006).
Oxidative Phosphorylation. The coupling of the phosphorylation of ATP to oxidation, in
the electron transport chain of the mitochondrial membrane (Brooks, Fahey, & Baldwin,
2005).
Oxidative stress. A state in which the production of ROS exceeds the capacity of the
enzymatic and non-enzymatic antioxidant system, resulting in a disturbance in redox
balance and cellular damage (Valko et al., 2007).
Radiation Therapy. The use of high energy irradiation to destroy malignant cancer cells.
There are two general types of radiation: brachytherapy (internal) and teletherapy
(external). Cancer cells are destroyed both by the radiation directly and the free radicals
it produces (Hellman, 2005).
Reactive Oxygen and Nitrogen Species (ROS). Extremely unstable molecules containing
an unpaired valence electron, also known as free radicals, which can cause damage to
tissues by stealing electrons from nearby molecules (Halliwell & Gutteridge, 2007). ROS
also act as important signaling molecules (Valko et al., 2007).
Superoxide. The most commonly produced free radical. It is an oxygen with an
additional electron (Halliwell & Gutteridge, 2007). Most free radical production in
healthy individuals occurs in the mitochondria, due to a “leakage” of electrons from 1-2%
of the oxygen in oxidative phosphorylation (Boveris & Chance, 1973), which can form a
superoxide radical (O2•-).
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CHAPTER II
REVIEW OF LITERATURE
Introduction
The primary purpose of this study was to determine the effects of a 10-week
prescribed aerobic and resistance exercise intervention on plasma markers of oxidative
stress and antioxidant enzyme capacity in cancer survivors versus a non-exercising,
cancer control group. Markers of oxidative stress measured were 8-OHdG and reactive
carbonyl derivatives. Trolox-equivalent antioxidant capacity was measured as a
universal marker of antioxidant capacity in the blood. Additionally, selected
physiological variables, including VO2 peak, muscular strength, and fatigue were
compared between groups. The relationship between oxidative stress and baseline
physiological variables was determined. Similarly, the relationship between the change
in oxidative stress and changes in physiological variables was determined. Baseline
oxidative stress and antioxidant enzyme capacity in cancer patients was compared to a
group of healthy individuals. The following literature review will include carcinogenesis,
cancer treatments and their side effects, the effect that exercise has on cancer patients
recovering from cancer treatment, and the role that oxidative stress plays in all of these
processes.
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Overview of Cancer
Cancer Incidence
Cancer is characterized by abnormal cell growth, resulting from a failure in the
normal growth and repair processes in the cell. As of January 2012, 13.7 million cancer
survivors were living in America, and more than 1.6 million new cases of cancer are
expected to have been diagnosed in 2013, making cancer the second leading cause of
death in the United States, next to cardiovascular disease (American Cancer Society,
2014). Fortunately, advancements in cancer detection and treatment methods have
markedly improved the survival rate for most cancer types. A consequence of reduced
mortality is an increase in the number of people living with the damaging side effects of
cancer treatments, including surgery, radiation, and chemotherapy.
Normal Cell Growth and Division
The normal cell cycle involves two distinct phases, called interphase and mitosis
(M phase) (Voet, Voet, & Pratt, 2008). During interphase, no cell division occurs, but
normal growth and metabolism take place, whereas cell division occurs during mitosis.
Interphase, which comprises the majority of the cell cycle, is divided into three events:
synthesis (S phase), and two gap phases (G1 and G2). Additionally, during the G0 phase,
or postmitotic stage, the cell is quiescent, meaning that the cell is not actively dividing or
preparing to divide. Depending on the type of cell and the current needs of the organism,
the length of the G0 phase varies, and may be permanent in cells that do not divide,
including mature cardiac muscle and nerve cells.
Cells proceed through the cell cycle in response to numerous external stimuli,
including growth factors and cellular space (Burke, 1996). Cell growth is also regulated
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by a series of checkpoints that will arrest the cell cycle if certain conditions are not met
(Voet et al., 2008). One checkpoint halts progression into mitosis until all cellular DNA
has been replicated. Other checkpoints in G1 and S arrests the cell cycle in response to
damaged DNA to allow time for DNA repair. If the appropriate cellular conditions are
not met after a period of time at a checkpoint, the cell will undergo apoptosis. These
checkpoints are crucial to the preservation of an organism’s DNA and thus the prevention
of mutations, including those resulting in cancer development.
The cell can transition from the G0 phase to the G1 phase in response to external
signals, such as apoptosis of an identical cell. During the G1 phase, cells undergo rapid
protein synthesis in preparation for ribonucleic acid (RNA) and deoxyribonucleic acid
(DNA) synthesis (Burke, 1996). Once initiated, the G1 phase lasts approximately 12 to
14 hours before proceeding to the S phase (Langhorne et al., 2007). During the S phase,
which typically lasts 7-20 hours, RNA and DNA are formed, as well as histones, the
basic protein of chromatin.

Two strands of the newly formed DNA, the body’s genetic

code, wrap themselves around the histones, forming a double helix structure. The strands
form bonds to one another between their nucleotide bases in specific pairs; the purines,
adenine (A) and guanine (G), bind respectively to the pyrimidines, thymine (T) and
cytosine (C).
The G2 phase follows the S phase, and lasts 1-12 hours (Burke, 1996). The cell
further prepares itself for mitosis by continued RNA synthesis, and development of
organelles and the mitotic spindle apparatus, where chromosomes are condensed.
Additionally, proofreading and repair is performed by enzymes, DNA ligase and the
DNA polymerases, which remove and replace nucleotides on the complementary strand

17
that are inappropriately matched with the original DNA strand (Guyton & Hall, 2000).
Mitosis (M phase) is the period of actual cell division, and is further divided into 4
phases: prophase, metaphase, anaphase, and telophase. During mitosis, the cell is divided
into 2 daughter cells containing the same number and type of chromosomes as the
original parent cell.

M
G2
Preparation
for mitosis
(19%)

Quiescence
(Variable)

Mitosis
and cell
division
(2%)

G0
G1

S
DNA
synthesis
(39%)
Synthesis of
components required of
DNA synthesis (40%)

Figure 1. The cell cycle. Adapted from Biochemistry, By D. Voet, J.G. Voet, and C.W.
Pratt, 2006. p. 1054. Copyright 2006 by John Wiley and Sons, Inc.

Cells within the late G1 and early S phases are more susceptible to carcinogenesis
(Ullrich, 2005). When a cell becomes cancerous, the cell cycle is completed more
quickly, as the G1 and G2 phases are shortened, with a greater relative proportion of the
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cell cycle engaged in cell proliferation(Voet et al., 2008). Rapidly proliferating cells are
more sensitive to radiation and chemotherapy, as many therapies are most effective
during the M phase, making cancer cells more susceptible to these treatments (Ullrich,
2005).
Carcinogenesis
Cancer cells are characterized by certain characteristics, including loss of
proliferative control and capacity to differentiate, altered biochemical properties,
chromosomal instability, and capacity to metastasize. Loss of proliferative control is the
primary characteristic shared by all cancer cells. Normally, cell division is initiated by
numerous factors, including cyclins and growth factors, and inhibited by others, such as
lack of cellular space (contact inhibition) (Burke, 1996; Langhorne et al., 2007;
Schneider et al., 2003). In a malignant cell, cell division continues even when the
cellular environment does not favor proliferation, resulting in uncontrolled growth. Loss
of capacity to differentiate indicates that cells do not attain the specific structural and
functional characteristics of the tissue from which they are derived, as determined by
their genetic coding (Langhorne et al., 2007). The degree of differentiation (welldifferentiated, poorly-differentiated, or undifferentiated) is an important clinical
indication of cancer progression. Altered biochemical properties allow for continued loss
of proliferative control and differentiation, in addition to increased rates of anaerobic
glycolysis, loss of cellular adhesiveness, and production of tumor-associated antigens and
metabolic by-products, including hormone-like substances. Some of these metabolic
alterations allow for some degree of biological and therapeutic targeting of cancer cells.
Chromosomal instability is implicated in initiating carcinogenesis, but can also cause
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continued cellular mutation, resulting in variable subpopulations of neoplasms within a
given tumor, some of which may be particularly resistant to cancer therapy (Langhorne et
al., 2007).
While the exact cause of most cancers is still undetermined (Pfeifer, 2007), there
are several known processes and events which may need to act in concert in order to
initiate carcinogenesis. The hypothesis that more than one insult, or “hit,” to a cell’s
genes cause cancer is called the “multiple hit theory” (Schneider et al., 2003). Because
the human body has numerous, redundant protective mechanisms against genetic
alteration, more than one hit is necessary to overwhelm this elaborate defense system.
Protective mechanisms include tumor suppressor genes (also known as antioncogenes),
which, in the presence of DNA alteration, can inhibit growth, prevent adhesion of
metastatic cells, repair DNA, or induce apoptosis, depending on the gene and biological
circumstances (Langhorne et al., 2007). Possible insults to a cell include radiation
(including solar), endogenous substances, (e.g., tobacco smoke, certain plastics,
laboratory chemicals), lifestyle (e.g., obesity, alcohol consumption, stress level, lack of
exercise, poor diet), and viruses (e.g., Human papilloma virus, Epstein-Barr, hepatitis B)
(Schneider et al., 2003; Ullrich, 2005). Any material known to stimulate the
development of cancer is known as a carcinogen. Carcinogens can cause genetic
mutations in several ways, including DNA replication errors, elimination, insertion, or
substitution of one of the components of the DNA strand.
Carcinogenesis is often described as occurring in two distinct events: initiation
and promotion. Initiation is the mutational change that occurs when a carcinogen
damages DNA by altering a given gene.

If the normal repair processes are in place, no

20
cancer occurs. Otherwise, the cell may become permanently damaged, ultimately
resulting in cellular death, or may develop into cancer in the presence of a cocarcinogen.
Promotion describes the interaction of the cocarcinogens, or promoting agents, with the
altered gene, resulting in damage to the proliferating mechanism of the cell (Langhorne et
al., 2007). The introduction of an activator, followed by the introduction of a promoter,
is necessary for the development of a tumor. A promoter does not mutate DNA or cause
cancer itself, but rather interacts with the initiator to allow carcinogenesis to proceed.
See figure 2. A final stage, progression, is sometimes described as the process of
progressive advancement of the size and severity of the neoplasm.

No Tumor
Tumor
No Tumor
No Tumor
Tumor
Time

Introduction of Initiator
Introduction of Promoter

Figure 2. Initiation and Promotion. Adapted from Oncology Nursing 5th Edition, by M.
Langhorne, 2007, p. 10.
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Cancer Types
Although every type of cell in the body is capable of becoming cancerous, there
are five broad classes of cancer. Carcinomas are solid tumors originating in epithelial
cells, particularly in secretory tissues such as breast, prostate and pancreas (Schneider et
al., 2003). Between 85% and 90% of all human cancers are carcinomas, making it by far
the most common cancer. Melanomas are cancers originating in melanocytes, pigmentproducing cells. These occur primarily in skin cells, but may occur elsewhere, including
mucosal tissue and within the eye. Sarcomas are cancers that develop in bone, muscle,
cartilage, fat or connective tissue and are fairly rare, accounting for less than 2% of all
cancers. Leukemia is a cancer of blood-synthesizing organs, primarily the bone marrow,
which results in abnormal leukocyte production. This type of cancer is diffuse, rather
than a solid tumor, and therefore requires different treatment strategies than other types of
cancer. Lymphomas are cancers of lymphoid tissue, and are broadly classified as
Hodgkin’s or Non-Hodgkin’s, according to cell type, degree of differentiation, growth
patterns, and type of reaction elicited by tumor cells (Langhorne et al., 2007). Although
lymphoma originates in the lymphatic system and is classified as hematological
malignancy, it presents as a solid tumor.
Cancer Stages and Grades
Most solid tumors are classified in severity using the TNM staging system. This
system classifies tumors according to tumor size, the degree of spread to regional lymph
nodes, and the presence or absence of distant metastases. Generally, stage I tumors are
limited to the site of origin, stage II cancers have spread to local tissues, and stage III
tumors have spread to lymph nodes and have extensive primary lesions and fixation to
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deeper structures (Schneider et al., 2003). A cancer is considered to be stage IV when
distinct metastases are present, regardless of other criteria. Refer to Table 1 on page 23.
Cancer grading is another method of evaluating the severity of a cancer. The
microscopic appearance of the cancer cells, as opposed to the tumor as a whole, is
considered, and differentiation is the primary indicator of cancer grade.
Metastasis is the spread of cancer beyond the site of origin through veins, arteries
and the lymphatic system. The ability to metastasize, the process in which cancer spreads
from the tissue of origin to distant sites, is a trait unique to cancer and is another indicator
of disease severity (Stetler-Stevenson & Kleiner, 2005). For metastasis to occur, cancer
cells detach from a primary tumor due to increased motility, enter the circulatory system,
and aggregate with blood borne elements (including other metastases), protecting them
from destruction (Langhorne et al., 2007). The cells must then leave the circulation and
penetrate the distant tissue (extravasation). Angiogenesis in the distant tissue provides
blood to the metastatic lesion, supporting growth and malignancy. Less than 1% of
metastases survive this process, and the longer they are in the circulatory system, the
more likely they will be destroyed. Metastases can invade any type of tissue, regardless
of the origin of cancer, but are common in local lymph nodes, lungs, bones, liver, and
brain (National Cancer Institute, 2013). Metastatic spread of cancer is typically
indicative of a more aggressive cancer, even compared to direct spread of cancer, which
penetrate and destroy adjoining tissues. Often, metastases are microscopic and
undetectable until further progression (Stetler-Stevenson & Kleiner, 2005). Because of
the potential existence of tiny, undetected metastases, chemotherapy is often included in
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a treatment regimen, even if the primary cancer has apparently been cleanly removed in
entirety with surgery (DeVita, 2005).
Table 1
General Staging of the TNM System
Tumor stage
Tumor size

Lymph node status

Metastasis

I

< 2cm

None

None

II

2-5 cm

No, or on same side

None

III

> 5 cm

Yes, on same side

None

IV

Does not matter

Does not matter

Yes

Adapted from Exercise and Cancer Recovery, by Schneider et al., 2003, p. 87.

Cancer Treatment
Surgery
In addition to removal of cancerous tissue as a cancer treatment, surgery can be
used to prevent or detect cancer. Certain precancerous conditions, such as moles and
other skin anomalies, have a high risk of developing into malignant tissue. Removal of
this tissue can therefore prevent the onset of cancer. Similarly, in individuals with a
significant genetic risk of developing a certain type of cancer, as indicated by family
history or genetic markers, may warrant prophylactic surgery to reduce the risk of cancer
(DeVita, 2005). There are several surgical methods that may be employed to obtain
tissue for the purpose of histological examination. Depending on the type of biopsy,
varying degrees of tissue removal are required for analysis to determine if the tissue is
cancerous, and to diagnose the stage of the cancer. Surgery, including open biopsies of
the lungs or liver, may also be used to diagnose opportunistic infections following
treatment-induced immune suppression (DeVita, 2005; Schneider et al., 2003).
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Surgery may be used alone as cancer treatment, or in combination with adjuvant
therapies, such as chemotherapy and radiation. The decision to include adjuvant therapy
is largely determined by the extent of the primary lesion. When the tumor is confined to
the site of origin, surgery alone is typically the preferred method (Rosenberg, 2005). The
side effects of surgery alone are less damaging, and removal of the tumor can often
permanently cure the patient of cancer. Because approximately 70% of patients
presenting solid tumors already have micrometastases beyond the primary site, adjuvant
therapy is often incorporated (DeVita, 2005). Beyond removal of the primary tumor
mass, surgery may be used to remove metastatic tissue or tissue that is a risk of becoming
metastatic (such as local lymph nodes), for reconstructive purposes, or for palliative
purposes, such as removal of a tumor mass to improve comfort. The initial health of the
patient is another determinant in cancer treatment (DeVita, 2005; Schneider et al., 2003).
Very frail or elderly individuals may decide to only have surgery to remove the primary
tumor burden to reduce the toxic side effects of radiation and chemotherapy, even if the
cancer has already metastasized.
Radiation
Although long-term exposure to high energy irradiation can be carcinogenic,
radiation therapy uses high energy irradiation to destroy malignant cancer cells. The
objective of radiotherapy is to sterilize cancer cells so that they are incapable of unlimited
proliferation (Hellman, 2005). There are two general types of radiation: brachytherapy
(internal) and teletherapy (external). With both types, the target area is small, and
therefore radiation is typically not used to treat metastatic cancers (Schneider et al.,
2003). In brachytherapy, radioactive isotopes are placed within the body, near the tumor.
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Placement of the implant is important in brachytherapy, because the dose of radiation is
related to the inverse square of the distance from the radiation source (Hellman, 2005).
Therefore, any cancerous tissue outside of a given radius may not be adequately affected
by the radiation dose. In teletherapy, beams of radiation from outside the body are aimed
at the target tissue. Dosage is determined both by intensity of the beam and exposure
time.
Radiation-associated damage to biological systems spans a time scale of ~25
orders of magnitude (Bensasson, Land, & Truscott, 1993). In the physical stage (10-18 to
10-12 seconds), the radiation is actually absorbed (direct effect of radiation). In the
chemical stage, (10-12 to 1 second), highly reactive excited states and reactive oxygen
species are formed. In the biological stage (seconds to decades), the biochemical and
cellular consequences of radiation are seen throughout the entire body. It was previously
thought that the antitumor effects of radiation are due entirely to the direct effect of
radiation on cell membranes and DNA, but it is now recognized that the production of
free radicals is important as well (Bensasson et al., 1993). ROS react with tumor cell
DNA, causing single or double strand breaks. The presence of cellular oxygen is
important for the formation of ROS. Because tumors may be more poorly perfused than
normal tissue, it is possible that radiation may damage healthy cells more than cancer
cells. To improve ROS production within the tumor, hyperbaria in conjunction with
radiotherapy has successfully improved clinical effectiveness (Kirk, Wingate, & Watson,
1976), but because this method is cumbersome, it is rarely used anymore. The formation
of other cytotoxic agents following radiation may also facilitate the antitumor effect of
radiation. These include numerous cytokines, such as tumor necrosis factor-α (TNF-α)
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(Ralph et al., 2002), interleukins-1 and -6 (Hallahan, Haimovitz-Friedman, Kufe, Fuks,
& Weichselbaum, 1993), and cell adhesion molecules (Hallahan, Kuchibhotla, & Wyble,
1996).
There are several possible effects of radiation on both normal and cancer cells:
cellular death (either apoptosis or necrosis), accelerated senescence, terminal
differentiation, or no or minor alterations in their divisional process (DeVita, 2005).
Cells are most likely to be destroyed while proliferating, particularly in the M and G2
phases, therefore making cancer cells more vulnerable to radiation than normal cells.
Even so, normal cells are considerably damaged by radiation therapy. Local side effects
of radiation therapy include pain, blistering, reduce range of motion, cell membrane
damage, necrosis, fibrosis, fistula formation, and ulcerations (Allavena, Conroy, Aletti,
Bey, & Lederlin, 1992; DeVita, 2005; Schneider et al., 2003). Whole body side effects
include nausea, pain, fatigue, diarrhea, lung fibrosis, anemia, and cardiomyopathy. Local
effects are typically associated with the radiation dose itself as well as cytotoxic agents
and ROS, while whole body effects are associated mostly with cytotoxic agents and ROS
production.
Chemotherapy
The use of chemotherapy is common, as more than half of cancer survivors have
undergone treatment with at least one drug (Langhorne et al., 2007). Chemotherapy can
be employed as the primary means of anti-cancer therapy (neoadjuvant therapy) to limit
the spread of localized tumors, particularly in late stage cancers, or as adjuvant therapy to
shrink tumors prior to radiation or surgery and destroy microscopic metastases following
tumor removal (Chu & Devita, 2005). Chemotherapy is also the primary method of
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combating hematological and metastatic cancers. There are numerous types of
chemotherapy, with varying anti-cancer mechanisms, but typically the drugs damage or
disable cells with abnormal growth cycles. The primary classes of chemotherapy drugs
are alkylating agents, antimetabolites, antitumor antibiotics, and alkaloids. Almost
universally, there is collateral damage to healthy cells, but less significantly than the
damage to cancer cells. As in radiation therapy, chemotherapy can itself induce future
cancer development, known as second cancers. (Van Leeuwen & Travis, 2005)
Typically, a chemotherapy regimen consists of drug administration every 2-4
weeks for 3-6 months. Administration methods can be oral (pill, liquid, capsule),
intravenous (single venipuncture, catheter, port), intraperitoneal, or via spinal taps
(Schneider et al., 2003). One challenge to the success of chemotherapy is the ability of
malignant cells to adapt to a given drug, thereby becoming “drug resistant.” To combat
drug resistance, as well as to increase the overall antitumor effectiveness and minimizing
the toxicity of the regimen, two or more different drugs are often administrated
concomitantly (Kramer, Zakher, & Kim, 1988). Typical side effects of chemotherapy are
whole-body and include fatigue, cachexia, anorexia, and nausea, as well as cardiac,
endothelial, pulmonary, gastrointestinal, hepatic, and neuroendocrine dysfunction
(Schneider et al., 2003). Local side effects usually are related to port implantation and
acute pain and cellular damage at the site of administration (Langhorne et al., 2007).
Treatment-related side effects not only affect quality of life and physical capacity, but can
be dose-limiting, decreasing overall effectiveness and reducing a cancer patient’s survival
time. Oxidative stress-induced side effects, particularly associated with anthracyline
therapy, will be discussed in depth later.
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Hormonal Therapy and Targeted Therapy
Hormonal therapy is most commonly used in cancers affecting primary or
secondary sexual organs, including breast, prostate, and endometrial carcinomas. These
cancers can be dependent upon binding of sex hormones to their receptors (if present) in
cancer cells to continue growth. Hormonal therapy retains cancer cells in quiescence (G1
or G0), preventing continued growth (Sing-Hung, 2007). A common treatment used in
breast cancer survivors is the anti-estrogen Tamoxifen, which may be used as an adjuvant
treatment for as many as five years. Tamoxifen is used to treat metastases and to prevent
recurrence (Schneider et al., 2003), as well as to prevent the onset of breast cancer in
post-menopausal women with genetic risk or precancerous conditions. Aromatase
inhibitors such as Arimidex® similarly decrease circulating levels of estrogen, but act
upon the enzyme aromatase in the adrenal glands, reducing the endogenous production of
hormones (Langhorne et al., 2007). Anti-androgens are used to target prostate cancer
using a similar mechanism as anti-estrogens. Luteinizing hormone releasing hormone
(LHRH) agonists such as goserelin acetate bind to LHRH receptors in the pituitary gland
and inhibit luteinizing hormone production, in turn reducing the endogenous production
of testosterone in males and estrogen in women. In advanced cases of breast or prostate
cancer, or in very old cancer patients, hormone therapy is used alone as a palliative
treatment by slowing or temporarily halting the growth of cancer without actually
eliminating the tumor mass. Despite typically resulting in fewer and less severe side
effects than radiation and chemotherapy, hormonal therapy is not without consequence,
as Tamoxifen may result in post-menopausal symptoms and thromboembolic events
(Sing-Hung, 2007). Tamoxifen has also been shown to induce oxidative stress (Ferlini et
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al., 1999; Nazarewicz et al., 2007), and, like radiation and chemotherapy, the induction of
ROS by Tamoxifen likely plays a role in its antitumor effects.
Much like hormonal therapy, targeted therapy exploits specific characteristics of
cancer cells, in this case mutant kinases, which can be used to identify and attack a tumor
(Sawyers, 2004). A well-known drug using this strategy is Herceptin (Trastuzumab), a
monoclonal antibody that targets ErbB-2 (HER-2), a tyrosine kinase receptor that is
involved in the development of breast cancer. These therapies have a relatively high
response rate when appropriately used, but as of yet, only a fraction of human cancers
contain known kinase-domain mutations. Another proposed form of targeted therapy
alters the redox balance within a cancer cell, either increasing oxidative stress by
inhibition of antioxidant (AOX) enzymes or induction of ROS production, or decreasing
oxidative stress, by activation of AOX enzymes or inhibition of ROS production (J.
Wang & Yi, 2008). These strategies will be discussed in a later section.
Immunotherapy
An alternate method of cancer treatment involves the use of cancer vaccines to
stimulate the immune system to destroy cancer cells. Because the molecular composition
of many tumor-associated antigens have been identified, it is possible to specifically
target cancer cells. The effect is similar to an autoimmune disease, in which the immune
system recognizes particular protein fragments and attacks these “self-antigens” (Dudley
et al., 2002). The primary advantage of this method is the significant reduction in side
effects, if used alone. Additionally, because the immune system is designed to protect
the entire body, as various leukocytes circulate in the circulatory and lymphatic systems,
immunotherapy would theoretically be an ideal method for destroying metastases remote
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from the primary lesion. Unfortunately, the objective response rate to immunotherapy
has, to date, been very low (2.6%) (Rosenberg, Yang, & Restifo, 2004).
Reactive Oxygen Species and Oxidative Stress
Reactive oxygen (and nitrogen) species (ROS / RNS) are extremely unstable
molecules containing an unpaired valence electron (Halliwell & Gutteridge, 2007). Also
known as free radicals, ROS can cause damage to tissues by stealing electrons from
nearby molecules, creating a new radical and propagating a chain reaction. Such a chain
reaction in lipid membranes can damage any cell, in a process called lipid peroxidation,
but damage also occurs to other cellular components, including proteins, causing skeletal
and cardiac muscle dysfunction, and nucleic acids, potentially resulting in DNA
modification.
ROS are formed in all organisms, including healthy humans. Although oxygen is
required for aerobic metabolism, and therefore human life, it can be toxic when it
becomes a radical. The most commonly produced ROS are superoxide (O2•-) and
hydroxyl radicals (OH·) (Halliwell & Gutteridge, 2007). The dot (·) indicates that a
molecule is a radical, with an unpaired electron. Additionally, non-radical oxygen
derivatives such as hydrogen peroxide (H2O2), singlet oxygen (1O2), lipid hydroperoxides
(LOOH), and various other hydroperoxides (ROOH), although not truly radicals, are
included in the ROS classification (Berlett & Stadtman, 1997). Most free radical
production in healthy individuals occurs in the mitochondria, due to a “leakage” of
electrons from 1-2% of the oxygen in oxidative phosphorylation (Boveris & Chance,
1973), which can form O2•-. Because this original value was determined using isolated
mitochondria in the presence of a non-physiological level of oxygen, this value may be
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an overestimation (Vollaard, Shearman, & Cooper, 2005). Superoxide production in this
manner occurs in complex I, but primarily occurs in complex III of the electron transport
chain, as the unstable intermediate semiquinone anion can directly transfer electrons to
molecular oxygen instead of reducing to ubiquinone (coenzyme Q) (Agostinelli & Seiler,
2006; Turrens, 1997). Because this process is non-enzymatic, a higher flux of oxygen
through the mitochondria typically results in greater O2•- production.
ROS production is an important element of biological defense against pathogens
and toxins. Free radical production occurs in leukocytes, which create superoxide to
destroy pathogens, in what is known as a respiratory burst. NAD(P)H oxidase catalyzes
the reaction (NADPH + 2O2 ↔ NADP+ + O2•- + H+ ). A downstream reaction of the
respiratory burst catalyzed by myeloperoxidase creates hypochlorous acid, a highly
reactive oxidant, from H2O2 and a chloride ion (Babior, 2000). The cytochrome P450
system in the endoplasmic reticulum, which plays diverse roles metabolizing steroids,
fat-soluble vitamins, fatty acids, eicosanoids, drugs, and carcinogens, is another source of
ROS in healthy individuals via a NADPH mechanism (Symons & King, 2003).
Oxidative stress produced by the P450 system have been found to mediate the chemical
toxicity of certain drugs, including alcohol and acetaminophen (Gonzalez, 2005)
Cyclooxygenase (COX) (Armstead, 2001) and xanthine oxygenase (XO) are
further pro-oxidant enzymes known to produce superoxide in both healthy and diseased
individuals. XO, like NAD(P)H, is expressed phagocytic cells, but also plays a role
innate immune function as it is expressed on the epithelial surface (Vorbach et al., 2003).
Xanthine oxidoreductase has two forms: xanthine reductase, which creates the
antioxidant uric acid, and xanthine oxidase, a pro-oxidant enzyme. Xanthine reductase is
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constitutively expressed, but is rapidly converted to xanthine oxidase (Vorbach et al.,
2003). Similarly, COX-2 is not constitutively expressed, but is highly inducible (Chan,
2001). These tightly regulated pro-oxidant enzymes illustrate the importance of ROS
creation in healthy individuals.
Superoxide can dismutate spontaneously or enzymatically, producing hydrogen
peroxide. Alternately, superoxide can reduce ferric iron(III) to ferrous(II) (Fe3+ + O2•- →
Fe2+ + O2) (Halliwell & Gutteridge, 2007). In another reaction known as the Fenton
reaction, ferrous iron(II) is oxidized by hydrogen peroxide, creating ferric iron(III), a
hydroxyl anion, and a hydroxyl radical (Fe2+ + H2O2 → Fe3+ + OH- + OH-·).

The

overall reaction (O2•- + H2O2 → OH- + OH-· + O2), known as the Haber-Weiss reaction,
therefore creates hydroxyl radicals from superoxide and hydrogen peroxide. Fortunately,
in healthy individuals, ferrous iron is not easily oxidized, as it is bound tightly in organic
complexes, but certain metabolic and disease states can make iron accumulate. Hydroxyl
radicals are extremely biologically reactive and are particularly damaging because there
is no enzymatic reaction that can eliminate OH-· (Manda, Nechifor, & Neagu, 2009).
Therefore, the only defenses against cellular damage from OH-· are effective repair
systems, or preventing their formation to begin with.
Another radical, nitric oxide (NO·), is produced primarily by NO synthase in
endothelial cells (eNOS), but has recently been shown to be produced in mitochondria
(Giulivi, Poderoso, & Boveris, 1998). Although NO· is more commonly known as a
signaling molecule, it is capable of reacting with O2•- to form peroxynitrite (ONOO-),
another highly reactive oxidant. Peroxynitrite is more stable than either NO or
superoxide, and is capable of further alteration, forming strong oxidants including
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hydroxyl-like and nitrogen dioxide radicals (Kojda & Harrison, 1999). Beyond the
damaging effects of peroxynitrite, inactivation of nitric oxide by superoxide is likely a
contributor of endothelial dysfunction. In much of the literature, reactive oxygen and
nitrogen species (RONS) are discussed as a single entity and in this manuscript will be
referred to, generally, as “ROS” unless otherwise specified.
Antioxidant Defense
Because ROS are continuously formed in healthy individuals, an antioxidant
defense system is in place to counteract normally produced free radicals. Antioxidants
are molecules that inhibit free radical reactions, typically by acting as a reducing agent by
donating an electron and ceasing the oxidative chain reaction. Enzymatic antioxidants,
including superoxide dismutases (SOD), catalases, glutathione peroxidases, thioredoxins,
and lactoperoxidases, are central to this system (Leffler, 1993). SOD, found in cytosol,
mitochondria, and extracellular spaces, catalyzes the dismutation of superoxide into
hydrogen peroxide and oxygen (2 O2•- + 2 H+ → H2O2 + O2) (Baskin & Salem, 1997).
While hydrogen peroxide is significantly less destructive than superoxide, it is still a
harmful toxin, which can be transformed into water by glutathione peroxidase (2 H2O2 +
2 GSH → GSSG + 2 H2O) or catalase (2 H2O2 → 2 H2O + O2). If SOD is active, but not
supported by catalase and glutathione peroxidase, the net result may be enhanced
oxidative stress, as H2O2 is more reactive than O2•- (Manda et al., 2009). Non-enzymatic
antioxidants such as ascorbic acid (vitamin C), α-tocopherol (vitamin E), flavonoids,
carotenoids, glutathione (GSH) are an important element of the mammalian antioxidant
system (Halliwell & Gutteridge, 2007). These antioxidants are typically exogenously
derived and can interact with dangerous free radicals and create less reactive radicals.
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There is evidence that some degree of exogenously-derived, non-enzymatic antioxidants
are sequestered, and released during periods of increased ROS production (Mastaloudis,
Leonard, & Traber, 2001). Endogenous non-enzymatic antioxidants include proteins like
albumin and ferritin, and metabolites, including uric acid, bilirubin and pyruvate, can also
effectively act as free radical buffers, preventing damage to more important molecules,
namely cellular elements (Manda et al., 2009).
The antioxidant defense system is capable of modification, primarily in response
to the production of some degree of oxidative stress. The concept of hormesis describes a
beneficial physiological response or adaptation to a mildly damaging stimulus (Ji et al.,
2006). The adaptive response to exercise is the most well-known example of hormesis,
and it has been suggested that a similar such effect occurs in response to oxidative stress.
Indeed, many of the beneficial adaptations that occur with chronic exercise may be
partially attributed to the presence of ROS during and follow exercise, which may act as
signaling molecules (Ji, 2008; Powers et al., 2009). The modulation of antioxidant
defense in response to exercise training is a paradigmatic example of this hormetic
response and will be discussed more in depth later. The human antioxidant defense
system can respond to acute and chronic exposure to ROS in the absence of exercise as
well. Acute (Sasaki, Akamatsu, & Horio, 1997) and chronic (Iizawa, Kato, Tagami,
Akamatsu, & Niwa, 1994) UVB radiation exposure has been shown to increase SOD
activity in human keratinocytes. Similarly, diabetic pancreatic β-cells can increase their
antioxidant defense (overexpression of numerous antioxidant enzymes) compared to
normal β-cells due to their chronically elevated ROS production (Lacraz et al., 2009).
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Oxidative Stress and Markers
of Oxidative Stress
When the generation of reactive oxygen and nitrogen species exceed cellular
adaptive and repair capacities, it is known as oxidative stress (Valko 2007). This occurs
when acute production of ROS and/or RNS is higher than normal, due to some
physiological or environmental stress, when the antioxidant enzyme system is
compromised, or both. If the antioxidant defense system is in place, ROS produced
during physiological or pathophysiological processes are never given the chance to cause
damage, and redox balance is maintained. Reductive stress is an alternate pathological
state, in which antioxidant activity, either endogenous or exogenous, far outstrips ROS
production, resulting in redox imbalance (Rajasekaran et al., 2007).
As previously mentioned, proteins, fats and nucleotides are all potential sites of
oxidative damage. Due to the extremely transient nature of reactive oxygen species, it is
difficult to perform a chemical analysis of ROS themselves. Rather, downstream
products of oxidative stress in blood and tissues may be analyzed via biochemical
analysis. An exception to this is hydrogen peroxide, which is radical-producing, but not a
radical itself, making it stable enough to measure directly (Bloomer, 2008). Perhaps the
most commonly used marker of oxidative stress in malondialdehyde (MDA), a stable end
product of lipid peroxidation. Because lipid peroxidation occurs in lipid membranes, all
cells are potentially targets of lipid peroxidation, making MDA a fairly good marker of
total body oxidative stress. MDA accumulation in tissue or plasma can be measured
directly, or with a thiobarbituric acid reactive substances (TBARS) assay, in which
thiobarbituric acid reacts with MDA to produce a fluorescent product (Vasankari, Kujala,
Heinonen, Kapanen, & Ahotupa, 1995). Other markers of lipid peroxidation include 4-
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hydroxynonenal (4-HNE) and F2 isoprostanes such as 8-iso-Prostaglandin F2alpha (8isoprostane). MDA itself is capable of further reactivity with nucleic acids, including
DNA, which may be possibly mutagenic (Marnett, 1999). A more common pathway to
DNA damage is by direct modification via superoxide and peroxynitrite. 8-Hydroxy2’deoxyguanosine (8-OHdG), a fairly ubiquitous byproduct of oxidative DNA damage, is
the primary biomarker for DNA oxidation and can be assessed in urine, serum,
cerebrospinal fluid, cells or tissues.
Carbonyl derivatives of proline, lysine, arginine and threonine are the most
common oxidation products of protein, and can be assayed in plasma, serum, cell lysates
or purified proteins (Paromov, Qui, Yang, Smith, & Stone, 2008). Similarly, advanced
oxidation protein products (AOPP) are makers of protein oxidation created during
oxidative stress through the reaction of plasma proteins with chlorinated oxidants such as
hypochlorous acid (Marsche et al., 2009; Witko-Sarsat et al., 1996). Although AOPP are
most commonly used clinically to screen for chronic diseases such as renal
complications, diabetes mellitus, and atherosclerosis, they are adequate markers of
general oxidative stress. 3-Nitrotyrosine, an end product of peroxynitrite reacting with
tyrosine, while theoretically could be used as a marker of protein oxidation, is in reality
used as a marker of peroxynitrite, and therefore nitrative damage.
A more direct measurement of ROS involves the use of florescent probes or spin
traps, which directly capture intracellularly produced radicals and convert them into more
stable molecules (Powers & Jackson, 2008). While this method allows for determination
of ROS production in different tissues and cellular compartments, there are disadvantages
beyond the complicated and invasive nature of the procedure. An increase in ROS
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production alone does not indicate a state of oxidative stress, as an increased activity of
the antioxidant system may maintain redox balance. Additionally, microprobes and spin
traps may disturb the intracellular environment, altering ROS production (Halliwell &
Gutteridge, 2007).
Another method of determining redox status in living systems is measurement of
antioxidant enzyme activity, and non-enzymatic antioxidant concentrations. Decreased
enzymatic antioxidant capacity indicates poor ability to handle an increased ROS load,
but does not actually indicate the level of ROS production. Commonly measured
antioxidant enzymes include superoxide dismutase, glutathione peroxidase, and catalase
(Finaud et al., 2006). Alternately, a measured reduction in non-enzymatic antioxidants,
such as glutathione, can indicate a chronic overproduction of ROS. In particular, ratio of
reduced glutathione to oxidized glutathione (GSH:GSSG) is a commonly used
determinant of oxidative stress (Serru et al., 2001). In normal, healthy individuals, the
GSH/GSSG ratio is approximately 10:1, but during chronic oxidative stress, GSH is
depleted by the action of glutathione peroxidase (Ji, Fu, & Mitchell, 1992; Serru et al.,
2001). Total antioxidant capacity of a tissue or blood sample can be determined, which,
while lacking specificity, may be a more practical assessment of an individual’s redox
status. Several methods of determining total antioxidant capacity, including the Trolox
equivalent antioxidant capacity (TEAC), oxygen radical absorbance capacity (ORAC),
and ferric reducing ability of plasma (FRAP) assays, compare the antioxidant power of a
given sample (e.g., blood, tissue, food items) to a standard antioxidant, Trolox (Wang et
al., 2004). This is often a practical method of determining redox status because the
interrelationship between all enzymatic and non-enzymatic antioxidants, and various

38
support mechanisms such as transporters, is complex and complimentary, meaning that
the expression of any single antioxidant may be misinterpreted. For example, the
overexpression of superoxide dismutase without a similar rise in catalase expression has
been shown to result in increased rather than decreased oxidative stress (McCord, 1993).
Reactive Oxygen Species as
Signaling Molecules
For years, ROS production was thought to be simply an unavoidable, damaging
by-product of working muscles during exercise. It had been long assumed that exercise
acutely induces oxidative stress simply because of the significant (100 to 200-fold)
increase in oxygen flux through the mitochondria, thereby increasing electron leak and
superoxide formation (Clanton, Zuo, & Klawitter, 1999). This was seemingly supported
by evidence of hyperoxia-induced ROS production, even in the absence of skeletal
muscle contraction (Flandin, Donati, Barazzone-Argiroffo, & Muzzin, 2005). This
notion was countered by the finding that hypoxia can also increase ROS production
(Bailey, 2001; Waypa et al., 2010). High altitude exposure similarly induces oxidative
stress, which may be implicated in acute mountain sickness (Bailey, Davies, Young,
Hullin, & Seddon, 2001; Bailey et al., 2009; Dosek, Ohno, Acs, Taylor, & Radak, 2007)
One explanation offered to explain these paradoxical effects was that the reduced
mitochondrial oxygen saturation (pO2) during exercise may cause ROS production
(Bailey, 2001). Mitochondria may act as oxygen sensors by inducing ROS in response to
low pO2, which in turn mediate transcriptional changes implicated in adaptation to
hypoxia and aerobic exercise (Brunelle et al., 2005; Chandel et al., 1998; Chandel et al.,
2000; Emerling et al., 2005).
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It is now recognized that ROS production by contracting muscle plays an
important role in the adaptive response to exercise (Jackson, 2005, 2009a; Powers et al.,
2009). Nitric oxide (first called endothelium-derived relaxing factor) has long been
recognized for its ability to vasodilate. When the NO-producing enzyme eNOS
(endothelial nitric oxide synthase) is downregulated or eliminated, vascular dilation is
prevented. (Fleming & Busse, 1999). Oxidative stress may actually mediate this, as
superoxide reacts readily with NO, producing peroxynitrite. Only recently were alternate
ROS identified as direct cellular signaling molecules. Low concentrations of ROS are
important for cellular signaling (Zhang 2007). For instance, low levels of ROS are
apparently crucial for normal force production, and a slight increase in ROS generation
causes an increase in force production (Reid, 2001). When higher levels of ROS are
present, a subsequent reduction in force production occurs, partially explaining the
development of fatigue in response to submaximal contractions (Reid, Khawli, & Moody,
1993). Modification of contractile function may be due to ROS exposure to redoxsensitive, sulfhydryl groups of myofibrillar proteins, and phosphatases and kinases of
multiple elements of the contractile system (Jackson, 2009a; Powers & Jackson, 2008),
including SERCA (Smith & Reid, 2006), ryanodine receptors (Zima & Blatter, 2006),
and myosin heavy chains (Powers et al., 1994).
Recently, the role of ROS as a mediator in numerous signaling pathways involved
in growth, differentiation, proliferation and apoptosis has gained attention (Ji, 2008).
Among these are the mitogen-activated protein kinase (MAP-K), nuclear factor (NF) κB,
activator protein 1 (AP-1) heat shock proteins, p53, and the p38 cascade. One primary
result of ROS activation of the MAP-K and NFκB pathways is increased expression of
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antioxidant enzymes (Allen & Tresini, 2000), so that with chronic ROS exposure,
antioxidant enzyme activity increases (Hammeren et al., 1992; Powers, Ji, &
Leeuwenburgh, 1999; Witt, Reznick, Viguie, Starke-Reed, & Packer, 1992). ROS
stimulated MAP-K activation can also acutely trigger glucose uptake in skeletal muscle,
both during muscle contraction (Sandstrom et al., 2006), and independent of active
contraction, (Chambers, Moylan, Smith, Goodyear, & Reid, 2009) indicating a metabolic
signaling role of ROS. Because these signaling cascades are implicated in numerous
acute and chronic responses to exercise, including muscular hypertrophy, angiogenesis,
and vascular adaptation (Ji, 2008), it is possible that these too may be ROS dependent to
some degree.
The precise redox balance of a healthy cell, in response to signaling cascades,
exercise, and exogenous stimuli, has a potent and sometimes counterintuitive effect. For
instance, a hormetic response to ROS in skeletal muscle adaptation is apparent, as ROS
signaling likely contributes both to muscle fiber adaptation following contractile activity,
as well as prolonged muscle disuse (Powers et al., 2009). This seemingly contradictory
interaction is likely due to the time course and magnitude of ROS generation. Exercise is
a relatively short (minutes to hours) and moderate stimulus for ROS production,
facilitating cellular adaptation and protection against future insult, while chronic, high
ROS production promotes cellular damage and death, as show in Table 2.
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Table 2
ROS Dose and Potential Health Effects
ROS dose
Causes
Acute extreme
ROS (oxidative
stress)

Radiation,
Chemotherapy

Chronic
continuous ROS
(oxidative
stress)

Sedentary lifestyle,
Poor diet, smoking,
UV exposure, air
pollution, Chronic
disease,
inflammation

Transient,
moderate ROS
(redox balance)

-Exercise
-Caloric Restriction

Benefits

Detriments

-Apoptosis/necrosis
of cancer cells

-Apoptosis/necrosis
of normal, healthy
cells
-Tissue damage
-Carcinogenic
-Induction of further
chronic disease

-Cellular signaling
-Cellular defense
(respiratory burst)
-Mediates hormetic
changes associated
with exercise
(Including ↑ AOX
enzymes, ↑ insulin
sensitivity, muscular
adaptations)

-Mimics oxidative
stress
Reduced capacity for
cellular defense and
signaling -Inhibition of cellular
and systemic
adaptation in
response to stimuli
(e.g. exercise)
Note: ROS production and degradation must be matched for optimal healthy and
physiological functioning.
Suboptimal
ROS (reductive
stress)

-Endogenous AOX
imbalance
-exogenous AOX
overdose
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The complex interaction between the so-called “tumor suppressor protein,” p53,
ROS, and antioxidant enzymes illustrates the intricate interrelationship between cellular
signaling, oxidative stress, and cancer etiology, pathology, and prevention. (Y. Chen et
al., 2007; Hussain et al., 2004; Liu et al., 2008; Tu et al., 2009). ROS act as both
upstream mediators of p53 signaling, as well as downstream second messengers of p53regulated apoptosis. Physiological levels of p53 help maintain cellular redox balance,
and this may be one of the tumor-suppressing mechanisms of p53. Alternately, both
hypo- and hyper-physiological levels of p53 result in ROS generation via antioxidant
suppression and/or prooxidant activation (Liu et al., 2008). Although p53 is known to
induce antioxidant enzymes, overexpression of p53 may increase cellular MnSOD and
glutathione peroxidase (GPX), but not catalase, potentially resulting in inadequate
removal of H2O2 (Hussain et al., 2004). In response to stressors, including oxidative
stress, a small proportion (~2%) of cellular p53 is translocated to the mitochondria,
signaling apoptosis (Marchenko, Zaika, & Moll, 2000). In this way, in response to mild
oxidative stress, p53 protects the mitochondria genome (Liu et al., 2008). Similarly, in
response to chemotherapeutic agents, ROS-activated p53 activity leads to apoptosis
(Ueno et al., 1999). When the degree of oxidative stress is more severe, the DNAbinding activity of p53 is abolished. Because p53 is pivotal for most DNA-damageinduced apoptosis, and p53 mutations are found in 70% of human cancers, its
dysregulation, either via ROS or other means, is implicated in cancer initiation (Brosh &
Rotter, 2009). Apoptotic dysregulation can additionally make these cancer cells resistant
to low dose radiation, as it depends on cancer apoptosis as its mechanism of action.
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Like with p53, ROS have been shown to act both upstream and downstream of
inflammatory cytokines. Tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), and
interferon-γ (IFN-γ), elicit mitochondrial ROS production (Yang et al., 2007), yet ROS
have been shown to induce production of macrophage inflammatory protein-2 (MIP-2),
tumor necrosis factor-α (TNF-α) and interleukin-6, (IL-6) (Naha, Davoren, Lyng, &
Byrne, 2010). Further demonstrating their diverse role in cellular signaling and
maintenance, ROS are known to be the second messengers responsible for regulation of
angiogenesis and tumor growth through vascular endothelial growth factor VEGF (C. Xia
et al., 2007), and they act as the initial signal for heat shock protein (HSP) 72 induction,
which in turn are molecular chaperones capable of cellular protection (Tang et al., 2007).
ROS Production with Acute
and Chronic Exercise
Contractile activity of skeletal muscle has been known to produce ROS since
1978, when Dillard et al. demonstrated that lipid peroxidation occurs during exercise
(Dillard, Litov, Savin, Dumelin, & Tappel, 1978). Since then, more than 300 articles
have directly investigated the effect of acute exercise on oxidative stress (FisherWellman & Bloomer, 2009). An early study reported that MDA increased in subjects
subjected to a graded exercise test to exhaustion, but not in those who exercised at 70%
of VO2 max or less (Lovlin, Cottle, Pyke, Kavanagh, & Belcastro, 1987). This helped
illustrate the dose-dependent nature of exercise-induced oxidative stress; a concept
already hypothesized because of increased flux through the electron transport chain, and
therefore increased electron leakage. Similarly, there was a significantly greater
concentration of plasma protein carbonyls following 120 minutes of steady state exercise
compared to 30 and 60 minutes of exercise at the same relative intensity (Bloomer,
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Davis, Consitt, & Wideman, 2007). Single bouts of exercise have been shown to alter
thiobarbituric acid reactive substances (TBARS), a marker of malondialdehyde and
phospholipid peroxidation (Radak et al., 1999), reactive carbonyl derivatives, a marker of
amino acid modification (Radak et al., 1998), and 8-hydroxydeoxyguanosine (8-OHdG),
a marker of DNA mutation (Asami et al., 1998; Niess, Hartmann, Grunert-Fuchs, Poch,
& Speit, 1996). Exercise can decrease the ratio of glutathione (GSH) to glutathione
disulfide (GSSD), indicating antioxidant depletion in response to oxidative stress
(Vollaard et al., 2005). As will be discussed later, transient, post-exercise oxidative stress
is a potent stimulus for increasing antioxidant enzyme activity, and ultimately confers
resistance to future ROS exposure.
Chronic exercise is also capable of measurably increasing markers of oxidative
stress. With chronic exercise, overtraining seems to induce oxidative stress, whereas
moderate exercise can reduce resting and post exercise ROS production (Finaud et al.,
2006; Ji, 2002). Excessive aerobic exercise, such as 30km/day for 8 days (Okamura et
al., 1997) and 10 hours/day for 30 days (Poulsen, Loft, & Vistisen, 1996) drastically
increased urinary 8-OHdG levels, even to a greater extent than intense, acute bouts of
exercise. Individuals with a compromised antioxidant defenses, such as cancer patients
during and following treatment, have a much lower threshold for such exercise-induced,
chronic oxidative stress.
While electron leak is clearly a primary source of ROS production, more recently,
alternate mechanisms of exercise-induced ROS have been proposed, supporting the
notion that ROS production is not simply a byproduct, but rather a tightly regulated
signaling system. Isometric contraction is capable of generating ROS, despite a
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negligible increase in mitochondrial oxygen flux (Alessio et al., 2000). More recently, it
was shown that mechanical loading (stretch) of isolated myotubes induced ROS
production, despite no change in oxygen flux (Chambers et al., 2009). The transverse
tubule NADPH oxidase produces superoxide in response to depolarization, stimulating
calcium release for muscle contraction (Espinosa et al., 2006; Hidalgo, Sanchez,
Barrientos, & Aracena-Parks, 2006), indicating superoxide’s vital signaling role in
muscular function, and an alternate pathway for exercise induced ROS production.
Similarly, NADPH oxidases of plasma membranes (Javesghani, Magder, Barreiro,
Quinn, & Hussain, 2002), as well as cardiac (Cherednichenko et al., 2004) and skeletal
(R. Xia, Webb, Gnall, Cutler, & Abramson, 2003) sarcoplasmic reticula may be
implicated in exercise-induced ROS production. Furthermore, following intense exercise
and muscular damage, phagocytic cells typically invade the area and contribute to the
total exercise-associated ROS production (Malech & Gallin, 1987). ROS production in
this manner can be significant enough to damage tissue that had been undamaged by the
exercise dose (Zerba, Komorowski, & Faulkner, 1990). Another consideration when
exercising outside is exposure to airborne pollutants that may directly or indirectly
increase oxidative stress (O'Neill et al., 1995). Alternate mechanisms may exist, but have
not been elucidated as of yet. For instance, the mitochondria from fast, type II muscle
fibers of rats have a greater inherent propensity to produce ROS (Anderson & Neufer,
2006). Interestingly, oxidative, type I muscle fibers still have higher antioxidant enzyme
capacity (Ji et al., 1992).
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Exercise Increases Antioxidant Capacity
Numerous studies indicate increased antioxidant enzyme activity (SOD, GPx,
CAT) in skeletal and cardiac muscle tissues and blood following endurance training in
animals and healthy humans (Finaud et al., 2006; Ji, 2002). While an acute bout of
exercise can transiently activate MnSOD gene transcription, substantial MnSOD
upregulation may require more chronic stimulation, or in other words, training (Hollander
et al., 1999). Aerobic training, in particular, has elicited augmentation of antioxidant
defense. Accumulation of 8-OHdG was significantly less in exercise trained (9wks
swimming) rats than age matched controls (Radak et al., 1999). Similarly, F2-isoprostane
levels (a measure of lipid peroxidation) decreased 34% in premenopausal women
following 15 weeks of aerobic exercise training (Schmitz et al., 2008). Surprisingly,
there is also evidence for mobilization of non-enzymatic antioxidants (vitamins C and E)
from body reserves during an exercise bout (Mastaloudis et al., 2001), but the plasticity
of this mechanism in response to training has not been characterized.
Regardless of the mechanism, acute exercise is clearly a potent mediator of ROS
formation. As discussed, these ROS are necessary signaling molecules, orchestrating
changes in muscle function, glucose uptake, and endothelial function. While exhaustive
exercise may result in transient oxidative stress, moderate levels of oxidative stress can
have a hormetic effect on antioxidant enzymes (Ji et al., 2006), imparting individual
tissues and the organism as a whole with a greater capacity to tolerate a serious oxidative
insult, such as ischemia-reperfusion injury, radiation, or chemotherapy.
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The Role of ROS in Aging and Diseases
Increased baseline oxidative stress in cancer patients may precipitate cancerrelated anorexia/cachexia (Mantovani et al., 2004). Specifically, cachexia has been
associated with elevated levels of muscle malondialdehyde, a marker of lipid
peroxidation and total body oxidative stress (Laviano et al., 2007). The mechanism
behind this may be an increase in protein degradation via the ubiquitin-proteasome
pathway upregulation in response to cancer or treatment-associated oxidative stress.
There is evidence indicating increased life span associated with calorie restriction (CR) in
many organisms, including rodents (Barger, Walford, & Weindruch, 2003; Masoro,
1988) primates, and humans (Cruzen & Colman, 2009; Ristow & Zarse, 2010), possibly
due to reduced free radical generation and increased antioxidant enzyme activity. Ristow
& Zarse, (2010) suggest an effect of mitochondrial hormesis (mitohormesis) in response
to both CR and exercise, in which exposure low level stress (ROS and otherwise) within
the mitochondria increases resistance to stress ameliorates oxidative stress which may
increase lifespan. In elderly rats (34 mo), a 50% loss of muscle mass occurred in hind
limb muscles but this was countered by CR (Weindruch, 1995). Caloric restriction
resulted in significantly increased GPX and CAT activity. Reactive oxygen species may
also contribute to sarcopenia and muscle aging, likely due to the combined effect of
premature cellular senescence, dysfunctional sarcoplasmic reticuli, and reduced
regenerative capacity (Fulle et al., 2004). Increased serum protein carbonyls were
associated with decreased grip strength in elderly women (mean age, 77.4 yrs),
suggesting that oxidative damage to contractile proteins may directly reduce strength and
therefore functional capacity (Howard et al., 2007).
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Although a low level of ROS production (“redox tone”) may be crucial for
contractile function at rest, increased ROS production results in oxidative stress and
decreased contractile function. Whereas antioxidant exposure at rest results in net
reduction in force development in response to electric stimulation (Reid et al., 1993),
during fatiguing stimulations, treatment with the superoxide scavenger, Tiron, augmented
force generation (Mohanraj, Merola, Wright, & Clanton, 1998). Oxidative stress can also
alter skeletal muscle function by modifying ryanodine receptors and the calcium pump in
SR membranes (Kagan, Ritov, Gorbunov, Menshikova, & Salama, 1998), specifically by
oxidation of critical channel proteins in the presence of high hydrogen peroxide levels
(Brotto & Nosek, 1996). Reactive oxygen species, therefore, may alter Ca++ movement
in and out of the cell, resulting in some degree of excitation-contraction uncoupling with
aging (Renganathan, Messi, & Delbono, 1997). Caloric restriction can preserve the
mechanical properties of hind-limb skeletal muscle in elderly rats, and is associated with
increased ryanodine receptor and dihydropyridine receptor activity (Mayhew,
Renganathan, & Delbono, 1998), possibly due to reduced oxidative damage.
Beyond its interrelationship with cancer (which will be discussed in full later),
oxidative stress has been implicated in the development or progression of numerous
chronic diseases, including diabetes (Houstis, Rosen, & Lander, 2006; Kojda & Harrison,
1999; Rudich et al., 1998; Wu, Chiou, Chang, & Wu, 2004), hypertension (Kojda &
Harrison, 1999), vascular disease (Kotur-Stevuljevic et al., 2007), cachexia (Mantovani et
al., 2004; McClung, Judge, Powers, & Yan, 2010), neurodegeneration (Pope, Land, &
Heales, 2008), cartilage degradation (Henrotin, Kurz, & Aigner, 2005), Parkinson’s
disease (Bloomer et al., 2008; Serra et al., 2001), and chronic heart failure (Eleuteri et al.,
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2009; Kojda & Harrison, 1999). Free radical damage is well recognized as a fundamental
mechanism of ischemia-reperfusion injury (Chan, 2001; Omar et al., 1990; Powers et al.,
1998). Some infectious diseases, such as influenza, Helicobacter pylori, and HIV, exert
their cytotoxicity via oxidative stress (Mates & Sanchez-Jimenez, 1999). Additionally,
generalized phenomena such as aging (Berlett & Stadtman, 1997; Finkel & Holbrook,
2000; Harman, 1956; Jackson, 2009b) fatigue, (Fulle et al., 2000; Richards, Roberts,
McGregor, Dunstan, & Butt, 2000; Richards, Wang, & Jelinek, 2007), muscle weakness
(Powers & Jackson, 2008; Smith & Reid, 2006) and muscle wasting (Moylan & Reid,
2007) are commonly attributed, at least in part, to oxidative stress.
Dietary and Other Exogenous Antioxidants
Dietary supplementation of antioxidants has been shown to prevent some of the
health promoting effects of exercise. Although chronic, continuous ROS exposure is
associated with insulin resistance (Houstis et al., 2006; Rudich et al., 1998), exercise
training, is well known to improve insulin sensitivity (Duncan et al., 2003; James,
Kraegen, & Chisholm, 1984). Ristow et al. (2009) demonstrated that the exerciseinduced ROS may be essential to mediate these changes. Both trained and untrained
groups improved indices of insulin sensitivity following exercise in the absence of
antioxidant supplementation (vitamin C and vitamin E), whereas antioxidants prevented
these improvements. Similarly, increased RNA expression of SOD and GPX was
inhibited by dietary antioxidant supplementation. Again, this demonstrates the beneficial
hormetic effect of repeated, transient ROS production due to exercise, and this may be
abrogated by dietary antioxidants.
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While exogenous SOD administration is an effective method of protection against
ischemia-reperfusion injury, very high doses of SOD can actually exacerbate the damage
(Omar et al., 1990). The apparent bell-shaped curve in the effectiveness of SOD in this
case may be due to over-scavenging of superoxide, which may actually reduce the
potential termination of lipid peroxidation by superoxide (LOO· + O2•- + H+ → LOOH +
O2) (McCord, 1993). This concept is supported by research showing that SOD
overproduction in transfected cells can mimic oxidative stress, by increased lipid
peroxidation (Elroy-Stein, Bernstein, & Groner, 1986). Additionally, endogenous
antioxidant enzymes are coordinately regulated, so that glutathione peroxidases and
catalases are upregulated in concert with SOD to match the currently level of ROS
production (McCord, 2008). Exogenous administration of any one of these alone will
likely result in aberrant redox regulation.
Because many cancer therapies are thought to initiate side effects such as
cardiotoxicity via oxidative stress, there have been numerous attempts to reduce such side
effects via antioxidant treatment. For instance, pretreatment of mice with
metallothionein, a free radical scavenging protein, attenuated doxorubicin-associated
cardiotoxicity without reducing its antitumor action (Naganuma, Satoh, & Imura, 1988).
Unfortunately, in humans, antioxidant therapy has failed to produce similarly positive
results (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). Moreover, antioxidant
supplementation has the potential to decrease oxidative damage to healthy tissues during
or following cancer treatment, it may also protect cancer cells, decreasing the
effectiveness of treatment. Lawenda et al., (2008) reviewed several clinical studies, and
concluded that antioxidant treatment, although potentially capable of reducing treatment-

51
related side effects, should be avoided because of the potential for reduced treatment
effectiveness. Most significant among these studies were two authored by Bairati et al.,
in which 540 cancer patients undergoing radiation were either given a placebo or
antioxidants (α-tocopherol with or without β-carotene). Although they reported a 38%
reduction in severe, acute side effect in the antioxidant group (Bairati, Meyer, Gelinas,
Fortin, Nabid, Brochet, Mercier, Tetu, Harel, Abdous, et al., 2005), this was accompanied
by a 29% and 56% reduction in the local tumor control rates for α-tocopherol and αtocopherol plus β-carotene, respectively. (Bairati, Meyer, Gelinas, Fortin, Nabid,
Brochet, Mercier, Tetu, Harel, Masse, et al., 2005). While some studies indicate that
antioxidant supplementation can reduce risk of mortality and recurrence (Nechuta et al.,
2011) and increase effectiveness of treatment (Chinery et al., 1997), and several authors
suggest that dietary AOX supplementation during treatment should be avoided because of
the contentious nature of the subject (Block, 2004; D'Andrea, 2005). A paper by
Achuthan et al. (2011) indicated that in chemotherapy resistant cancers, a primary
mechanism behind the failure of treatment regimens is low level of ROS associated with
the hypoxic environment in the cell. This suggests that reduced ROS in tumorous tissues
may support the survival of cancer cells.
Venkataraman et al. found that SOD overexpression inhibited the growth of
androgen-independent prostate cancer cells (Venkataraman et al., 2005), but in the
presence of a stressor (hyperthermia), SOD promoted cell survival (Venkataraman et al.,
2004). This illustrates the intricacies of redox balance, whereas cells are protected by
SOD in the presence of an environmental stressor, but are hindered by SOD in the
absence of a stressor. The supplementation of antioxidants during chemotherapy and
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radiation may similarly protect cancer cells from the environment stress of treatment
(Conklin, 2000). There is recent evidence that a state of reductive stress, characterized by
excessive levels of reducing equivalents, may be implicated in human disease, namely
cardiomyopathy caused by mutations in the alpha B-crystallin gene of mice (Rajasekaran
et al., 2007). It is possible that on overabundance of dietary antioxidants may similarly
result in other unfavorable effects, including the development and progression of cancer
(D. P. Jones & Go, 2010).
Cancer and Oxidative Stress
The interrelationship between cancer and oxidative stress is interesting, in that
oxidative stress is implicated in both the etiology and pathology of cancer (Laviano et al.,
2007; Loft & Poulsen, 1996; Toyokuni, Okamoto, Yodoi, & Hiai, 1995; C. Xia et al.,
2007). Reactive oxygen species are implicated in initiation, promotion and progression
of cancer, as well as inhibition of processes that can normally interrupt the cell cycle and
repair damage within cancer cells or otherwise initiate apoptosis (Valko et al., 2006).
The rise in ROS associated with breast cancer is common enough that a reduced
GSH/GSSG ratio has been identified as an important biochemical parameter for detecting
breast malignancy (Yeh et al., 2006). Further complicating things, both ROS and
antioxidants have been proposed as a treatments for cancer in recent years (Renschler,
2004; Tandon, Sharma, Mahajan, & Bardi, 2005; Trachootham, Alexandre, & Huang,
2009; J. Wang & Yi, 2008). Alternately, oxidative stress is capable of interfering with
cancer treatment (Shacter, Williams, Hinson, Senturker, & Lee, 2000), yet there is
evidence that antioxidants may also interfere with cancer treatment (Lawenda et al.,
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2008). Clearly, the normal physiological redox balance is delicate and complicated, and
is dependent on cell type, as well as endogenous and environmental stressors.
Oxidative Stress
A cursory comparison of exogenous sources of ROS production with known
carcinogens reveals striking parallels (e.g., chemotherapeutics, UV light, ionizing
radiation, environmental toxins). It is therefore not surprising that soon after the
discovery of ROS, Harman (1962) hypothesized that oxidative stress was implicated with
not just aging, but cancer as well. An abundance of epidemiological evidence supports
the notion that oxidative stress may promote cancer (Bjelakovic, Nikolova, Simonetti, &
Gluud, 2008; Dai et al., 2009; Hopkins, Fedirko, Jones, Terry, & Bostick, 2010; Li et al.,
2009; Loft & Poulsen, 1996; Matsui & Rai, 2008; Minelli, Bellezza, Conte, & Culig,
2009; Singh & Kulawiec, 2009; Valko et al., 2006; Zipprich et al., 2009). Additionally,
secondary cancers caused by radiation therapy are likely associated with oxidative stress
(Bostrom & Soloway, 2007). Several mechanisms confirming this interaction have been
identified (Loft & Poulsen, 1996; Valko et al., 2006), and will be discussed in the
proceeding section.
Mechanisms of ROS-Mediated
Carcinogenesis
ROS may potentiate carcinogenesis at various steps in cancer initiation,
promotion and progression. ROS are implicated in initiation by creating genomic
instability. For instance, hydroxyl radicals can react with guanosine to form 8hydroxydeoxyguanosine (8-OhdG), potentially resulting in G:C to T:A transversion point
mutations (Loft & Poulsen, 1996; Wu et al., 2004). As discussed previously, DNA
damage alone is not sufficient for cancer initiation. ROS-mediated signaling cascades
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can potentiate survival of cancer cells via proliferation, angiogenesis, metastasis and
resistance to apoptosis (Halliwell, 2007).
ROS promote cell proliferation primarily through activation of growth factor
receptors and intracellular signaling pathways (J. Wang & Yi, 2008). Elevated ROS
activate NFκB and AP-1, both of which mediate tumor cell proliferation (Laurent et al.,
2005). Additionally, ROS are capable of inhibiting protein tyrosine phosphatases, control
elements of numerous growth factor receptors, including platelet-derived growth factor
receptor (PDGFR), by oxidizing cysteine residues on their active site, ultimately
abolishing their negative regulatory function (Chiarugi, 2005; Meng, Fukada, & Tonks,
2002). In other words, even in the presence of their ligands, these growth factors
receptors are perpetually inactivated in the presence of sufficient ROS, resulting in
unconstrained growth.
ROS can similarly interact with protein tyrosine kinases, which are activated by
oxidation of their thiol groups, resulting in aberrant growth signaling (Chiarugi, 2005).
Vascular endothelial growth factor (VEGF) can promote tumor angiogenesis, and
NADPH oxidase (NOX)-associated H2O2 production has been shown to increase VEGF
expression (Arbiser et al., 2002). Supporting the notion that ROS mediate angiogenesis
via VEGF, Xia et al. (2007) demonstrated that NOX4 knockdown in ovarian cancer cells
resulted in decreased expression of VEGF and tumor angiogenesis. The metastatic
potential of several types of tumors is also associated with ROS level (Lim et al., 2005),
possibly due to altered expression of integrins, improved metastatic invasion, and
avoidance of anoikis, a type of programmed cell death associated with detachment from
the extracellular matrix (J. Wang & Yi, 2008). The size of benign tumors has been
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shown to be correlated with level of 8-OHdG, and therefore may trigger the transition
from benign to malignant tumor (Loft & Poulsen, 1996).
The precise redox status of a cancer cell, depending on cell type and cancer stage,
can alter the interaction between ROS and cancer treatment. Figure 3 (Valko et al., 2006)
shows the continuum of ROS exposure in cancer development. Lee and Shacter (1999)
found that H2O2 induced apoptosis in lymphoma within a very limited concentration
range (~50μm), but induced necrosis instead at higher concentrations (~75-100 μm).
Although the primary objective of cancer killing is achieved, necrosis invariably leads to
inflammation and more significant side effects. Shacter et al. (2000) later found that
including the antioxidants agents Desferal, Tempol, and dimethylsulfoxide in various
chemotherapy regimens enhanced chemotherapy-induced apoptosis and phagocytosis of
cancer cells, while reducing H2O2 associated ATP depletion, and subsequently cellular
necrosis and/or pyknosis (nucleus degeneration). Recalling that these effects are in
contrast to other studies, the disparity may be explained by variations in cancer type,
treatment type, and type of antioxidant treatment.
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Figure 3. The level of free radicals at various stages of carcinogenic process.
From “Free radicals, metals and antioxidants in oxidative stress-induced cancer”
in Chemico-Biological Interactions by Valko et al., 2006, pg 20.

Antioxidant Enzymes in Cancer Cells
Cancer cells have altered antioxidant enzyme expression (Oberley, 2002; Oberley
& Oberley, 1997; Trachootham et al., 2009). Depending on the type of tumor and the
location of the cell, manganese superoxide dismutase (MnSOD, found in mitochondria)
may be either increased or decreased, but enzyme activity is universally altered (Oberley,
2002). Most cancer cells exhibit reduced MnSOD, but metastatic prostate cells have
been shown to have increased MnSOD imparting particular resistance to treatment.
Similarly, cells at the invading edge of tumors often exhibited elevated levels of MnSOD.
Because there are no longitudinal studies on oxidative stress and cancer, it is difficult to
determine whether altered antioxidant enzyme expression is a cause, side effect, or
comorbidity of cancer. As has been mentioned previously, oxidative damage to DNA is
implicated in cancer development, and impaired antioxidant defenses may contribute to
this initial redox imbalance.
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Cancer Treatment Side Effects
Treatments for cancer such as surgery, chemo, radiation, and hormone therapies
result in detrimental physical and psychological side effects. The most frequently
reported symptom is cancer-related fatigue, which, according to the National Cancer
Institute, occurs in 14 to 96% of cancer survivors who have been treated for cancer
(National Cancer National Cancer Institute, 2013). Other side effects include
immunosuppression, cardiomyopathy, neurological dysfunction, and reduced aerobic
fitness and muscular strength. Loss of physical function and the ordeal of cancer
treatment can be a psychological, social, and economic burden, resulting in a further
reduction in quality of life and an increased level of depression
Immune System
Both radiation and chemotherapy are associated with hematological toxicities and
cause myelosuppression by damaging the blood cell-producing machinery of the bone
marrow and directly destroying mature, circulating leukocytes (Schneider et al., 2003).
Leukopenia is a condition in which the total leukocyte count is reduced. Neutropenia
describes an absolute decrease in the number of circulating neutrophils, and greatly
increases the risk of infection. Lymphocytopenia results from low white blood cells
production in the lymph system. Thrombocytopenia is a condition characterized by low
levels of circulating platelets. All of these conditions result in immunosuppression, and
can result from cancer therapy, or the disease itself. Extreme immunosuppression can
become the limiting factor in treatment dosage, and increases the risk of prescribing
exercise to cancer patients, as intense and even moderate exercise can also suppress the
immune system (Langhorne et al., 2007; Schneider et al., 2003)
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Cardiorespiratory Fitness
Data from the Rocky Mountain Cancer Rehabilitation Institute (RMCRI)
illustrates the severely reduced cardiorespiratory fitness of cancer survivors. Average
VO2 peak values for the RMCRI cancer population were markedly lower than the general
US population, with a median VO2 value of 22 mL/kg/min, and a mean of 21.6 ± 6.3
mL/kg/min (unpublished data). When using norms for the general US population
(Thomson, Gordon, & Pescatello, 2010), the mean value for all age and gender groups
were classified as “very poor.” Similarly, individuals who had been treated with
chemotherapy in childhood retained significantly reduced cardiorespiratory fitness, as
evidenced by VO2 max values that are often only 50% - 70% of age- and gender-matched
controls (Johnson et al., 1997). Even in very fit cancer patients, radiation and
chemotherapy can substantially reduce cardiorespiratory fitness. Schumacher et al.
(2008) showed that a 37% decrease in total hemoglobin mass in an elite endurance athlete
following cancer diagnosis and chemotherapy was associated with a 42% reduction in
aerobic capacity. Additionally, Wiley (1998) demonstrated an average decrease in
VO2max from 28.23 ± 5.54 mL/kg/min before surgery and chemotherapy, to 24.52 ± 6.13
mL/kg/min after both surgery and chemotherapy in ten women with stage II breast
cancer. Primary causes of decrements in cardiorespiratory fitness include anemia
(Barrett-Lee et al., 2006; Glaspy, 2001; Harrison et al., 2001), cardiotoxicity (Ascensao,
Ferreira, Oliveira, & Magalhaes, 2006; Chaiswing et al., 2004; B. Chen, Peng,
Pentassuglia, Lim, & Sawyer, 2007; Chicco, Hydock, Schneider, & Hayward, 2006;
Hayward & Hydock, 2007; Hydock, Lien, Schneider, & Hayward, 2008; Kanter et al.,
1985; Wonders, Hydock, Schneider, & Hayward, 2008), skeletal muscle degradation (Al-

59
Majid & Waters, 2008; Bonetto et al., 2009; Laviano et al., 2007), and mitochondrial and
metabolic dysfunction (Kovacic, Pozos, Somanathan, Shangari, & O'Brien, 2005).
Cardiovascular System
Reduced cardiorespiratory fitness following cancer therapy is often demonstrated
by the damage to systems supporting aerobic capacity, particularly in the animal model.
The majority of cancer patients receiving chemotherapy (Barrett-Lee et al., 2006; Kitano
et al., 2007) and radiation (Harrison et al., 2001) develop anemia. Numerous
chemotherapy treatments, particularly antitumor anthracyclines such as doxorubicin, are
characterized by a dose dependent cardiotoxicity (Simunek et al., 2009), resulting in
altered myosin heavy chain expression, reduced left ventricular mass, relative wall
thickness, fractional shortening, and mean and maximal flow velocity in rats (Chicco,
Hydock, et al., 2006; Hayward & Hydock, 2007; Hydock, Lien, & Hayward, 2009).
Doxorubicin cardiotoxicity-caused morphological damage within the myocardium is
often apparent when left ventricular ejection fraction (LVEF) falls below 45%, and may
result in congestive heart failure (Ng et al., 2006). In animal studies, doxorubicin has
been shown to inactivate important mitochondrial enzymes, such as myocardial
cytochrome c oxidase (Chandran et al., 2009). Further treatment-associated side effects,
including additional mitochondrial (Miyagawa et al., 2010) and cardiac pathologies
(Meinardi et al., 1999), cachexia (Samuels et al., 2000; Takahashi, Yasumoto, & Mai,
2005), and pulmonary and endothelial dysfunction, are well established in the clinical
oncology and cancer rehabilitation literature (DeVita, 2005; Schneider et al., 2003). The
individual or combined effects of any of these pathophysiological defects, in addition to
the tumor burden itself, is capable of reducing aerobic capacity. Furthermore, the
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majority of cancer survivors experience fatigue following cancer treatment (Kasper &
Sarna, 2000; Smets, Garssen, Schuster-Uitterhoeve, & de Haes, 1993; Winningham,
2001), which often results in reduced physical activity and subsequent deconditioning.
Animal models also indicate reduced physical activity with chemotherapy treatment.
Hydock et al. found that voluntary wheel running in rats reduced significantly within two
weeks of doxorubicin treatment, and was reduced to less than 50% of baseline by week 5
(Hydock, Wonders, Schneider, & Hayward, 2009).
Doxorubicin, in particular, has been extensively studied because it is a very
effective antineoplastic agent, but is associated with severe, dose-dependent
cardiotoxicity (Ascensao et al., 2006; B. Chen et al., 2007; Chicco, Hydock, et al., 2006;
Hayward & Hydock, 2007; Hydock et al., 2008; Wonders et al., 2008). Oxidative stress
is among the mechanisms attributed to the DOX-induced cardiomyopathy (Chaiswing et
al., 2004; Kanter et al., 1985), in addition to apoptosis (Arola et al., 2000), metabolic
alterations (Wakasugi et al., 1993), and cardiac myosin heavy chain shifts (Hydock,
Wonders, et al., 2009). While the primary antineoplastic mechanisms of DOX are
inhibition of topoisomerase II and intercalation in DNA, resulting in inhibition of DNA
replication and RNA transcription, the induction of ROS may contribute to antitumor
activity (Figure 4). Some authors even argue that “induction of oxidative stress is
responsible for most if not all biological activity” of anthracyclines (Taatjes et al., 1998).
Antioxidant therapy has been investigated as a means to minimize doxorubicin
cardiotoxicity, with mixed results. Grape seed proanthocyanidins, a dietary antioxidant
supplement, have been shown to improve tumor response rates and mitigate DOXinduced myocardial oxidative stress in tumor-bearing mice (X. Y. Zhang, Li, Wu, & Gao,
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2005). In contrast, patients receiving high doses of vitamin E or N-acetylcysteine failed
to exhibit reduction of cardiomyopathy in clinical trials (Myers et al., 1983; Unverferth et
al., 1983). The use of the iron chelator dexrazoxane (DRZ) has also been used as a
method to reduce cardiotoxicity (Moss, 2007). While DRZ is able to reduce the
incidence of contractile dysfunction, the possibility that it may reduce DOX efficacy has
prevented its universal use.

Figure 4. Doxorubicin-induced generation of ROS/RNS in the heart. From Collateral
damage in cancer chemotherapy: oxidative stress in nontargeted tissues in Molecular
Interventions, 7(3). By Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., and St
Clair, D. K. Copyright 2007, p. 147-156.
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Fatigue
Fatigue associated with both cancer and cancer treatments has been well
documented for decades (Piper, Lindsey, & Dodd, 1989; Questad, Malec, Harvey,
Kienker, & Romsaas, 1982; Rieger, 1988; Smets et al., 1993). Fatigue is the most
frequently reported symptom in cancer survivors and is similar in nature to chronic
fatigue syndrome, as both are more chronic and debilitating than standard fatigue,
causing individuals to alter their behavior and demeanor, but all patients experience
cancer-related fatigue differently (de Jong, Courtens, Abu-Saad, & Schouten, 2002).
Because fatigue is both a physiological and psychological condition, it is difficult to
pinpoint a specific mechanism, but there are likely many. Some proposed factors
contributing to fatigue are muscular wasting related to cachexia, sleep disturbances,
psychological depression, (Piper, Lindsey, & Dodd, 1987), anemia (de Jong et al., 2002),
increased metabolic byproducts (e.g., inflammatory cytokines) and metabolic imbalance
due to increased energy requirement (e.g., due to tumor growth), decreased metabolic
capacity (mitochondrial damage), and decreased substrate availability (due to anorexia,
nausea, or vomiting) (Glaspy, 2001).
While there is a lack of evidence explicitly relating oxidative stress to cancerrelated fatigue, most of the proposed mechanisms of fatigue can be driven by ROS and
oxidative stress. Indirect evidence comes from Gramignano et al., who demonstrated
that four weeks of L-carnitine administration successfully reduced both fatigue, and
resulted in a non-significant decrease in oxidative stress in patients currently undergoing
cancer treatment (Gramignano et al., 2006). Chronic fatigue syndrome, a very similar
pathology, has been associated with oxidative stress (Jammes, Steinberg, Mambrini,
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Bregeon, & Delliaux, 2005) and glutathione deficiency (Bounous & Molson, 1999). The
hypothesized interaction between oxidative stress and fatigue warrants further
investigation.
Muscular Strength
Decreased strength following cancer treatment is a significant factor in decreased
quality of life in cancer patients (Courneya & Friedenreich, 1999; Extermann et al., 2006;
Kasper & Sarna, 2000; Schneider et al., 2003). The primary mechanism of loss of
muscular strength with cancer and cancer treatment appears to be related to cachexia and
muscle wasting. Numerous studies link cancer and treatment-related ROS production
with cachexia, among other potential mechanisms (Laviano et al., 2007; Mantovani et al.,
2004). Oxidative protein damage has been shown to be associated with poor grip
strength in healthy elderly women (Howard et al., 2007).

The loss of muscle mass and

cardiovascular fitness is compounded by significant decreases in physical activity
following treatment. Studies have shown that muscular endurance declines after only
two weeks of physical inactivity in healthy individuals (Haddad, Roy, Zhong, Edgerton,
& Baldwin, 2003), and oxidative enzymatic activity decreases following 3 months of
inactivity (Coyle et al., 1984). Fortunately, it has been demonstrated that resistance
exercise can prevent or reverse losses in muscular strength (Schneider et al., 2007a) and
muscle wasting. This exercise-induced protection against muscle wasting appears to be
at least partially due to a reduced oxidative damage in the skeletal muscles of rats treated
with DOX. Exercise was shown to diminish skeletal muscle protein oxidation and
increase antioxidant enzymes, and subsequently reduce expression of autophagy genes
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(Smuder, Kavazis, Min, & Powers, 2011a) and proteases such as caspase-3 (Smuder,
Kavazis, Min, & Powers, 2011b).
Cancer Treatment-Related Side Effects
and Oxidative Stress
Both cancer and its treatments induce considerable oxidative stress. Even the
physiological stress of surgery is capable of producing enough ROS as a side effect to
facilitate increased growth of metastatic tumors (Hyoudou, Nishikawa, Kobayashi,
Umeyama, et al., 2006).

Because treatment-associated oxidative stress is implicated in

cancer-related fatigue (Fulle et al., 2000), cachexia (Laviano et al., 2007),
cardiomyopathy (Ascensao et al., 2005b), and neuropathy (Kannarkat, Lasher, & Schiff,
2007), it often governs the tolerance limit of treatment. Treatment-associated oxidative
stress also can result in second malignancies, also known as treatment-induce cancer
(Bostrom & Soloway, 2007). Additionally, cancer cells have lower levels of MnSOD,
GPx and CAT, but produce high levels of hydrogen peroxide (Oberley, 2002), resulting
in greater oxidative stress in cancer patients even prior to cancer therapy.
Cancer treatments, particularly radiation and chemotherapy, are associated with
significant, whole-body side effects, many of which are associated with oxidative stress.
Whereas radiation therapy actually depends on free radical generation as a means of
destroying cancer cells (Ahn et al., 2006), oxidative stress associated with chemotherapy
is often a side effect. Doxorubicin (DOX), for instance, is a very effective anti-cancer
agent, but is known for its cardiotoxic effects (Chaiswing et al., 2004; Y. Chen et al.,
2007; Gilliam et al., 2009; Hayward & Hydock, 2007; Shacter et al., 2000; Simunek et
al., 2009). Although DOX kills cancer cells through DNA inhibition and topoisomerase
II inhibition, it damages heart, kidney and brain tissue through oxidative stress. Of the
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Table 3
Chemotherapy drugs known to induce significant oxidative stress
Class (subclass)

Drug Name

Trade Name

bleomycin
mitomycin
Doxorubicin
epirubicin
daunorubicin

Blenoxane
Mitomycin-C, MTC
Adriamycin
Ellence
Daunomycin

Anti-neoplastic antibiotics

(Anthracyclines)

Alkylating agents
(Mustard gas
derivatives)

(Alkyl sulfonate)
Platinum coordinating
complexes

mechlorethamine
cytophosphane /
cyclophosphamide
ifosfamide
Uramustine
Melphalan
chlorambucil
Busulfan

cisplatin
carboplatin
oxaliplatin
Nedaplatin
satraplatin
triplatin tetranitrate

chlormethine, mustine,
Mustargen
Endoxan, Cytoxan, Neosar,
Procytox, Revimmune
Mitoxana, Ifex
Alkeran
Leukeran
Busulfex, Myleran

Aqupla

Nitrosoureas
Carmustine
Lomustine
Streptozotocin

Streptozocin, STZ, Zanosar

etoposide
teniposide

Eposin, Etopophos, Vepesid,
VP-16
Vumon, VM-26

topotecan
irinotecan

Hycamtin
Camptosar, Campto

Epipodophyllotoxins

Camptothecins

Other
fluorouracil (5-FU)
cytarabine
tamoxifen

Adrucil, Carac, Efudex and
Fluoroplex
cytosine arabinoside or Ara-C
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132 FDA approved anticancer drugs, 56 are known to induce oxidative stress (Chen et
al., 2007). Table 3 lists chemotherapy drugs known to induce substantial oxidative stress.
While late effects of radiation treatment have been associated with chronic oxidative
stress (Robbins & Zhao, 2004; Zhao & Robbins, 2009), there is little information
regarding long-term effects of chemotherapy on oxidative stress.
Currently, there is no good characterization of the time-course of chronic
oxidative stress status following the end of cancer chemotherapy or radiation treatment in
the literature. Many papers evaluate oxidative stress while patients are undergoing
treatment (Cetin et al., 2004; Conklin, 2000; Honda, Yamada, Tomonaga, Ichinose, &
Kamihira, 2000; Sabitha & Shyamaladevi, 1999; Weijl et al., 1998) or within hours and
days after treatment (Sangeetha, Das, Koratkar, & Suryaprabha, 1990), but rarely
evaluate markers of oxidative stress or antioxidants more than a week after the end of
treatment. In mice, extracellular MDA levels remained elevated one week after
chemotherapy, and oxidized glutathione was significantly higher than controls 6 weeks
after treatment (Abushamaa, Sporn, & Folz, 2002). Unfortunately, it is difficult to
extrapolate these data to humans due to varying lifespans. Jonas et al. (Jonas et al., 2000)
found that GSH/GSSG ratio continually decreased over the two weeks following the end
of treatment, indicating either that treatment directly impairs the antioxidant system, or
that chronic oxidative stress is capable of depleting the glutathione pool and diminish
reductive capacity.
While some studies show increased oxidative stress in response to treatment
(Abushamaa et al., 2002; Cetin et al., 2004; Faber, Coudray, Hida, Mousseau, & Favier,
1995; Sangeetha et al., 1990), others indicate a lower level of oxidative stress following
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treatment compared to pretreatment, likely due to reduced tumor burden. For instance,
Gadjeva et al. (Gadjeva, Dimov, & Georgieva, 2008) found that plasma MDA
concentration dropped in melanoma patients following surgery. While chemotherapy
subsequently increased oxidative stress compared to post-surgery levels, MDA levels
were still significantly lower than pre-surgery values. This discrepancy is likely due to
variations in treatment method and cancer type. Moreover, Erhola et al. (Erhola et al.,
1997) found that the overall response to chemotherapy (“complete or partial remission”,
versus “no change or progressive disease”) determined whether urinary 8-OHdG
concentration increased or decreased. Therefore it appears that it is justifiable to further
investigate the level of oxidative stress in patients in the weeks and months following
cancer treatment.
Targeted delivery of SOD (Hyoudou et al., 2008) or catalase (Hyoudou,
Nishikawa, Kobayashi, Umeyama, et al., 2006) to cancer cells have the potential to
inhibit proliferation and metastasis, largely by decreasing the ROS-mediated growth
signaling. At this time, no clinical trials have been conducted to confirm the
effectiveness of these strategies. An alternate strategy to reduce ROS in cancer cells is
inhibition of NADPH oxidase, which in turn reduces VEGF signaling, which may inhibit
tumor growth. NADPH oxidase inhibition with minodronate (Kubo et al., 2006; Sato et
al., 2006) and histamine (Agarwala & Sabbagh, 2001) have been demonstrated to be
effective cancer treatment methods in clinical trials. In the case of ROS production
following oncological surgery, administration of catalase successfully inhibited
metastatic growth (Hyoudou, Nishikawa, Kobayashi, Kuramoto, et al., 2006).
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Alternately, the use of targeted ROS production has been used as a cancer
treatment, both as a single agent, employing ROS to destroy cancer cells, or as an
adjuvant therapy to facilitate the therapeutic effects of radiation and chemotherapy (Fang
et al., 2009; Manda et al., 2009; Trachootham et al., 2009; J. Wang & Yi, 2008). Because
cancer cells often have chronically elevated oxidative stress due to increased ROS
production, reduced antioxidant capacity, or both, exogenous ROS may be sufficient to
trigger cellular death. Indeed, most cancer therapies increase ROS as a primary or
secondary mechanism of antitumor activity. Procarbazine, a ROS-producing
antineoplastic drug, has been used alone and in conjunction with radiation since the
1960s (Renschler, 2004). Even then, Berneis and colleagues recognized that ROS
mediated the anticancer effects of the drug (Berneis, Kofler, Bollag, Kaiser, &
Langemann, 1963). Radiation therapy has been used as a treatment for cancer for even
longer, about 100 years, owing largely to Marie Curie, but the production of ROS by
radiation was not recognized until 1948 (Stein & Weiss, 1948). Later, Harman identified
the implication of free radicals in the ability of radiation to both treat and cause cancer
(Harman, 1956, 1962).
Today, we have alternate methods of ROS induction to treat cancer. As
previously mentioned, augmenting ROS induction with hyperbaria during radiation
treatment can improve its efficacy. Another approach to this involves administration of
radiation sensitizers, which include the drug classes tirapazamine, 2-nitroimidazoles, and
indolequinones (Kovacic, 2007). A more recently developed anticancer modality is
called photodynamic therapy (J. Wang & Yi, 2008). In this treatment, a drug
(photosensitizer) is injected into the bloodstream, and is absorbed by all body cells, but

69
tends to stay in cancer cells longer. Approximately 24 to 72 hours later, the
photosensitizer is activated by light, producing ROS that can destroy the cells containing
the drug (Dolmans, Fukumura, & Jain, 2003). Inhibition of antioxidant enzyme defense
within tumor cells to induce ROS has also been explored. Β-phenylethyl isothiocyanate
is a natural compound that depletes cellular GSH and inhibits the GPx enzyme, resulting
in severe ROS accumulation in malignant cells (Trachootham et al., 2006).
Methoxyestradiol, an anticancer agent in clinical trials, inhibits SOD and induces
apoptosis in leukemia cells (J. Wang & Yi, 2008).
One particularly valuable use of pro-oxidant therapy may the reduction of drugresistance in tumors. A decreased reductive state, specifically increased glutathione
redox potential, has been long recognized as a factor in acquired multidrug resistance
(Kramer et al., 1988). The introduction of either a NADPH oxidase (NOX1)
(Wartenberg et al., 2005) or a ROS-producing agent (emodin) (Pelicano, Carney, &
Huang, 2004) into cancer cells can reduce multi-drug resistance via decreased expression
of the multi-drug resistance transport and hypoxia-inducible factor 1α.
Exercise Before, During, and Following
Cancer Treatment
The beneficial effects of exercise on cardiopulmonary function, strength, and
overall health status in healthy individuals has been well-documented for decades. The
role of exercise to promote improved physical and mental health and rehabilitation in the
cancer population during and following cancer treatments has only more recently become
recognized as important. In the 1980s, Winninghan et al. conducted some of the first
studies investigating the effect of exercise on cancer treatment-related side effects
(MacVicar, Winningham, & Nickel, 1989; Winningham, 1983; Winningham &

70
MacVicar, 1988; Winningham, MacVicar, Bondoc, Anderson, & Minton, 1989). In the
more than 20 years since then, a growing body of evidence has supported the use of
exercise as a means to rehabilitate individuals from cancer and treatment-related side
effects.
Exercise during treatment is known to increase tolerance for higher doses of
chemotherapy (Chicco, Schneider, et al., 2006), and exercise following treatment can
reduce or reverse the damaging side effect of cancer treatments (Hydock et al., 2007) and
even reduce the chance for cancer recurrence (Courneya, 2003). In particular, resistance
and aerobic exercise have been found to be beneficial as a means to reduce fatigue, while
improving quality of life (QOL), muscular strength and endurance, and cardiorespiratory
endurance (Courneya et al., 2007; Schneider et al., 2007a, 2007c). Exercise following
surgery has been shown to be beneficial in increasing the natural killer (NK) cell
cytotoxic activity (NKCA) , suggesting that exercise may play a role in cancer treatment,
rather than simply rehabilitation (Na et al., 2000). Like so many physiological and
pathophysiological processes, NKCA are known be mediated (in this case, inhibited) by
ROS, (Betten, Dahlgren, Mellqvist, Hermodsson, & Hellstrand, 2004) perhaps explaining
the increase following exercise and the decrease associated with cancer (Mellqvist et al.,
2000).
Cardiorespiratory Fitness
While it may seem intuitive that an aerobic exercise intervention improves
cardiorespiratory fitness in cancer survivors, the reasons for the reduced fitness level in
this population are complex and multifactorial, potentially altering the normal
physiological alterations in response to exercise. Because exercise was not a commonly
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prescribed intervention in cancer survivors until 15 years ago, there had previously been
little evidence to support the exercise as a rehabilitation modality. There is now a very
large body of evidence demonstrating the effectiveness of an exercise intervention for the
improvement of cardiorespiratory fitness (Courneya et al., 2003; Courneya et al., 2007;
Dimeo et al., 2004; Schneider et al., 2007c; Segal et al., 2009). Unpublished data from
the Rocky Mountain Cancer Rehabilitation Institute indicates that improvement in
cardiopulmonary fitness, and fatigue following a 3-month, multimodal exercise program
did not differ between cancer types, regardless of baseline values. A recent study in
leukemia patients currently receiving high-dose treatment indicated that an in-hospital
exercise intervention significantly improved performance in a submaximal cycle
ergometer test time to termination, from 8.9 ± 8.8 minutes at baseline to 17 ± 14.3
minutes post-intervention (Battaglini et al., 2009). In a 2011 meta-analysis investigating
the effect of exercise on VO2 peak, pooled data of all six studies (571 adult cancer
patients; 344 exercise and 227 usual care control) indicated that exercise training
significantly increased VO2 peak (+2.90 ml·kg-1·min-1), whereas usual care was
associated with a decline in VO2 peak (-1.02 ml·kg-1·min-1) (L. W. Jones, Liang, et al.,
2011).
There has been relatively scarce clinical confirmation of mechanisms of exerciseinduced improvements in (or maintenance of) cardiorespiratory fitness in cancer patients
during or following cancer treatment. In a study by Dimeo et al. (1997), cancer survivors
who participated in an exercise program following high dose chemotherapy had higher
aerobic capacity as well as increased hemoglobin concentration compared to nonexercisers. Animal studies indicate numerous potential mechanisms of improved or
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maintained cardiorespiratory fitness, many of which include cardiac preservation via
increased myocardial antioxidant status (Kanter et al., 1985; Pushpalatha, Nishanth, &
Sathyavelu Reddy, 2007; Simunek et al., 2009; Wouters, Kremer, Miller, Herman, &
Lipshultz, 2005). Other possible mechanisms include reduced inflammatory cytokines
(Battaglini et al., 2009), increased or maintained muscle mass (Laviano et al., 2007) and
mitochondrial hormesis (Ji et al., 2006; Ristow & Zarse, 2010).
Fatigue
Because cancer related fatigue is multifactorial, appropriate treatment for this
condition is difficult to determine. Treating this fatigue as a psychological pathology
alone, using pharmacological methods (Bruera, Roca, Cedaro, Carraro, & Chacon, 1985;
Rozans, Dreisbach, Lertora, & Kahn, 2002) or counseling (Gramignano et al., 2006), has
been generally ineffective. Alternately, exercise has been shown to have significant
therapeutic benefit (Dimeo, 2001), and daytime inactivity may actually worsen fatigue
symptoms (Berger & Farr, 1999). Various methods of prescribed exercise, including
resistance and aerobic exercise, both supervised and at home, have been shown to
improve fatigue symptoms in cancer patients following treatment (Courneya &
Friedenreich, 1999; Courneya et al., 2007; F. Dimeo et al., 2003; F. Dimeo, Schwartz,
Wesel, Voigt, & Thiel, 2008; F. C. Dimeo, 2001; Hsieh et al., 2008; Peddle, Au, &
Courneya, 2008; Saylor & Smith, 2009; Schneider, Hsieh, Sprod, Carter, & Hayward,
2007b; Schneider et al., 2007c; Schwartz, 2007; Smets et al., 1993).
Studies have indicated that the effect of exercise on cancer-related fatigue may be
associated with modulation of 5-HT neurotransmitter regulation, vagal afferent
activation, muscle and ATP metabolism, hypothalamic–pituitary–adrenal axis function,
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circadian rhythms, and/or cytokine regulation (Ryan et al., 2007). To date, there has been
no research regarding the interaction between cancer related fatigue and oxidative stress.
Because individuals with chronic fatigue disorders have an amplified oxidative stress
response from an acute exercise bout (Jammes et al., 2005) it is reasonable to postulate
that an exercise intervention capable of increasing antioxidant enzyme capacity may
reduce postexertional fatigue following an exercise intervention.
Muscular Strength
As has been noted, cancer patients often suffer from muscle wasting disorders, or
more generalized losses in muscular strength. A whole-body, 6-month exercise
intervention was capable of significantly increasing muscular fitness for bench press
(+47.6%), lat pull-down (+51.1%), leg press (+67.1%), shoulder press (+41.8%), and
curl-up crunches (+32.5%) in cancer patients following the end of treatment (Schneider et
al., 2007a). Remarkably, this exercise intervention also increased muscular fitness for lat
pull-down (+83.6%) and leg press (49.7%) in cancer patients still undergoing radiation or
chemotherapy. Similarly, Courneya et al., (2007) found that an isolated resistance
exercise training (RET) program increased muscular strength in breast cancer patients
receiving chemotherapy 25% to 35%. This finding was accompanied by an increased
chemotherapy completion rate, from 84.1% in a usual care group, versus 89.8% in the
RET group, as well as an increase from 65.9% (usual care) to 78.0% (RET) of patients
who received at least 85% of their planned relative dose intensity. These findings
indicate that exercise training can increase treatment tolerance as well as muscular
strength, possibly due to reduced treatment toxicity related to oxidative damage.
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Despite the recognition that oxidative damage plays a role in cancer treatment
side effects, the literature describing these mechanisms often fail to suggest exercise as a
means of attenuating this damage. Instead, antioxidant or pharmacological treatment is
suggested. A noteworthy exception to this is paper by Peng et al. (2005), which
acknowledged the biological and therapeutic benefits of exercise as a strategy of
improving physiological function and quality of life in cancer survivors. The authors also
mention the difficulties of attracting research funding for a therapy that is inherently free,
and therefore is not a wise investment for private funding agencies or pharmaceutical
companies. Simultaneously, cancer rehabilitation researchers espouse the use of
exercise, but rarely investigate the underlying mechanisms for the efficacy of exercise.
Therefore, further biochemical and genetic studies regarding the mechanisms underlying
the effectiveness of exercise as a means to minimize side effects in cancer patients during
and following treatment are warranted.
Counteracting Cancer Treatment-Associated
Oxidative Stress With Exercise
Although it was in a non-cancer population, Parise et al. (2005) offer some insight
for the prescription of exercise as an intervention to counteract oxidative stress. This
study evaluated antioxidant enzyme activity in the vastus lateralis muscle of both legs of
older males (71 ± 7 yrs) following unilateral resistance exercise training. There was a
significant increase in catalase and CuZnSOD activity, as well as muscular strength in the
subjects’ training leg, but not in the untrained leg. This demonstrates the importance of
total body exercise interventions in cancer survivors, as training effects and changes in
antioxidant enzyme capacity are local. Additionally, it may be surmised that because of
this localized change in antioxidant capacity, antioxidant enzymes should increase in
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active tissue, but not in cancer cells. Krause et al. indicated that antioxidant enzymes
may not be sufficient to protect cardiac cells against damage, as illustrated by a lack of
effect by antioxidant therapy. Additional aspects of antioxidant defense, such as
multidrug resistance-associated proteins (MRP) and MRP1 gene product (a GS-X pump
ATPase), a physiological GSSG transporter, may play a role in total body antioxidant
capacity (Krause et al., 2007). This illustrates that exercise, and multi-system,
multidimensional, intervention, may be superior to pharmacological interventions as a
method to reduce treatment-related side effects mediated by ROS.
Wonders et al., (2008) reported that doxorubicin treatment increased left
ventricular MDA concentrations in sedentary rats, but rats that had performed an acute
exercise bout 24 hours before receiving treatment had no increase in MDA . This
accompanied an attenuation of doxorubicin cardiotoxicity, indicating a protective role of
exercise, possibly via resistance to oxidative stress. Yamashita et al., (1999), found that a
single bout of exercise resulted in time sensitive changes in infarct size in mice exposed
to left ventricular artery occlusion. Exercise was most protective against infarction at 0.5
and 48 hours prior to LVA occlusion, which was mirrored by significant increases in
MnSOD activity at those time points only. Furthermore, mice treated with N-2
mercaptopropionyl glycine (MPG), a synthetic analog of glutathione, completely
eliminated the protective effect of exercise against infarction at both 0.5h and 48h as well
as the increase MnSOD activity. The antioxidant activity of MPG prevented the
moderate, transient oxidative stress normally produced by exercise, thereby interrupting
the redox-sensitive signaling cascade, which would ultimately increase MnSOD via the
hormesis. Both of these studies suggest that the protective mechanism of exercise against
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chemotherapy induced damage (in these instances, cardiotoxicity) is at least partly due to
upregulation of antioxidant enzymes following a transient, low level increase in oxidative
stress (i.e., exercise). Unfortunately, there has been no research investigating the role of
exercise (and subsequently increased antioxidant capacity and reduced chronic oxidative
stress) following treatment as a mediator of reduced chronic side effects related to cancer
treatment.
Perhaps the best evidence for improved antioxidant defense in cancer survivors is
a 1985 study by Kanter et al. (1985). This group randomly assigned rats to exercise (n =
53) and nonexercise (n = 52) groups. After nine weeks of swim training, nine rats from
each group were sacrificed and tissue and blood samples were taken. The remaining rats
were then subdivided into swim trained, swim trained-DOX treated, sedentary, and
sedentary-DOX treated. After an additional twelve weeks, tissue and blood samples were
taken, and the rats were tested for CAT, SOD, and GPx. Swim training significantly
reduced cardiotoxicity of doxorubicin and increased blood values for all three antioxidant
enzymes (Table 4). Heart antioxidant levels of DOX treated swimmers were lower
compared to nontreated swimmers, indicating that DOX not only produces ROS, but also
decreases antioxidant enzyme capacity. Therefore it seems wise to prescribe exercise to
patients for a time before chemotherapy, if possible, to augment antioxidant capacity
before treatment. This also indicates that certain cancer treatment regimens may induce
both acute (ROS production) and chronic (antioxidant defense disturbances) changes in
redox balance in cancer patients.
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Table 4
Enzyme activity following 9 weeks of exercise training
Group
Catalase
Glutathione Peroxidase

Superoxide Dismutase

Swim

122.2 ± 21.0*

10.9 ± 0.6*

247.1 ± 21.2*

Sedentary

74.9 ± 11.8

8.3 ± 0.6

164.2 ± 18.5

Note: Values are expressed as enzyme units/ml blood. * Significantly greater than
sedentary. Adapted from Kanter et al. 1985.

A more recent article by Ascensao et al., (2005a) expanded on these findings.
Using a similar swim-training protocol as Kanter, this group found that DOX treatment
increased GSSG and GSSG% (indicating a strain on the glutathione antioxidant system)
but this effect was countered by swim training. Cardiac damage was evaluated by
cardiac troponin I (cTnI) presence in the plasma. Exercise trained mice treated with
DOX had significantly less cTnI than non-exercise trained mice treated with DOX (0.65
vs. 1.40 ng/ml). Although swim training did not result in significant differences in total
antioxidant status or CAT, SOD, GPx, or glutathione reductase activity between exercise
and non-exercise DOX groups, there were clearly changes in antioxidant defense, as
reduced glutathione levels increased substantially compared to exercised mice treated
with a placebo or non-exercise mice treated with DOX. Additionally, both exercise
groups (DOX and placebo) had significantly lower cardiac muscle protein carbonyls than
the non-exercised DOX group.
Although there have been few human studies investigating the effect of exercise
on antioxidant capacity in cancer patients, Bloomer et al. (2008) studied the effect of
resistance training on blood oxidative stress in Parkinson disease, another disease
implicated with oxidative stress. Thirteen subjects with Parkinson’s disease completed
this study, with six engaged in a resistance exercise program, and seven in a no-exercise
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control group. Eight weeks of low volume resistance training (2d/wk) in Parkinson
disease patients showed trends toward increased antioxidant capacity (SOD, CAT, GPx,
Trolox-equivalent antioxidant capacity) and reduced hydrogen peroxide (H2O2) and
malondialdehyde levels, but were not significant. Post hoc power analyses indicated that
a total sample size of 16 and 22 subjects would be needed to observe a statistically
detected interaction effect for MDA and H2O2, respectively. It should be noted that there
was no significant difference in baseline oxidative stress or antioxidant biomarkers
between Parkinson’s disease patients and a healthy control population.
Summary
Reactive oxygen species, once thought to be nothing more than biochemical
byproducts of aerobic metabolism, are now recognized as crucial signaling molecules at
low levels, but cytotoxic and potentially carcinogenic at high levels. This duality makes
the study of ROS complicated, particularly in relation to chronic diseases, including
cancer. Cancer patients often have high systemic oxidative stress, which is further
aggravated by cancer treatments, particularly radiation and chemotherapy. Most cancer
cells have marked oxidative stress due to increased ROS production and compromised
antioxidant defense, but certain cancer cells, such as prostate and metastatic cells, are
known to have increased antioxidant enzyme capacity. ROS are thought to play a role in
cancer risk and etiology, but cancer itself is known to increase ROS production, resulting
in further cellular mutation and proliferation. Ironically, ROS are known to induce
apoptosis and necrosis in cancer cells, and ROS production is a mechanism shared by all
non-surgical cancer treatments.
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ROS in cancer patients are likely associated with many of the side effects of
cancer and its treatments, including fatigue, cachexia and anorexia, muscle weakness, and
reduced cardiorespiratory function. Therefore, it is reasonable to employ strategies
which counteract both the oxidative stress and physiological decrements associated with
cancer and its treatments. Both AOX therapy and exercise are potential strategies.
Because antioxidants have been shown to protect cancer cells in some circumstances, this
method is not suggested without further research, even following treatment, as
micrometastases may still be present. Additionally, because the delicate redox balance is
dose-responsive and synergistic by nature, exogenous administration of antioxidants may
be unwise even as a preventative measure without a complete understanding of the
interactions. Therefore, exercise is a recommended strategy to reduce ROS and cancer
treatment side effects without artificially altering the redox status and potentially
protecting cancer cells.
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CHAPTER III
METHODOLOGY
Introduction
The primary purpose of this study is to determine the effects of a 10-week aerobic
and resistance prescribed exercise intervention on plasma markers of oxidative stress and
antioxidant enzyme capacity in cancer survivors versus a non-exercising control group.
Markers of oxidative stress that were measured included 8-OHdG and reactive carbonyl
derivatives. Trolox-equivalent antioxidant capacity (TEAC) was measured as a universal
marker of antioxidant capacity in the blood. Additionally, selected physiological
variables, including peak VO2, muscular strength, and fatigue were compared between
groups. Baseline oxidative stress and antioxidant enzyme capacity in cancer patients
were compared to healthy individuals. The relationship between oxidative stress and
baseline physiological variables was determined. Similarly, the relationship between the
change in oxidative stress and changes in physiological variables was determined. This
chapter describes the research methodology for the study and includes discussion of the
experimental design, data collection procedures, and data analysis.
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Experimental Design
This study consisted of a 10-week prescribed exercise intervention in cancer
patients following oxidative stress-inducing cancer treatments, including radiation and
several chemotherapy agents (see Table 3 on page 65). Subjects had completed radiation
or chemotherapy treatment within the previous 6 weeks. Currently there is no good
characterization of the time-course of chronic oxidative stress status following the end of
cancer chemotherapy or radiation treatment in the literature. Many papers evaluate
oxidative stress while patients are undergoing treatment (Cetin et al., 2004; Conklin,
2000; Honda et al., 2000; Sabitha & Shyamaladevi, 1999; Weijl et al., 1998) or within
hours and days after treatment (Sangeetha et al., 1990), but rarely evaluate markers of
oxidative stress or antioxidants more than a week after the end of treatment. In mice,
extracellular MDA levels remained elevated one week after chemotherapy, and oxidized
glutathione was significantly higher than controls 6 weeks after treatment (Abushamaa et
al., 2002). Unfortunately, it is difficult to extrapolate these data to humans due to varying
lifespans. Jonas et al. (Jonas et al., 2000) found that GSH/GSSG ratio continually
decreased over the two weeks following the end of treatment, indicating either that
treatment directly impairs the antioxidant system, or that chronic oxidative stress is
capable of depleting the glutathione pool and diminish reductive capacity.
Cancer patients were assigned to an exercise group or a standard care control
group. Pre- and post- intervention fasting blood samples were drawn from cancer
patients to determine markers of oxidative stress (8-OhdG, protein carbonyls) and
antioxidant capacity (Trolox equivalent antioxidant status). An initial screening and
physical assessment was conducted in each cancer survivor in the exercise and control
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groups. These assessments determined fatigue, cardiorespiratory endurance, and
muscular strength. Additionally a group of age-matched healthy individuals without
cancer (NC) completed the Piper Fatigue questionnaire (Appendix A) and had fasting
blood samples drawn to determine the relative degree of fatigue and oxidative stress in
cancer patients at baseline. Reassessments were obtained after a 10-week individually
prescribed exercise intervention. The same physiological and psychological parameters
were assessed using identical protocols during the initial assessment. See Figure 5 for
experimental design.

Figure 5. Experimental design

Subjects
Sixteen cancer survivors and eight healthy, age-matched subjects were recruited
for participation in this study. A similar study on Parkinson’s disease patients (Bloomer
et al., 2008) determined that a sample size of 16 would be needed for adequate power,
and this study was only twice per week, and only consisted of three sets of leg press, leg
curl, and calf press for each session. Cancer patients were recruited from walk-in and
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referred clients at RMCRI, as well as at McKee Hospital in Loveland, Poudre Valley
Hospital in Fort Collins, and Northern Colorado Medical Center in Greeley.
Additionally, a newspaper article in the Greeley tribune was used to promote this study.
All cancer diagnoses were considered for this study, but subjects were required to
have undergone radiation treatment, or one of the listed chemotherapy drugs (Table 3).
Cancer patient inclusion criteria consisted of: (1) completed radiation or approved cancer
therapy regimen within 6 weeks of initial blood draw, (2) currently sedentary (less than
two days/week or 20 minutes of aerobic or resistance exercise) (Brooks et al., 2005), (3)
have not consistently supplemented with dietary antioxidants, including vitamins C and
E, in the previous month (dietary half-life of ascorbate, for instance, is 8-40 days) (Otten,
Hellwig, & Meyers, 2006), (4) non-smokers (for at least 6 months), and (5) were able to
walk comfortably on a treadmill. Non-cancer, healthy controls were primarily recruited
from among the faculty and staff at the University of Northern Colorado via campuswide email and by word of mouth. This group was asked to fast for 12 hours, and avoid
strenuous physical activity for 72 hours prior to their single, baseline blood draw.
Inclusion criteria for the non-cancer group included: (1) currently sedentary (less than
two days/week or 20 minutes of aerobic or resistance exercise), (2) no history of cancer
or other disease, (3) have not consistently supplemented with dietary antioxidants in the
previous month, and (4) non-smokers. The University of Northern Colorado
Institutional Review Board (IRB) approved all procedures.
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Data Collection Procedures
An initial phone interview with potential clients determined eligibility to
participate, which and included a complete cancer history discussion, and availability and
willingness to complete the study. Subjects were informed that the study includes
participation in 10 weeks of one-on-one exercise training at the Rocky Mountain Cancer
Rehabilitation Institute, or standard care. Additionally, subjects were verbally given
information regarding the nature of data collection, including the risk involved in a
standard blood draw, and a maximal, graded treadmill test. After this brief discussion
and clearance to exercise for high cardiac risk subjects by the RMCRI Medical Director,
subjects met with the lead investigator and signed an informed consent.
Prior to arrival at RMCRI, subjects were mailed questionnaires to complete,
including the Piper Fatigue Scale (Piper et al., 1998), lifetime physical activity, and
medical history. For 72 hours prior to the blood draw, subjects were asked to avoid
exhaustive exercise and antioxidant supplementation. The day before the cancer patient’s
initial exercise assessment, a 12-hour fasting blood sample was taken by the lead
investigator, the RMCRI medical director, or an otherwise experienced phlebotomist. On
the day of the initial assessment, the standard RMCRI assessment protocol (details to
follow) was utilized. Height, weight, cardiorespiratory endurance, and muscular strength
were evaluated, and results were used to develop individualized exercise interventions.
Piper Fatigue Inventory
The Piper Fatigue Inventory (Piper et al., 1998) was used to assess total cancerrelated fatigue, as well as the subscales of behavioral, affective, sensory, and
cognitive/mood fatigue. The behavioral fatigue subscale includes six questions and was
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used to assess the impact of fatigue on school and/or work, interacting with friends, and
overall interference with activities that are enjoyable. The affective fatigue subscale
includes five questions and assessed the emotional meaning attributed to fatigue. The
sensory fatigue subscale includes five questions and assessed the mental, physical, and
emotional symptoms of fatigue. The cognitive and/or mood fatigue subscale includes six
questions and assessed the impact of fatigue on concentration, memory, and the ability to
think clearly. The average score on the 22 total questions from the subscales provides the
total fatigue score. The range of possible scores on the subscales as well as total fatigue
ranges from “0” to “10”. A score of a “0” indicates that the cancer survivor has no
fatigue; scores ranging from “1” to “3” are indicative of mild fatigue; scores “4” to “6”
suggest moderate fatigue; and scores of “7” or greater indicate severe fatigue.
Maximal Treadmill Testing
The RMCRI treadmill protocol (Table 5) was developed at the Rocky Mountain
Cancer Rehabilitation Institute as a cancer-specific protocol, more suitable for the cancer
population. Unlike the Bruce treadmill protocol, there are no abrupt increases in speed
and grade. Smaller changes in effort and patient stride provide a more manageable
progression through stages and results in reduced premature peripheral fatigue and more
valid maximal treadmill tests (Bruce, Kusumi, & Hosmer, 1973). The RMCRI treadmill
protocol begins at 1.0 mph and 0% grade during the first stage. For the next three stages,
the speed increases 0.5 mph, but grade is maintained at 0%. Stage 5 increases the grade
to 2% but maintains speed at 2.5 mph, and stage 6increases to 3.0 mph and 2% grade.
Stage 7 is 3.3 mph and 3% grade, and every subsequent stage increases 0.1 mph and 1%
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grade. The subjects continue until volitional fatigue, at which point grade is reduced to
0% and speed is reduced to 1.5 mph for a three minute recovery period.

Table 5
RMCRI Treadmill Protocol
Stage
Speed (mph)

Grade (%)

Time

1

1.0

0

1 min

2

1.5

0

1 min

3

2.0

0

1 min

4

2.5

0

1 min

5

2.5

2

1 min

6

3.0

2

1 min

7

3.3

3

1 min

8

3.4

4

1 min

9

3.5

5

1 min

10

3.6

6

1 min

11

3.7

7

1 min

12

3.8

8

1 min

13

3.9

9

1 min

14

4.0

10

1 min

15

4.1

11

1 min

16

4.2

12

1 min

17

4.3

13

1 min

18

4.4

14

1 min

19

4.5

15

1 min

20

4.6

16

1 min

21

4.7

17

1 min

Cool-Down

1.5

0

3 min

Prior to each incremental treadmill test, subjects were fitted with a heart rate
monitor (Polar Inc., Lake Success, NY). Instructions regarding the specific changes in
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speed and grade during each one-minute stage were given and the participant was
encouraged to walk or run until exhaustion or volitional fatigue (to VO2peak). Blood
pressure was assessed at rest, every three minutes during exercise, at immediate post
exercise, and after three minutes of recovery (slow walking). Rating of perceived
exertion was assessed every three minutes of exercise, according to Borg’s 1-10 scale
(Table 6). Heart rate and oxygen saturation was assessed at the end of every one-minute
stage. Subjects were asked to only use handrails throughout the test if they required it for
balance support. If they felt they would need handrails, they were asked to use them
throughout the test.
Table 6
Borg Scale: Rating of Perceived Exertion
Maximum Exertion
10
Very, very hard
9
8
7
Very hard
6
5
Hard
4
Somewhat hard
3
Moderate
2
Light
1
Very light
0
No exertion

Adapted from Category-Ratio Perceived Exertion Scale: Relationship to Blood and
Muscle Lactates and Heart Rate. Med Sci Sports Exerc, 15:523-528, 1983.

For individuals who were walking during the final stage, the ACSM metabolic
equation (VO2 (ml/kg/min) = (0.1 × S) + (1.8 × S × G) + 3.5 ml/kg/min) was used,
whereas the equation (VO2 (ml/kg/min) = (0.2 × S) + (0.9 × S × G) + 3.5 ml/kg/min) was
used for individuals running during their final stage. For both equations “S” represents
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treadmill speed, expressed as meters/minute, and “G” represents treadmill grade,
expressed as a decimal, such that 0.08 would represent a grade of 8%, for example.

Muscular Strength Assessment
A true 1-repetition max (1-RM) assessment of strength can be the most accurate
and reliable method of muscular strength assessment, but may be subject to variability
due to unfamiliarity with weight lifting, lack of adequate facilities, and risk of injury,
even in healthy individuals. In the cancer population, the variability and risk for injury
are even greater. Therefore, the Brzycki equation,
1-RM = weight lifted (lb) / (1.0278 – (repetitions to failure × 0.0278))
can be used to estimate 1-RM using the number of repetitions of a given submaximal
load to fatigue, provided that the repetitions do not exceed 10 (Brzycki, 1993). Muscular
strength was assessed using the lat pull-down, shoulder press, chest press, seated row, leg
press, leg extension, and leg curl exercises, using Cybex® gym equipment (Cybex
International, Medford MA). The goal was to choose a weight that will elicit muscle
failure in 4-6 repetitions. Suggested values for the initial amount of weight lifted for the
exercises were based upon previous muscular strength data from RMCRI (Table 7)
(Schneider et al., 2003). Repetitions were performed without resting until muscle failure,
or until the subject’s form deteriorates. If the client exceeded 10 repetitions for any
exercise, they were stopped, and proceeded with the other muscular strength exercises.
Following all exercises, those exercises which had been stopped were completed after
increasing the weight to elicit muscle failure in less than 10 repetitions.
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Table 7
Suggested initial resistance (% of Body Weight)
Exercise
Men

Women

Lat Pull-down

0.900

0.500

Shoulder Press

0.350

0.150

Chest Press

0.750

0.250

Seated Row

0.750

0.300

Leg Press

1.500

0.750

Leg Extension

0.750

0.400

Leg Curl

0.750

0.400

Lat Pull-Down
The participant sat on the bench seat with thighs positioned comfortably
underneath the roller pads, which were adjusted if needed. The participant's hands were
positioned on the bar slightly outside shoulder width, with palms facing inward
(supinated) and torso remaining upright throughout the lift, without leaning forward or
backward. A full repetition included a down motion, in which the training arm was
pulled down until it is approximately even with the middle of the chest, and an up motion
in which the training arm was allowed to rise until arms were extended but not locked.
Shoulder Press
The back of the seat was adjusted so that it was in the upright position, ensuring
that the seat was locked. The participant sat on the seat with back and buttocks against
the backrest. The participant's hands were placed on the lower handles at a comfortable
width, depending on body size. Feet were placed flat on the floor approximately shoulder
width apart. A full repetition included an up motion in which that training arm was raised

90
until arms were extended but not locked, and a down motion in which the training arm
was lowered until the weight touched the top of the weight stack.
Chest Press
The participant sat on the seat with back and buttocks against the backrest and
feet placed flat on the floor approximately shoulder-width apart. The seat was adjusted
so the handles were at mid-chest height. A full repetition included an up motion in
which the subject pressed outward until arms were at near full extension, and a down
motion in which arms were lowered until elbows were at a 90o angle.
Seated Row
Seat height was adjusted to align the top of the participant’s shoulders with the
top of the handles. The chest pad was adjusted to allow both hands to reach the handles
with arm fully extended. The participant sat upright, grasped the handles, and brought
their elbows back, attempting to pinch shoulder blades together. The handles were
returned to the starting position in a controlled manner, without slamming the weights
back onto the stack.
Leg Press
The participant sat on the leg press seat with back flat against the backrest and
buttocks tucked as far back as possible. The backrest was adjusted forward or backward
until the upper leg was approximately perpendicular to the floor and there was a 90o bend
in the participant's knees. The participant placed feet on the platform approximately
shoulder width apart and in a position in which the quadriceps and hamstrings were
exercised as evenly as possible. Prior to increasing the weight to the value indicated in
Table 7, the participant performed several repetitions with no weight in order to
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determine this position. A full repetition included an up motion in which the platform
was pushed out until legs were fully extended, but knees not locked, and a down motion
in which the platform was allowed to move back toward the participant until the weight
touched the top of the weight stack.
Leg Extension
The back pad was adjusted to ensure that the participant’s knees were aligned
with axis of rotation. The participant’s thighs were positioned parallel to each other and
the shin pad was lifted to the appropriate position on the lower shin to ensure comfortable
positioning. The participant’s was instructed to relax ankles, grip handles firmly, and
maintain proper posture by pressing back against the back pad. A full repetition
including an up motion, in which the knees were straightened as far as possible without
“kicking,” and a controlled down motion in which the lower leg slowly returned to the
starting position without slamming the weights back onto the stack.
Leg Curl
The back pad was adjusted to ensure that the participant’s knees were aligned
with axis of rotation. The leg starting position (0-12) was set so that knees were fully
extended. The leg pad was adjusted for comfortable positioning slightly above ankles.
The subject sat with lower legs resting upon pad, thighs parallel to each other and ankles
relaxed. The thigh pad was lowered to fit securely across participant’s thighs, while they
held the grip handles on the thigh pad. A full repetition included a down motion in which
the participant flexed their knees until they reached at least 90o without moving the pelvis
or spine, and a controlled up motion in which the participant returned their legs to the
starting position without slamming the weights back onto the stack.
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Exercise Intervention
The lead investigator and Certified Cancer Exercise Specialists developed
individualized exercise prescriptions and exercise interventions tailored to each subject in
the exercise group based upon cancer history, health status, and results of the initial
physical assessments. Subjects attended one-on-one supervised exercise sessions three
days per week for the 10 week intervention. Prior to each training session, the lead
investigator or Certified Cancer Exercise Specialists asked each participant a series of
questions that elucidated whether it was necessary to alter that day’s exercise intervention
(Appendix E). Questions focused on how the participant felt after the last exercise
session, if the participant had any soreness or specific problems that would affect
training, and if changes in medication or treatment had been implemented since the last
exercise session. The exercise sessions lasted one hour each, and consisted of 25 minutes
of aerobic exercise, 25 minutes of resistance training, and 10-minutes of flexibility and/or
balance training. Because the exercise intervention was personalized, there were some
variations, but subjects spent a majority of the exercise session performing cardiovascular
fitness, muscular strength and muscular endurance exercises.
The mode of aerobic exercise selected for each participant was based on the mode
offering the greatest anticipated benefit. Options included treadmill walking, stationary
cycling, and recumbent stepping. Initially, exercise intensity was based on the results
from the treadmill assessment. Intensity was monitored via heart rate and RPE. The
Karvonen, or percent heart rate reserve (HRR), method was used to determine exercise
heart rate intensity utilizing the formula:
(220-age) − resting HR] × percent of exercise intensity + resting HR.
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See Table 8 for recommended exercise intensity based on health and fitness status upon
inclusion into the study. High intensity exercise was avoided, as it can result in excessive
ROS production which may magnify, rather than reduce, chronic oxidative stress in
cancer survivors due to inadequate antioxidant defenses associated with the disease and
its treatments (Finaud et al., 2006; Fisher-Wellman & Bloomer, 2009; Poulsen et al.,
1996).
Table 8
Recommended Exercise Intensity
Health and fitness status

Recommended intensity

Sedentary, poor health, low fitness

Start at 30-45% HRR; RPE of 1-3

Moderate health, average fitness

Start at 50-60% HRR; RPE of 4-5

Adapted from Exercise and Cancer Recovery, Schneider 2003, p. 87. Copyright 2003
Human Kinetics Publishers, Inc.

Resistance training followed the aerobic portion of the exercise session. Subjects
progressively increased the resistance load over the 10-week intervention, and progressed
through various modalities, including resistance tubing, Cybex® weight machines and
free weights. Stability balls, balance pads, and Bosu ™ balls were integrated into the
resistance training exercises to increase proprioception and balance. Larger muscles were
targeted first (chest, back, and thighs), followed by the smaller muscle groups (biceps and
triceps). Patients performed 2-3 sets of each exercise, with 8-12 repetitions per set.
Resistance was based upon the initial assessment, and was monitored by heart rate
response to the exercise and RPE.
Cancer patients in the standard care control group were asked to maintain their
current dietary and physical activity habits. Although standard care cannot be
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“standardized” between hospitals and patients, it did not involve routine, systematic
exercises (van Waart, Stuiver, van Harten, Sonke, & Aaronson, 2010). Following the 10week study period, control subjects had the opportunity to exercise at RMCRI for three
months at no cost. A stretching intervention was not utilized for the control group, as it
may acutely increase oxidative stress, and chronically augment the antioxidant defense
system. Although a control, stretching group was used by Campbell et al. (2010) without
any change in F2-isoprostane levels in obese and overweight women, there was no
significant difference between those engaged in aerobic exercise or stretching regimens.
Moreover, passive stretch of isolated muscle fibers has been shown to increase cytosolic
oxidant activity, (Chambers et al., 2009) and presumably could result in a hormetic
response in antioxidant status over 12 weeks. Along the same lines, yoga is not a viable
control intervention, as 40 days of yoga asanas (postures) reduced serum MDA from 5.9
± 3.6 to 2.9 ± 2.3 mmol/ml in patients with non-insulin dependent diabetes mellitus (S.
Singh et al., 2001).
Evaluation of Oxidative Stress
Blood was drawn from cancer patients on the day prior to both the initial
assessment and the reassessment 10 weeks later. A minimum of 4mL of blood was
withdrawn into sterile tubes containing potassium-EDTA and immediately put on ice.
Samples were centrifuged at 3,000 rpm for 10 minutes, and the plasma was separated and
stored in multiple aliquots at -80°C until analysis. All assays were performed in
duplicate or triplicate on the first thaw. Protein carbonyls and 8-OHdG were measured in
plasma using an enzyme-linked immunosorbent assay (ELISA) according to the
procedures recommended by the manufacturer (Cell Biolabs, Inc., San Diego, CA).
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Antioxidant capacity was measured in serum using the Trolox-equivalent antioxidant
capacity (TEAC) assay using procedures outlined by the reagent provider (Sigma
Chemical, St. Louis, MO).
Biochemical Assays
Reactive carbonyl derivatives were measured as a marker of oxidative protein
damage. A pilot study at RMCRI indicated that an exercise intervention reduced plasma
protein carbonyl concentration by 76% in an individual undergoing high dose
chemotherapy (unpublished data). Oxidative DNA damage was determined by plasma 8OHdG. This value is associated with the risk of cancer development and recurrence
(Yamamoto et al., 1996). To assess plasma antioxidant capacity and concentrations of 8OHdG and protein carbonyls, the following biochemical methodologies were used.
Protein Carbonyls
The OxiSelect ™ Protein Carbonyl ELISA kit (Cell Biolabs, Inc., San Diego, CA)
was used to assess byproducts of protein oxidation present in blood plasma. In this
enzyme immunoassay, 100 µl of 10 µl/mL diluted protein samples or standards with
known concentrations of oxidized bovine serum albumin (BSA) were adsorbed to each
well in the provided 96-well Protein Binding Plate and incubated overnight at 4ºC.
Protein carbonyls present in the plasma sample or standard were derivatized to
dinitrophenylhydrazine (DNPH), and probed with an anti-DNP antibody and a
horseradish peroxidase (HRP) conjugated secondary antibody. After adding a stop
solution, the results were read immediately at 405 nm using a plate reader.
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8-OHdG
The OxiSelect ™ Oxidative DNA Damage ELISA kit (8-OHdG Quantitation)
(Cell Biolabs, Inc., San Diego, CA) was also utilized for analysis of DNA oxidation. 50
µl of plasma or 8-OHdG standard was added to each well of a 96-well 8-OHdG
Conjugate coated plate provided by the manufacturer. Following a 10 minute
incubation, 50 µl of anti-8-OHdG antibody was added to each well and incubated for an
hour. Wells were washed and 100 µl of HRP secondary antibody was added and
incubated for another hour. After washing well, 100 µl of room temperature substrate
solution was added to each wells and incubated for approximately 30 minutes. 100 µl of
stop solution was added to each well and the results were read immediately at 450 nm
using a plate reader.
Trolox Equivalent Antioxidant Capacity
A commercially available assay kit (Sigma-Aldrich, Saint Louis, MO) was use to
evaluate plasma antioxidant capacity, with 6-hydroxy-2,5,7,8-tetramethylchroman-2carboxylic acid (Trolox) serving as a control antioxidant. The principle of this assay is
the formation of a ferryl myoglobin radical from metmyoglobin (derived from horse
heart) and hydrogen peroxide. This oxidizes with 2,2’azino-bis(3-ethylbenzthiazoline-6sulfonic acid) (ABTS) to produce ABTS•+, a soluble chromogen radical that can be
determined spectrophotometrically at 405nm. Antioxidants present in blood plasma
samples or Trolox standards suppress the production of this radical in a concentration
dependent manner, with a proportional decrease in color intensity. 10 µl or Trolox
standard or test sample and 20 µl or Myoglobin Working Solution was added to each well
in a 96 well plate. ABTS Substrate working solution was incubated in wells for 5
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minutes, at which time a stop solution was added and the plate was read within an hour at
405 nm using a plate reader
Other studies have examined exercise-associated changes in antioxidant enzyme
capacity in healthy (Bloomer, 2008; Ji, 2002; Powers et al., 1999), diseased (Bloomer et
al., 2008; Fisher-Wellman, Bell, & Bloomer, 2009) and elderly (Carvalho et al., 2010;
Hammeren et al., 1992) populations. Because the antioxidant defense system is complex
and not fully elucidated, measurement of individual enzymes may not appropriately
represent the dynamics of antioxidant status, as other mechanisms (non-enzymatic
antioxidant status, transport mechanisms) may be involved in the adaptive response to
exercise. For instance, despite an attenuation of doxorubicin- associated lipid
peroxidation (as measured by MDA) and cardiotoxicity, exercise pre-training in rats
failed to increase SOD activity (Chicco, Schneider, & Hayward, 2005).

It should be

noted that null findings in some studies were likely due to an insufficient variety of
analyzed biomarkers (Fisher-Wellman et al., 2009). Therefore, TEAC may be a suitable
marker for examination of changes in antioxidant status, as it is non-specific, and
determines total antioxidant activity in a sample.
Statistical Analysis
Data were presented as means  SD. Subjects’ baseline characteristics in the two
cancer groups (exercise training versus control) and the non cancer group were compared
using independent t-tests. A repeated measures 2 (group) × 2 (pre- and post-intervention)
analysis of variance (ANOVA) with Bonferroni post hoc was used to determine
differences within (across time) and between the two groups related to markers of
oxidative stress, antioxidant capacity, VO2peak, muscular strength, and fatigue. Based on
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a normal probability plot and the Kolmogorov-Smirnov test, the residuals from the
model(s) show no evidence of a lack of normality. Therefore the standard repeatedmeasures ANOVA model appears appropriate for the data. Spearman correlation
coefficients were calculated to determine associations between baseline markers of
oxidative stress and baseline VO2peak, muscular strength, and fatigue. Additionally,
Spearman correlation coefficients were calculated to determine associations between
post-intervention changes in markers of oxidative stress and post-intervention changes in
VO2peak, muscular strength, and fatigue. Although repeated measures ANOVA was
used for analysis of change within the cancer population, the nonlinear Spearman's rank
correlation was used due to the expectation of a nonlinear trend, as antioxidant and
oxidative stress values may plateau at optimal levels in both healthy and cancer subjects,
even as fitness and fatigue parameters continue to improve. A significance level of α =
0.05 was used for all statistical analyses.
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CHAPTER IV
CANCER RELATED FATIGUE AND MARKERS OF OXIDATIVE
STRESS IN CANCER PATIENTS FOLLOWING
AN EXERCISE INTERVENTION
Abstract
PURPOSE. The last two decades have produced an abundance of research indicating
that exercise interventions in cancer patients are capable of reducing cancer-treatment
related side effects, including fatigue. Cancer-related fatigue is a somewhat nebulous
concept, as both physiological and psychological factors contribute to this phenomenon.
Although the underlying mechanisms of cancer-related fatigue are not fully
characterized, treatment-associated oxidative stress is thought to play a role. The
purpose of this study was to determine the effect of an exercise intervention on blood
markers of oxidative stress, antioxidant status, and cancer-related fatigue compared to a
cancer control group. METHODOLOGY. An initial fasting blood draw and fatigue
questionnaire were administered to fifteen cancer patients within six weeks of completing
radiation or chemotherapy treatment, as well as seven age-matched individuals with no
history of cancer (NC) to compare baseline values. Eight of the cancer patients
participated in a 10-week exercise intervention (EX), while seven continued standard care
(CON). Following the intervention, another fasting blood draw and fatigue questionnaire
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were administered. Changes in plasma 8-OHdG and antioxidant status were compared
between the EX and cancer CON groups. Baseline markers of oxidative stress were
compared between NC subjects and cancer patients. A correlation analysis of fatigue and
oxidative stress in all subjects was conducted. RESULTS. Mean total fatigue scores
decreased significantly from 5.0 ± 2.2 to 2.6 ± 1.5 (p < 0.05) in EX, whereas changes in
CON (4.7 ± 2.5 to 3.2 ± 2.4) were not significant. All fatigue subscales significantly
decreased in EX, while only cognitive fatigue increased significantly in CON (p < 0.05).
No group by time interaction effect between groups was found for fatigue scores. Total
antioxidant capacity increased significantly over time in EX (p < 0.01), but not in CON.
No significant changes over time were found in 8-OHdG, but a group by time interaction
effect was detected (p < 0.05). Baseline antioxidant capacity significantly correlated (p <
0.05) with total (r = -0.41) affective (r = -0.39), sensory (r = -0.40), and cognitive fatigue
(r = -0.57). Increases in antioxidant capacity were correlated with reductions in affective
(r = -0.49), sensory (r = -0.47), and cognitive fatigue (r = -0.58). Although 8-OHdG was
not correlated with any fatigue parameter at baseline, changes in total (r = 0.46) and
affective (r = 0.47) fatigue exhibited significant correlations with changes in 8-OHdG
over time. CONCLUSION. An exercise intervention reduced fatigue in cancer patients
following cessation of treatment, whereas standard care resulted in non-significant
reductions in fatigue. Oxidative stress may be implicated in cancer-related fatigue, while
improved antioxidant capacity following an exercise intervention may play a role in
mitigating fatigue.
Introduction
The National Cancer Institute estimates that 13.7 million Americans with a
history of cancer were alive in 2012, and about 1,665,540 new cancer cases are expected
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to be diagnosed in 2014 (American Cancer Society, 2014). Although survival rates
continue to improve, these patients can expect to experience adverse side effects of
surgery, radiation, chemotherapy, and other treatment modalities that may last for years.
Typical side effects include muscle weakness (Christensen et al., 2014; Schneider et al.,
2007a), reduced cardiorespiratory fitness (Burnett, Kluding, Porter, Fabian, & Klemp,
2013), and general fatigue (Campos, Hassan, Riechelmann, & Del Giglio, 2011; Puetz &
Herring, 2012), resulting in an overall decrease in quality of life.
Acute and chronic cancer-related fatigue associated with radiation therapy,
chemotherapeutic agents, and the tumor burden itself, have been well documented for
decades (Piper et al., 1989; Questad et al., 1982; Rieger, 1988; Smets et al., 1993). Up to
90% of cancer patients report experiencing fatigue following cancer treatment, and it is
commonly reported as the most problematic side effect for cancer survivors (Hofman,
Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow, 2007). Cancer-related fatigue is
similar in nature to chronic fatigue syndrome in terms of symptoms and etiology
(Rovigatti, 2012). Both conditions are more chronic and debilitating than standard
fatigue, causing individuals to alter their behavior and demeanor, but all patients
experience cancer-related fatigue differently (de Jong et al., 2002).
Because fatigue is both a physiological and psychological condition, it is difficult
to identify a specific mechanism, but there are likely many. Some proposed factors
contributing to fatigue are muscular wasting related to cachexia (Christensen et al., 2014;
Gilliam & St Clair, 2011); sleep disturbances (Roscoe et al., 2007); psychological
depression; (Piper et al., 1987); anemia (de Jong et al., 2002); and metabolic imbalance
due to increased energy requirement (e.g., due to tumor growth), decreased metabolic
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capacity (mitochondrial damage), or decreased substrate availability associated with
anorexia, nausea, or vomiting (Glaspy, 2001). Additionally, many of the mechanisms
responsible for exercise-associated fatigue have been postulated to contribute to cancerrelated fatigue, including serotonin dysregulation, hypothalamic-pituitary-adrenal (HPA)
axis dysfunction, vagal afferent nerve activation, and cytokine dysregulation (Ryan et al.,
2007).
Although cancer-related fatigue is undoubtedly a product of a combination of
these physiological and psychological factors, and may vary between individuals,
oxidative stress is thought to play a pivotal role in many pathological processes
associated with cancer and its treatments (Fang et al., 2009; Robbins & Zhao, 2004; Zhao
& Robbins, 2009). Oxidative stress is a state in which reactive oxygen species (ROS) are
produced at a rate that exceeds cellular adaptive and repair capacities, resulting in
damage to local tissues, including lipid membranes, protein structures, and nucleic acids,
(Halliwell & Gutteridge, 2007). Cancer cells often are characterized by elevated levels of
oxidative stress. ROS production associated with breast cancer is common enough that a
decreased GSH/GSSG ratio (reduced to oxidized glutathione ratio) has been identified as
an important biochemical parameter for detecting breast malignancy (Yeh et al., 2006).
Additionally, radiation and many chemotherapy regimens depend on ROS as an
antineoplastic mechanism (Kovacic, 2007; Tandon et al., 2005). Although ROS exert a
greater cytotoxic effect on cancer cells, cancer treatments are associated with collateral
oxidative damage to healthy tissues (Chen, Jungsuwadee, Butterfield, & St Clair, 2007).
Any disruption in antioxidant capacity of healthy cells can alter redox balance and health
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status, potentially resulting in acute and chronic side effects, including cancer-related
fatigue.
While cancer-related fatigue has been theoretically tied to oxidative stress
(Gilliam & St Clair, 2011), and many of the proposed mechanisms previously mentioned
can be driven by ROS and oxidative stress, there is a general lack of evidence explicitly
relating oxidative stress to cancer-related fatigue. Gramignano et al. (2006),
demonstrated that four weeks of L-carnitine administration simultaneously reduced
fatigue and resulted in a non-significant decrease in oxidative stress in patients currently
undergoing cancer treatment. Additionally, chronic fatigue syndrome has been
associated with oxidative stress (Fulle et al., 2000; Jammes et al., 2005; Richards et al.,
2000; Richards et al., 2007) and deficiency of the antioxidant glutathione (Bounous &
Molson, 1999). Maes et al. (2009) found that 8-hydroxy-deoxyguanosine (8-OHdG), a
marker of oxidative damage to DNA, was elevated in individuals suffering from both
depression and chronic fatigue syndrome. DNA oxidation is linked to oncogenesis, as
well as atherosclerosis and neurodegeneration, factors that are associated with
psychological and cognitive dysfunction. Accordingly, oxidative stress may represent a
potential mechanistic link between cancer and psychological dysregulation, including
cancer-related fatigue.
Until recently, oncologists and primary care physicians treating cancer patients
prescribed rest as a strategy to counteract cancer-related fatigue. Although it is somewhat
counterintuitive, research has shown that physical activity is a more effective method of
reducing acute and chronic fatigue in cancer survivors. Whereas exercise has been
shown to have significant therapeutic benefit (Brown et al., 2011; F. C. Dimeo, 2001;
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Schneider & Hayward, 2013), daytime inactivity may actually worsen fatigue symptoms
(Berger & Farr, 1999). In particular, resistance and aerobic exercise have been found to
be beneficial as a means to reduce fatigue, while improving quality of life (Ferrer,
Huedo-Medina, Johnson, Ryan, & Pescatello, 2011), muscular strength and endurance
(Focht et al., 2013; Schneider et al., 2007a), cardiorespiratory endurance (Courneya et al.,
2007; L. W. Jones, Liang, et al., 2011; Lakoski, Eves, Douglas, & Jones, 2012; Schneider
et al., 2007c), and even survival rates (Holmes, Chen, Feskanich, Kroenke, & Colditz,
2005; Irwin et al., 2011). Various methods of prescribed exercise, including resistance
and aerobic exercise, both supervised and at home, have been shown to improve fatigue
symptoms in cancer patients following treatment (Brown et al., 2011) .
Although exercise interventions are known to improve antioxidant capacity in
healthy individuals (Ji, 2008; Powers, Sollanek, Wiggs, Demirel, & Smuder, 2014;
Radak, Chung, Koltai, Taylor, & Goto, 2008), minimal research on exercise-associated
oxidative stress modifications in cancer patients is available. Allgayer et al (2008)
demonstrated reductions in urinary 8-OHdG excretion, from 8.47 to 5.81 ng/mg
creatinine (p = 0.02), after two weeks of moderate intensity exercise, while two weeks of
high intensity exercise training resulted in a non-significant increase in 8-OHdG
excretion. More recently, Jones et al (2011) demonstrated a nonsignificant gain (+ 32%,
p = 0.08) in F2-isoprostanes following a high intensity 3-month exercise program. These
disparate results indicate that, among other factors, exercise intensity likely plays a role
in the redox balance response to exercise interventions. In animal models, exercise has
been shown to attenuate oxidative damage and reduce treatment-associated side effects
following treatment with doxorubicin (Ascensao et al., 2005a; Wonders et al., 2008).

105
Interestingly, individual antioxidant enzymes, such as superoxide dismutase, have been
shown to increase with exercise training in rodents in some studies (Kanter et al., 1985)
but not others (Chicco et al., 2005). This may be explained by the plastic and timesensitive nature of redox signaling. For instance, although exercise training in rats
resulted in increased activity of the antioxidant enzyme catalase in left ventricular tissue,
upon cessation of exercise, catalase activity returned to pre-exercise values by day 9
(Lennon et al., 2004).
It is possible that the exercise-mediated reductions in oxidative stress are in part
responsible for exercise-associated decreases in cancer-related fatigue, but to date, this
relationship is largely uncharacterized. Therefore, the purpose of this study was to
investigate changes in total antioxidant capacity, DNA oxidation, and fatigue parameters
in cancer patients following a whole body exercise intervention versus a cancer control
group. Furthermore, correlations between baseline fatigue and oxidative stress, as well as
changes in oxidative stress and fatigue parameters were evaluated.
Methodology
This study consisted of a 10-week prescribed exercise intervention in cancer
patients following oxidative stress-inducing cancer treatments, including radiation or
chemotherapy. Subjects had completed radiation or chemotherapy treatment within the
previous 6 weeks, with an average time out of treatment of 4 weeks. Fifteen cancer
patients and seven individuals with no history of cancer or other chronic diseases (NC)
participated in this study. Cancer patients were admitted to either an exercise intervention
group (EX) or a standard care group (CON) based upon date of initial contact (pseudorandomization), while NC subjects were only evaluated at baseline. Cancer patients were
recruited from walk-in and oncologist referred patients at the Rocky Mountain Cancer
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Rehabilitation Institute (RMCRI) at the University of Northern Colorado (UNC) in
Greeley, Colorado. Additionally, oncology patient navigators and clinical oncology
research specialists at Northern Colorado Medical Center in Greeley, Poudre Valley
Hospital in Fort Collins, and McKee Hospital in Loveland, Colorado identified qualifying
individuals as they completed radiation or chemotherapy treatments. Newspaper articles
in the Greeley Tribune and UNC today, posters at the local American Cancer Society
office and outpatient oncology waiting areas, and a recruitment page on the RMCRI
webpage were used to promote this study.
Twenty six cancer patients made contact with the primary investigator, but
exclusion criteria or attrition resulted in the loss of 11 potential subjects. Refer to Figure
6 for flow of the subjects through this study. All cancer diagnoses were considered for
this study, but subjects were required to have undergone radiation or a chemotherapy
treatment explicitly known to elicit oxidative stress, either as a side effect or as an
antineoplastic mechanism. Chemotherapy agents included anti-neoplastic antibiotics,
alkylating agents, platinum coordinating complexes, epipodophyllotoxins, fluorouracil
and tamoxifen (Y. Chen et al., 2007; Conklin, 2004; Look & Musch, 1994). Cancer
patient inclusion criteria consisted of: (1) completed radiation or approved cancer therapy
regimen within six weeks of initial blood draw, (2) currently sedentary (less than two
days/week or 20 minutes of aerobic or resistance exercise) (Brooks et al., 2005), (3) have
not consistently supplemented with dietary antioxidants, including vitamins C and E, in
the previous month, (4) non-smokers (for at least 2 months), and (5) were able to walk
comfortably on a treadmill.
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Initial Pool:
26 non-smoking, sedentary cancer patients who had completed chemotherapy or radiation within
the previous 6 weeks contacted the PI directly or were identified by RMCRI, a nurse navigator, or
another member of the local oncology community.
Exclusion criteria:
1 patient too physically active
Attrition:
2 patients failed to return phone calls after initial contact
2 patients missed the scheduled initial blood draw or assessment, and never agreed to reschedule
1 patient “too busy to participate”
2 patients were unwilling to make commitment to more cancer-related appointments
1 cancelled initial assessment appointment because the drive for training was too far
1 patient diagnosed with brain metastasis after initial blood draw but prior to initial assessment
1 patient returned to chemotherapy after 4 weeks of exercise training
8 subjects participated in a 10-week exercise intervention
7 subjects were cancer control subjects, and received standard care for 10 weeks
Total sample size:
15 subjects completed the 10-week intervention, blood draw and reassessment of fitness

Figure 6. Flow of cancer patients through the study.

Non-cancer, healthy controls were primarily recruited from among the faculty and
staff at the University of Northern Colorado via campus-wide email and by word of
mouth. Inclusion criteria for the non-cancer group included: (1) currently sedentary (less
than two days/week or 20 minutes of aerobic or resistance exercise), (2) no history of
cancer or other major chronic disease, (3) have not consistently supplemented with
dietary antioxidants in the previous month, and (4) non-smokers. The University of
Northern Colorado Institutional Review Board (IRB) approved all procedures.
Prior to arrival at RMCRI, all cancer and non-cancer subjects were provided with
the Piper Fatigue Scale (Piper et al., 1998) to complete within 24 hours of the initial
blood draw. For 72 hours prior to the blood draw, subjects were asked to avoid
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exhaustive exercise and antioxidant supplementation. The day before the cancer patient’s
initial exercise assessment, a 12-hour fasting blood sample was taken by the lead
investigator or an otherwise experienced phlebotomist.
Piper Fatigue Inventory
The Piper Fatigue Inventory (Piper et al., 1998) was used to assess total cancerrelated fatigue, as well as the subscales of behavioral, affective, sensory, and
cognitive/mood fatigue. The behavioral fatigue subscale includes six questions and was
used to assess the impact of fatigue on school and/or work, interacting with friends, and
overall interference with activities that are enjoyable. The affective fatigue subscale
includes five questions and assessed the emotional meaning attributed to fatigue. The
sensory fatigue subscale includes five questions and assessed the mental, physical, and
emotional symptoms of fatigue. The cognitive and/or mood fatigue subscale includes six
questions and assessed the impact of fatigue on concentration, memory, and the ability to
think clearly. The average score on the 22 total questions from the subscales provides the
total fatigue score. The range of possible scores on the subscales as well as total fatigue
ranges from “0” to “10”. A score of a “0” indicates that the cancer survivor has no
fatigue; scores ranging from “1” to “3” are indicative of mild fatigue; scores “4” to “6”
suggest moderate fatigue; and scores of “7” or greater indicate severe fatigue.
Fitness Assessment
In order to appropriately prescribe an individualized exercise intervention, an
initial assessment of cardiorespiratory endurance, muscular strength, flexibility, and
balance was performed. An incremental treadmill test to volitional fatigue was used to
assess initial cardiorespiratory fitness. A battery of seven muscular strength
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measurements (predicted one-repetition maximum [1-RM]) was utilized to allow for
appropriate prescription of resistance exercise, and included lat pull-down, shoulder
press, chest press, seated row, leg press, leg extension, and leg curl exercises, using
Cybex® gym equipment (Cybex International, Medford MA). Flexibility was assessed
with a modified sit and reach test and the back scratch test, while the Bertec Balance
Check™ Screener and Trainer Package (Bertec Corporation, Columbus OH) was used to
assess postural stability and limits of stability. The RMCRI treadmill protocol, an
internally validated graded exercise test to volitional fatigue, determined maximal aerobic
capacity.
Exercise Intervention
Each exercise participant completed a 10-week exercise intervention that was
individually supervised by a cancer exercise specialist 3 days per week. Each 1-hour
session was in accordance with the subject’s prescribed training modes, intensity, and
volume, based upon their goals and assessment results. Exercise sessions varied
depending on the subject’s health and fitness status, but typically included a 5-minute
warm-up, 20 minutes of aerobic exercise, 25 minutes of resistance training, and 10
minutes of flexibility and balance training. Blood pressure and HR were measured at the
beginning and end of the exercise session, and HR, RPE, and SaO2 were monitored
throughout. Aerobic exercise intensity was based on the survivors’ initial VO2peak, and
was generally low to moderate intensity, generally ranging from 30% to 60% of heart rate
reserve (HRR). The Karvonen or percent heart rate reserve method was used to determine
exercise heart rate intensity using the formula
[(220-age) − resting HR] × percent of exercise intensity + resting HR.
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Subjects with poor overall health status health or low fitness were initially prescribed an
intensity level of 30%-45% HRR or a RPE of 1-3, whereas subjects with a moderate
health status or average fitness began their aerobic exercises at 50%-60% of HRR or an
RPE of 4-5. The mode of aerobic exercise selected for each subject was based on the
mode offering the greatest anticipated benefit. Options included outdoor or treadmill
walking, stationary cycling, or recumbent stepping. Although rate of progression varied
significantly by subject, cancer exercise specialists aimed to increase increases speed or
resistance weekly, while keeping RPE values below 5 and HR values below 75% HRR.
At the beginning of the intervention, initial percent of 1-RM corresponded with
the percent of HRR values for aerobic exercise, based upon initial health and fitness
status (30%-45% 1-RM for low fitness, 50%-60% for average fitness). Cybex Eagle
Selectorized Strength Machines© (Cybex International Inc, Medway, MA, USA), free
weights, resistance bands and body weight exercises were all used for the exercise
intervention, depending upon fitness, mobility, and comfort of the cancer patient.
Muscular endurance was emphasized over hypertrophic training, as subjects performed 815 repetitions per set and typically ended each set at muscular fatigue rather than muscle
failure. Resistance was increased when 8-15 repetitions no longer resulted in muscular
fatigue.
All cancer patients were asked to avoid any substantial changes in their diet,
assuming a physician or nutritionist did not prescribe a change in eating habits. Subjects
in the standard care control group were asked to maintain their exercise habits during the
10-week study period. Although standard care cannot be “standardized” between
hospitals and patients, it did not involve routine, systematic exercises (van Waart et al.,
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2010). Neither yoga nor stretching programs were utilized for the control group because
both interventions have the potential to alter markers of oxidative stress and antioxidant
capacity (Chambers et al., 2009; S. Singh et al., 2001). Control subjects were asked to
complete an exit survey inquiring about any changes in physical activity, dietary habits,
medications, and medical procedures. Following the 10-week study period, control
subjects had the opportunity to exercise at RMCRI for three months at no cost.
Blood Handling and Analysis
A minimum of 4mL of blood was withdrawn into sterile tubes containing
potassium-EDTA and immediately put on ice. Samples were centrifuged at 3,000 rpm
for 10 minutes, and the plasma was separated and stored in multiple aliquots at -80°C
until analysis. All assays were performed in duplicate or triplicate on the first thaw.
Oxidative DNA damage was determined by plasma 8-OHdG ,which was measured using
an enzyme-linked immunosorbent assay (ELISA) according to the procedures
recommended by the manufacturer (Cell Biolabs, Inc., San Diego, CA). This value is
associated with the risk of cancer development and recurrence (Yamamoto et al., 1996).
Antioxidant capacity was measured in plasma using the Trolox-equivalent antioxidant
capacity (TEAC) assay using procedures outlined by the reagent provider (Sigma
Chemical, St. Louis, MO).
Statistical Analyses
Data are presented as means  SD.

Subjects’ baseline characteristics in the two

cancer groups (EX versus CON) and the NC group were compared using independent ttests. A repeated measures 2 (group) × 2 (pre- and post-intervention) analysis of
variance (ANOVA) with Bonferroni post hoc was used to determine differences within
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(across time) and between the two groups related to markers of DNA oxidation,
antioxidant capacity, and fatigue. A Kolmogorov-Smirnov was used to ensure that the
normality assumption was met for this data set. Spearman correlation coefficients were
calculated to determine associations between baseline markers of oxidative stress and
baseline fatigue. Additionally, Spearman correlation coefficients were calculated to
determine associations between post-intervention changes in markers of oxidative stress
and post-intervention changes in fatigue. A significance level of α = 0.05 was used for
all statistical analyses.
Results
Baseline subject characteristics for the EX, CON, and NC groups are summarized
in Table 9. The two cancer groups had statistically similar height, weight, body mass
index, and time out of treatment, and no significant differences in age were found
between the three groups. Although exit surveys in control subjects indicated no notable
changes in dietary habits, qualitative physical activity in this group increased from
baseline as, even in the absence of an exercise intervention, time out of treatment resulted
in greater vigor for activities of daily living and leisure time activity. Increases in
housework, light yard work, and walking were most commonly reported, but no control
subjects reported participation in a structured exercise program.
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Table 9
Subject Characteristics
Exercise

Control

Non-Cancer

N

8

7

7

Age (years)

64.0 ± 10.8

62.4 ± 9.7

55.1 ± 9.7

Females

7

4

5

Males

1

3

2

Height (in)

65.4 ± 2.5

66.8 ± 4.7

-

Weight (lbs)

174.0 ± 32.3

179.5 ± 40.8

-

BMI

28.4 ± 4.3

28.1 ± 3.8

-

Primary treatment (# of subjects)
Radiation

4

4

-

Chemo

3

4

-

Days out of Treatment

29.9 ± 18.6

31.4 ± 21.7

-

Exercise adherence rate (%)

83.9 ± 12.8

-

-

Baseline fatigue parameters, including total fatigue as well as all four
subcategories of the Piper Fatigue Scale, were significantly elevated in the cancer
population compared to the age-matched, non-cancer population (Table 10). Mean total
fatigue values were greater than 4 out of 10 in both cancer groups, resulting in a
“moderate fatigue” classification. In the EX group, 3 subjects reported mild fatigue, 4
subjects reported moderate fatigue, and 1 subject was severely fatigued. The CON group
displayed similar baseline fatigue distribution, as 2 subjects were mildly fatigued, 4
subjects moderately fatigued, and 1 subject severely fatigued. The NC group had a total
fatigue score of 1.0, which corresponds with the cutoff for “no fatigue” and “mild
fatigue.” Four subjects were classified as having “no fatigue” and 3 were classified with
“mild fatigue.”
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Table 10
Baseline Fatigue Scores
Total
4.8 ± 2.3 a

Cancer (N = 15)
NC (N=7)
a

Behavioral
4.4 ± 3.1 a

1.0 ± 1.0

0.9 ± 1.3

Affective
5.5 ± 2.4 a
0.7 ± 0.8

Sensory
5.5 ± 2.3 a
1.4 ± 1.3

Cognitive
4.8 ± 2.1 a
1.2 ± 1.2

Significantly greater than NC

Following the 10 week study period, total fatigue and all four fatigue
subcategories were significantly reduced in EX, while only cognitive fatigue significantly
diminished in CON. Fatigue parameter means at all time points are displayed in Figures
7-11, and changes over time are tabulated in Table 11. No group by time interaction
effects were found between EX and CON for any fatigue parameter. Mean total fatigue
in the EX group fell from 5.0 ± 2.3 to 2.6 ± 1.9 (p < 0.01), indicating a change in group
mean classification from “moderate fatigue” to “mild fatigue.” The only subject in this
group failing to downgrade classification status was the individual with mild fatigue at
baseline, and therefore little room for improvement. Mean total fatigue in the CON
group dropped from 4.6 ± 2.4 at baseline to 3.2 ± 2.4 at follow-up, but this represented
neither a statistically significant change, nor a change in group mean classification.
Additional post-hoc analysis revealed that behavioral and affective fatigue in the exercise
group no longer statistically differed from the NC group (p > 0.05) following the 10week exercise intervention.
Table 11
Changes in Fatigue Scores
Total

Behavioral

Affective

Sensory

Cognitive

EX (N=8)

-2.4 ± 0.9 a

-2.6 ± 2.4 b

-3.4 ± 1.9 a

-2.5 ± 1.2 a

-1.8 ± 1.1 a

CON (N=7)

-1.5 ± 2.1

-1.2 ± 2.1

-1.6 ± 2.9

-1.5 ± 2.2

-2.2 ± 1.7 a

a
b

Significant change over time (p < 0.01)
Significant change over time (p < 0.05)
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6

Total Fatigue Score

5
4

*

3
2

#

1
0
EX Pre

EX Post

CON Pre

CON Post

NC

Figure 7. Total fatigue scores for all groups and time points.
*= significantly different than EX Pre (p < 0.01). # = Significantly different than EX Pre,
CON Pre (p < 0.01), EX Post and CON Post (p < 0.05).
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Figure 8. Behavioral fatigue scores for all groups and time points.
*= significantly different than EX Pre (p < 0.05). # = Significantly different than EX Pre,
CON Pre (p < 0.01), and CON Post (p < 0.05).
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Figure 9. Affective fatigue scores for all groups and time points.
*= significantly different than EX Pre (p < 0.01). # = Significantly different than EX Pre,
CON Pre, and CON Post (p < 0.01).
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Figure 10. Sensory fatigue scores for all groups and time points.
*= significantly different than EX Pre (p < 0.01). # = Significantly different than EX Pre,
CON Pre (p < 0.01), EX Post and CON Post (p < 0.05).
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Cognitive Fatigue Score
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Figure 11. Cognitive fatigue scores for all groups and time points.
* = significantly different than EX Pre (p < 0.01). † = significantly different than CON
Pre (p < 0.01). # = significantly different than EX Pre, CON Pre (p < 0.01), EX Post and
CON Post (p < 0.05).
Baseline markers of oxidative stress in cancer and NC patients are found in Table
12. Plasma antioxidant status, as determined by TEAC, did not differ between EX and
CON, but was significantly greater in NC than in the cancer patients (p < 0.01). Plasma
8-OHdG, a marker of DNA oxidation, did not differ between any of the groups at
baseline. (p > 0.05).
Table 12
Baseline Oxidative Stress Parameters
TEAC (mM Trolox)
Cancer (N = 15)

0.27 ± 0.06

NC (N=7)

0.37 ± 0.07

a

a

8-OHdG (ng/mL)
0.42 ± 0.26
0.33 ± 0.18

Significantly lower than NC (p < 0.01)

Changes in antioxidant capacity and DNA oxidation for EX and CON are
presented in Table 13. TEAC increased significantly in EX, from 0.28 ± 0.07 mM to
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0.39 ± 0.05 mM Trolox equivalence (p < 0.01), while in CON, TEAC increased from
0.26 ± 0.05 to 0.32 ± 0.08 mM, but this did not represent a significant improvement (p >
0.05). Following the 10-week study period, antioxidant capacity in NC no longer
differed significantly from either cancer group (p > 0.05). DNA oxidation did not change
significantly over time in either group, but there was a significant interaction effect
between EX and CON (p < 0.05). EX decreased plasma 8-OHdG concentration from
0.47 ± 0.33 to 0.29 ± 0.18 ng/mL, whereas CON increased from 0.35 ± 0.14 to 0.49 ±
0.22 ng/mL.
Table 13
Changes in Oxidative Stress Parameters
TEAC (mM Trolox)

8-OHdG (ng/mL)

EX (N=8)

+ 0.11 ± 0.09 a

- 0.18 ± 0.26 b

CON (N=7)

+ 0.06 ± 0.09

+ 0.13 ± 0.19

a
b

Significant increase from baseline (p < 0.01)
Significant group by time interaction effect, compared to CON (p < 0.05)

0.45

*

#

Trolox Equivalent
Antioxidant Capacity
(mM)

0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
EX Pre

EX Post

CON Pre

CON Post

NC

Figure 12. Trolox Equivalent Antioxidant Capacity for all groups and time points.
*= significantly different than EX Pre (p < 0.01). # = significantly different than EX Pre
(p < 0.05) and CON Pre (p < 0.01).
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8-OHdG concentration
(ng/mL)
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0.1
0.0
EX Pre
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CON Post
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Figure 13. 8-OHdG plasma concentration for all groups and time points.
† = significant group by time interaction effect, compared to CON (p < 0.05).
Spearman correlation analysis revealed negative correlations between baseline
antioxidant capacity and total (r = -0.41, p < 0.05), affective (r = -0.39, p < 0.05), sensory
(r = -0.40, p < 0.05), and cognitive fatigue (r = -0.57, p < 0.01). No correlations between
baseline 8-OHdG and fatigue were detected. Significant negative relationships (p < 0.05)
between changes in TEAC and changes in affective (r = -0.49), sensory (r = -0.47), and
cognitive fatigue (r = -0.58) were revealed. Similarly, changes in 8-OHdG and changes
in total (r = 0.46) and affective fatigue (r = 0.47) exhibited significant correlations (p <
0.05). There was no significant relationship between changes in TEAC and 8-OHdG.
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Table 14
Correlations Between Oxidative Stress and Fatigue Parameters at Baseline
Correlation
TEAC

Behavioral

Affective

Sensory

Cognitive

-0.41

-0.33

-0.39

-0.4

-0.57

Significance

0.029

Correlation

0.28

a

0.0659

0.036

0.30

0.27

a

0.033

a

0.003 a

0.26

0.19

Significance
0.105
0.088
0.109
0.118
Significant correlation between blood parameter and fatigue score (p < 0.05)

0.199

8-OHdG
a

Total Fatigue

Table 15
Correlations Between Changes in Oxidative Stress and Fatigue Parameters
Correlation
TEAC

Behavioral

Affective

Sensory

Cognitive

-0.37

-0.097

-0.49

-0.47

-0.58

Significance

0.0887

0.3661

0.0321

Correlation

0.49

0.62

0.34

a

0.039

a

0.0124 a

0.26

-0.01

Significance
0.033
0.007
0.106
0.174
Significant correlation between blood parameter and fatigue score (p < 0.05)

0.485

8-OHdG
a

Total Fatigue

a

a

Adverse Events and Exercise Adherence
Several of the EX patients exhibited chronic musculoskeletal limitations at
baseline, including osteoarthritis, rheumatoid arthritis, and complications associated with
previous surgery (including knee surgery, hip replacement, double mastectomy, wrist
surgery, lumbar fusion, and Whipple procedure for pancreatic cancer). Because of the
individualized nature of the exercise intervention, modification of the exercise program
was sufficient to allow for continued exercise participation and completion of the
intervention in all EX subjects. Overall, exercise adherence was good, with subjects
attending 84% ± 13% of scheduled sessions. One patient missed three sessions during
the intervention due to hip pain associated with a previously failed hip replacement, and
another missed two sessions due to complications with a breast expander placed

121
following double mastectomy. Otherwise, scheduling conflicts and acute respiratory
infections accounted for most missed training sessions.
Conclusions
Results from this study indicate that exercise training is an effective method of
reducing fatigue in cancer patients who have completed treatment within the prior 6
weeks. It appears that time out of treatment is an important variable in that it clearly has
a restorative effect on its own, as cognitive fatigue was significantly reduced in the CON
group and there were no significant interaction effects between EX and CON for any
fatigue variable. The attenuation of only cognitive fatigue in CON may indicate that
physiological components of cancer-related fatigue are more persistent than the cognitive
impairments in patients who are not actively counteracting the cancer treatment-induced
physiological damage with physical activity. It should be noted though, that reported
increases in physical activity and activities of daily living in several CON subjects
represent control group contamination. This may partially explain the universal trend of
reduced fatigue in control subjects, and subsequently no significant group by time
interaction effects for fatigue parameters. Nonetheless, significant correlations between
antioxidant capacity and both baseline and changes in fatigue indicate that improved
antioxidant capacity may play a role in reduced fatigue, regardless of physical activity
level.
Despite a lack of significant change in 8-OHdG over time, there was a significant
group by time interaction effect between EX and CON. Matsumoto et al (2003) found
that hepatic cancer patients with higher 8-OHdG levels in noncancerous liver regions
were more likely to experience a cancer recurrence than those with lower 8-OHdG levels
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(p < 0.01). Therefore, it is possible that variable 8-OHdG response over time between
the groups may be implicated in a reduced risk for cancer recurrence following the
cessation of treatment in exercise subjects compared to standard care. Indeed, it has been
reported that higher levels of physical activity are associated with an improved diseasefree survival rate (Ibrahim & Al-Homaidh, 2011), and exercise following treatment may
reduce the chance for cancer recurrence (Courneya, 2003; Loprinzi, Cardinal, WintersStone, Smit, & Loprinzi, 2012).
While antioxidant capacity was greater in NC than cancer patients at baseline, 8OHdG did not differ between cancer and NC groups at baseline. This may be explained
by the fact that all subjects were out of treatment, and presumably free of cancer burden.
Gadjeva et al. (2008) found that plasma malondialdehyde (MDA) concentration dropped
in melanoma patients following surgery due to the reduced cancer-induced oxidative
stress. While chemotherapy subsequently increased oxidative stress compared to postsurgery levels, MDA levels were still significantly lower than pre-surgery values.
Without pre-treatment data in our study, it is difficult to draw conclusions about this
potential interaction.
There appeared to be a responder / non-responder effect in regards to 8-OHdG.
Three EX subjects reduced 8-OHdG by more than 0.3 ng/mL, while the remainder
changed less than 0.03 ng/mL. In contrast, while three CON subjects increased 0.2
ng/mL or more, the remainder changed approximately 0.1 ng/mL, with half exhibiting
decreases. Kennedy et al (2005) found that in patients with chronic fatigue syndrome,
oxidative stress, as measured by 8-iso-prostaglandin-F2α-isoprostanes, were correlated
with fatigue symptoms in normotensive, nonobese individuals, but was not in obese or

123
hypertensive individuals. This indicates that oxidative stress may significantly affect
fatigue in cancer survivors, but due to the multi-causal nature of fatigue, this relationship
may be uncoupled in certain clinical subsets of the cancer population where other
physiological factors exist, including body composition, cardiac health, and medication
status.
It is not entirely clear why there was a rise in 8-OHdG in the control group during
the study period. Although the cancer treatments investigated in this study all are known
to acutely introduce oxidative stress, the time frame of the persistence of markers of
oxidative stress is still not wholly characterized, and may be affected by an undetected
cancer burden. For instance, Erhola et al. (Erhola et al., 1997) found that the overall
response to radiation and chemotherapy (“complete or partial remission”, versus “no
change or progressive disease”) determined whether urinary 8-OHdG concentration
increased or decreased with treatment. Furthermore, Jonas et al. (Jonas et al., 2000)
found that GSH/GSSG ratio continually decreased over the two weeks following the end
of chemotherapy, indicating that treatment either directly impairs the antioxidant system,
or that chronic oxidative stress is capable of depleting the glutathione pool and diminish
reductive capacity. Regardless, these data indicate that in certain cancer populations,
oxidative stress may worsen for a period of time after the cessation of treatment, but the
effects of variable prognostic criteria and differing cancer stages, types, and treatment
regimens on the timeframe of chronic oxidative stress are unknown at this time.
As expected, baseline fatigue was greater, and antioxidant capacity lower, in
cancer patients compared to non cancer patients. Previously, sparse data existed
regarding the time course of antioxidant capacity following the cessation of treatment.
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The current study indicates that additional time out of treatment (in this case, from one
month to more than three months) helps restore antioxidant capacity, albeit
nonsignificantly. Exercise, on the other hand resulted in a more robust, and statistically
significant, increase in antioxidant capacity. Moreover, significant correlations between
increased antioxidant capacity and reduced fatigue indicate that systemic oxidative stress
may be a potential mechanism for cancer-related fatigue, much as it has been
hypothesized in chronic fatigue syndrome (Kennedy et al., 2005). Results from our data
presented here support the current physical activity guidelines for cancer survivors, which
suggest moderate physical activity as a means to reduce treatment-associated side effects
(Rock et al., 2012), an effect that may be in part due to changes in antioxidant capacity
and oxidative stress.
Limitations
Pseudo-randomization resulted in different gender characteristics between the EX
and CON groups, but as this was a repeated measures experiment and because changes in
fatigue parameters over time were not expected to be gender-dependent, this is unlikely
to represent sampling bias. NC fatigue values were unexpectedly classified as borderline
“mild fatigue,” but this may have been influenced by the timing of the fatigue
questionnaires, which were administered immediately prior to the early morning, fasted
blood draws. Due to the self-selected nature of participation in this study, it is possible
that psychological factors beyond the scope of this study may have independently
affected fatigue values at baseline or fatigue changes over time. Although no substantial
dietary alterations were explicitly reported by either the EX or CON group at follow-up,
diets were not controlled and food logs were not utilized to evaluate subjects’
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consumption of antioxidant-containing foods. It is possible that whole foods containing
variable antioxidant compositions affected plasma antioxidant capacity or oxidative stress
at either baseline or follow-up. Finally, although exercise interventions were similar,
individualization of exercise regimens for each cancer patient based upon specific needs
may have affected the biochemical and fatigue responses to exercise and could
potentially limit the generalizability of this study.

126

CHAPTER V
OXIDATIVE STRESS, MUSCULAR STRENGTH AND
CARDIOPULMONARY ALTERATIONS
FOLLOWING AN EXERCISE
INTERVENTION IN
CANCER SURVIVORS
Abstract
PURPOSE: Exercise interventions in cancer patients have been shown to reduce cancertreatment related side effects, including muscle wasting and diminished cardiorespiratory
fitness (CRF). Despite this, the underlying mechanisms associated with the protective
aspects of exercise are generally uncharacterized, but treatment-associated oxidative
stress is thought to play a role. The purpose of this study was to determine the effect of
an exercise intervention (EX) on muscular strength, CRF and blood markers of protein
oxidation compared to a non-exercising, cancer control group (CON).
METHODOLOGY: Assessments of muscular strength and CRF and an initial fasting
blood draw and were administered to fifteen cancer patients within six weeks of
completing radiation or chemotherapy treatment. Eight of the cancer patients
participated in a 10-week exercise intervention while seven continued standard care.
Following the intervention, subjects completed a reassessment of strength and CRF and
another fasted blood draw. Changes in plasma protein carbonyls and antioxidant status
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were compared between the EX and CON groups using repeated measures ANOVA.
Baseline markers of oxidative stress were compared between cancer patients and agematched individuals with no cancer history (NC). A correlation analysis of changes in
fitness parameters and oxidative stress in cancer patients was conducted. RESULTS:
Baseline total antioxidant capacity was significantly lower, and plasma protein carbonyls
significantly higher in cancer patients compared to NC (p < 0.05). An exercise
intervention significantly increased antioxidant capacity and decreased protein carbonyls,
while standard care did not (p < 0.01). Improvements in composite arm (41%) and leg
strength (34%), isometric handgrip strength (11%), and VO2peak (16%) all significantly
improved in the EX group (p < 0.05), while none of these parameters significantly
changed in CON. No significant correlations between changes antioxidant capacity or
protein oxidation and improvements in fitness parameters were revealed.
CONCLUSIONS: A whole-body exercise intervention is an effective method of
increasing muscular strength, CRF and antioxidant capacity, while reducing markers of
protein oxidation. Despite concurrent changes in oxidative stress, strength and CRF,
Spearman correlations did not suggest a direct relationship between improvements in
fitness parameters and reduction in oxidative stress.
Introduction
Between 1990 and 2010, cancer related mortality dropped from 215 to 172 deaths
per 100,000 persons, demonstrating improved efficacy of cancer treatment methods
(Howlader, 2012). Although this is an encouraging trend, the adverse side effects of
surgery, radiation, chemotherapy, and other treatment modalities are associated with
severe physiological side effects that may last for years. Typical side effects include
muscle dysfunction (Christensen et al., 2014) and reduced CRF (Burnett et al., 2013).
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While these decrements are multi-causal and multi-factorial, oxidative stress is thought to
play a pivotal role in many pathological processes associated with cancer and its
treatments (Fang et al., 2009; Robbins & Zhao, 2004; Zhao & Robbins, 2009).
Oxidative stress is a state in which reactive oxygen species (ROS) are produced at
a rate that exceeds cellular adaptive and repair capacities (Halliwell & Gutteridge, 2007).
The interrelationship between oxidative stress and cancer is complex. The development
and progression of cancer are associated with high levels of oxidative stress-induced
DNA modification (Valko et al., 2006), but cancer cells themselves can produce
increased levels of ROS, perpetuating dysfunction and cancer growth (Hileman, Liu,
Albitar, Keating, & Huang, 2004). In certain cancers, this allows for therapeutic
selectivity, and many modes of cancer treatment depend on extremely high doses of ROS
as a mechanism of cancer killing, including radiation and many chemotherapy regimens
(Kovacic, 2007). Unfortunately, treatment-associated oxidative stress typically affects
healthy tissue in addition to malignant tissue, resulting in both acute and chronic side
effects (Ascensao et al., 2005b; Laviano et al., 2007). Doxorubicin (DOX), for instance,
is a highly effective antineoplastic agent used for various cancers, yet causes a dosedependent cardiotoxicity associated with oxidative stress (Chaiswing et al., 2004;
Hayward et al., 2013; Kanter et al., 1985). More recently, DOX has been shown to elicit
a similar degree of dysfunction in skeletal, smooth, and cardiac muscle tissues (Hayward
et al., 2013). While the primary antineoplastic mechanisms of DOX are inhibition of
topoisomerase II and intercalation in DNA (Chen, Jungsuwadee, Butterfield, & St Clair,
2007), resulting in inhibition of DNA replication and RNA transcription, the induction of
ROS may contribute to antitumor activity (Taatjes et al., 1998). Other common
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chemotherapy drugs, including tamoxifen, etoposide, 5-fluorouracil, alkylating agents
and platinum coordinating complexes are known to induce significant oxidative stress,
either as an antineoplastic mechanism or as a side effect (Y. Chen et al., 2007; Conklin,
2000). Radiation, by nature, is characterized by ROS production and exerts its
physiological effects, both beneficial and harmful, via this mechanism (Ahn et al., 2006;
Azzam, Jay-Gerin, & Pain, 2012).
Muscular dysfunction in cancer patients is likely caused by numerous factors,
including physical inactivity, malnutrition, inflammatory cytokines, oxidative stress and
advanced age (Christensen et al., 2014). Numerous studies link cancer and treatmentrelated ROS production with cachexia, among other potential mechanisms (Laviano et
al., 2007; Mantovani et al., 2004). In healthy elderly women, oxidative protein damage
has been shown to be associated with poor grip strength (Howard et al., 2007). The loss
of muscle mass and cardiovascular fitness is compounded by significant decreases in
physical activity following treatment. Studies have shown that muscular endurance
declines after only two weeks of physical inactivity in healthy individuals (Haddad et al.,
2003), while mitochondrial enzyme activity decreases following 3 months of inactivity
(Coyle et al., 1984).
The selective reduction of oxidative stress in healthy tissues is a strategy which
holds promise to reduce treatment-associated side effects while maintaining treatment
efficacy. Although antioxidant supplementation may seem like a more direct method of
increasing antioxidant capacity in cancer survivors as a strategy to reduce treatment
associated side effects, this approach has been discouraged by several authors because of
the protective effect it may have on cancer cells (D'Andrea, 2005; Lawenda et al., 2008),
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although some groups disagree (Pathak et al., 2005). Post treatment, this concern is less
pronounced, but the endogenous antioxidant system is complex and coordinately
regulated, such that a supplementation of one antioxidant may result in the
downregulation of others (McCord, 2008). Exogenous administration of any one of these
alone could result in aberrant redox regulation (Kong & Lillehei, 1998), with the
possibility of promoting oncogenesis and cancer recurrence (Acharya, Das, Chandhok, &
Saha, 2010), particularly in the presence of undetected metastases. Furthermore, dietary
antioxidant interventions have not proven particularly effective in the treatment
treatment-associated side effects (Lawenda et al., 2008; Myers et al., 1983; Unverferth et
al., 1983).
An increasingly popular rehabilitation method in cancer patients is prescriptive,
whole-body exercise. Exercise has been shown to minimize many side effects of cancer
treatment, including reduced CRF (Courneya et al., 2003; Courneya et al., 2007; Dimeo
et al., 2004; Schneider et al., 2007c; Segal et al., 2009) and muscular strength (Lakoski et
al., 2012; Schmidt et al., 2013; Schneider et al., 2007a). In a 2011 meta-analysis
investigating the effect of exercise on VO2peak, pooled data of six studies (571 adult
cancer patients; 344 exercise and 227 usual care control) indicated that exercise training
significantly increased VO2 peak (+2.9 ml·kg-1·min-1), whereas usual care was associated
with a decline in VO2 peak (-1.0 ml·kg-1·min-1) (L. W. Jones, Liang, et al., 2011).
Similarly, a recent review of the impact of resistance exercise programs on muscular
strength in over 1,000 cancer patients during or following treatment revealed large effectsize improvements (Cohen’s d = 0.86) in muscular strength (Focht et al., 2013). A multicenter randomized, controlled study (n=242) demonstrated the magnitude of strength
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gain, as an isolated resistance exercise training program increased muscular strength 25%
to 35% in breast cancer patients receiving chemotherapy (Courneya et al., 2007).
Exercise may, in part, exert its rehabilitative effects by preferentially increasing
antioxidant capacity in the tissues that are stressed by exercise. For instance, in healthy
individuals, unilateral leg exercise resulted in increased antioxidant enzyme activity in
the trained leg but not the untrained leg (Parise et al., 2005). It may be surmised that
because of this localized change in antioxidant capacity, antioxidant capacity should
increase in active tissue, but not in cancer cells. This also demonstrates the importance of
total body exercise interventions in cancer survivors, as training effects and changes in
antioxidant enzyme capacity may be local.
Minimal research regarding exercise-associated changes in oxidative stress in
cancer patients has been published. The existing studies investigating this relationship in
human cancer populations are not in agreement, as both increases and decreases in
oxidative stress have been reported (Allgayer et al., 2008; L. W. Jones, Eves, et al.,
2011). In non-cancer populations, exercise training can elicit acute and chronic
augmentation of antioxidant defense and reductions in oxidative stress. Superoxide
dismutase concentrations in skeletal muscle samples were significantly elevated for
several days following a single non-damaging cycling bout, with a peak at 2 days, but
values returned to baseline levels by day 6 (Khassaf et al., 2001). In obese individuals
with no history of cancer, an exercise intervention resulted in significant increases in
VO2peak and decreases in F2-isoprostane levels (a measure of lipid peroxidation), and
these changes exhibited a negative linearly relationship (Campbell et al., 2010).
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Similarly, F2-isoprostane levels decreased 34% in premenopausal women following 15
weeks of aerobic exercise training (Schmitz et al., 2008).
Animal models provide us with more compelling evidence that exercise-induced
alterations in oxidative stress can influence CRF and muscular strength improvements
following cancer treatments. Kanter (1985) found that a swim-training protocol in rats
improved antioxidant capacity and counteracted doxorubicin-mediated cardiotoxicity.
Ascensao et al. (2005a) mirrored these results, and also found that cardiac damage,
evaluated by cardiac troponin I (cTnI) presence in the plasma, and cardiac muscle protein
carbonyls were significantly lower in exercise trained mice treated with DOX than nonexercise trained mice treated with DOX. Treadmill training in rats has been shown to
reduce cardiotoxicity concurrently with increased glutathione peroxidase expression
(Chicco, Hydock, et al., 2006) while an acute exercise bout had a cardioprotective effect
accompanied by a reduction in myocardial lipid peroxidation (Wonders et al., 2008).
More recently, Smuder et al. (2011) found that exercise training protects against
doxorubicin-associated increases in both protein carbonyls and proteolysis in skeletal
muscle tissue.
To address the lack of human research on the potential role that oxidative stress
has in the restorative effects of exercise following cancer treatment, the purpose of this
study was to investigate the effects of a 10-week exercise intervention on CRF, muscular
strength, and plasma markers of antioxidant capacity and protein oxidation.
Methodology
Fifteen cancer patients and seven healthy age-matched individuals with no history
of cancer or other chronic diseases participated in this study. This study consisted of a
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10-week prescribed exercise intervention in an exercise group (EX), while a control
group (CON) had standard care for the study period. Subjects were admitted to study
groups based upon date of initial contact (pseudo-randomization). Cancer patients had
completed oxidative stress-inducing cancer treatments, namely radiation or chemotherapy
treatment, within the previous 6 weeks, with an average time out of treatment of four
weeks.

Cancer patients were recruited from walk-in and oncologist-referred patients at

the Rocky Mountain Cancer Rehabilitation Institute (RMCRI) at the University of
Northern Colorado (UNC) in Greeley, Colorado. Additionally, oncology patient
navigators and clinical oncology research specialists at Northern Colorado Medical
Center in Greeley, Poudre Valley Hospital in Fort Collins, and McKee Hospital in
Loveland, Colorado identified qualifying individuals as they completed radiation or
chemotherapy treatments. Newspaper articles in the Greeley Tribune and UNC today,
posters at the local American Cancer Society office and outpatient oncology waiting
areas, and a recruitment page on the RMCRI webpage were used to promote this study.
Twenty six cancer patients made contact with the primary investigator, but
exclusion criteria or attrition resulted in the loss of 11 potential subjects. Refer to Figure
14 for flow of the subjects through this study. All cancer diagnoses were considered for
this study, but subjects were required to have undergone radiation or a chemotherapy
treatment explicitly known to elicit oxidative stress, either as a side effect or as an
antineoplastic mechanism. Chemotherapy agents included anti-neoplastic antibiotics,
alkylating agents, platinum coordinating complexes, epipodophyllotoxins, fluorouracil
and tamoxifen (Y. Chen et al., 2007; Conklin, 2004; Look & Musch, 1994). Cancer
patient inclusion criteria consisted of: (1) completed radiation or approved cancer therapy
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regimen within six weeks of initial blood draw, (2) currently sedentary (less than two
days/week or 20 minutes of aerobic or resistance exercise) (Brooks et al., 2005), (3) have
not consistently supplemented with dietary antioxidants, including vitamins C and E, in
the previous month, (4) non-smokers (for at least 2 months), and (5) were able to walk
comfortably on a treadmill.
Initial Pool:
26 non-smoking, sedentary cancer patients who had completed chemotherapy or radiation within
the previous 6 weeks contacted the PI directly or were identified by RMCRI, a nurse navigator, or
another member of the local oncology community.
Exclusion criteria:
1 patient too physically active
Attrition:
2 patients failed to return phone calls after initial contact
2 patients missed the scheduled initial blood draw or assessment, and never agreed to reschedule
1 patient “too busy to participate”
2 patients were unwilling to make commitment to more cancer-related appointments
1 cancelled initial assessment appointment because the drive for training was too far
1 patient diagnosed with brain metastasis after initial blood draw but prior to initial assessment
1 patient returned to chemotherapy after 4 weeks of exercise training
8 subjects participated in a 10-week exercise intervention
7 subjects were cancer control subjects, and received standard care for 10 weeks
Total sample size:
14 subjects completed the 10-week intervention, blood draw and reassessment of fitness
1 control subject completed the final blood draw, but not reassessment of fitness

Figure 14. Flow of cancer patients through the study.

Non-cancer, healthy controls were primarily recruited from among the faculty and
staff at the University of Northern Colorado via campus-wide email and by word of
mouth. Inclusion criteria for the non-cancer group included: (1) currently sedentary (less
than two days/week or 20 minutes of aerobic or resistance exercise), (2) no history of
cancer or other major chronic disease, (3) have not consistently supplemented with
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dietary antioxidants in the previous month, and (4) non-smokers. The University of
Northern Colorado Institutional Review Board (IRB) approved all procedures.
For 72 hours prior to the blood draw, subjects were asked to avoid exhaustive
exercise and antioxidant supplementation. The day before the cancer patient’s initial
exercise assessment, a 12-hour fasting blood sample was taken by the lead investigator or
an otherwise experienced phlebotomist.
Maximal Treadmill Testing
The RMCRI treadmill protocol (Table 16) was developed at the Rocky Mountain
Cancer Rehabilitation Institute as a cancer-specific protocol, more suitable for the cancer
population. Unlike the Bruce treadmill protocol, there are no abrupt increases in speed
and grade (Bruce et al., 1973). Smaller changes in effort and patient stride provide a
more manageable progression through stages and results in reduced premature peripheral
fatigue and more valid maximal treadmill tests.
Prior to each incremental treadmill test, subjects were fitted with a heart rate
monitor (Polar Inc., Lake Success, NY). Instructions regarding the specific changes in
speed and grade during each one-minute stage were given and the participant was
encouraged to walk or run until exhaustion or volitional fatigue (to VO2peak). Blood
pressure was assessed at rest, every three minutes during exercise, immediately post
exercise, and after three minutes of recovery (slow walking). Rating of perceived
exertion was assessed every three minutes of exercise, according to Borg’s 1-10 scale.
Heart rate and oxygen saturation were assessed at the end of every 1-minute stage.
Subjects were asked to use handrails only if it was required for balance support. If
handrails were required for support, subjects were asked to use them throughout the test.
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ACSM metabolic equations were utilized to quantify VO2peak at time of volitional
fatigue (Pescatello, Arena, Riebe, & Thompson, 2014).
Table 16
RMCRI Treadmill Protocol
Stage

Speed (mph)

Grade (%)

Time

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Cool-Down

1.0
1.5
2.0
2.5
2.5
3.0
3.3
3.4
3.5
3.6
3.7
3.8
3.9
4.0
4.1
4.2
4.3
1.5

0
0
0
0
2
2
3
4
5
6
7
8
9
10
11
12
13
0

1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
1 min
3 min

Muscular Strength Assessment
A true 1-repetition max (1-RM) assessment of strength can be the most accurate
and reliable method of muscular strength assessment, but may be subject to variability
due to unfamiliarity with weight lifting, lack of adequate facilities, and risk of injury,
even in healthy individuals. In the cancer population, the variability and risk for injury
are even greater. Therefore, the Brzycki equation,
1-RM = weight lifted (lb) / (1.0278 – (repetitions to failure × 0.0278))
was used to estimate 1-RM using the number of repetitions of a given submaximal load
to fatigue, provided that the repetitions do not exceed 10 (Brzycki, 1993). Muscular

137
strength was assessed using the lat pull-down, shoulder press, chest press, seated row, leg
press, leg extension, and leg curl exercises, using Cybex® gym equipment (Cybex
International, Medford MA). The goal was to choose a weight that elicited muscle failure
in 4-6 repetitions. Suggested values for the initial amount of weight lifted for each
exercise were based upon previous muscular strength data from RMCRI (Schneider et al.,
2003) but varied greatly between individual (Table 17). Repetitions were performed
without resting until muscle failure, or until the subject’s form deteriorated. If the subject
exceeded 10 repetitions for any exercise, he or she was stopped, and moved on the other
muscular strength exercises. Following all exercises, those exercises which had been
stopped were completed after increasing the weight to elicit muscle failure in less than 10
repetitions. For the purposes of data analysis, a composite score (sum of weight lifted)
was used for upper body strength (lat pull-down, shoulder press, chest press, seated row)
and lower body strength (leg press, leg extension, and leg curl.
Table 17
Suggested initial resistance (% of Body Weight)
Exercise

Men

Women

Lat Pull-down
Shoulder Press
Chest Press
Seated Row
Leg Press
Leg Extension
Leg Curl

0.900
0.350
0.750
0.750
1.500
0.750
0.750

0.500
0.150
0.250
0.300
0.750
0.400
0.400

Following 1-RM testing, a Takei TKK 5101 handgrip dynamometer (Takei
Scientific Instruments, Tokyo, Japan) was utilized to evaluate maximal isometric
handgrip strength in both hands. Subjects held the dynamometer parallel to their side
with the dial facing away from their body, and three maximal isometric contractions were
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performed on each side. The average of the best trial for each hand was used for
analysis. In order to appropriately prescribe an individualized exercise intervention, an
evaluation of flexibility and balance was performed at the time of intake. Flexibility was
assessed with a modified sit and reach test and the back scratch test, while the Bertec
Balance Check™ Screener and Trainer Package (Bertec Corporation, Columbus, OH)
was used to assess postural stability and limits of stability.
Exercise Intervention
Each exercise participant completed a 10-week exercise intervention that was
individually supervised by a cancer exercise specialist 3 days per week. Each 1-hour
session was in accordance with the subject’s prescribed training modes, intensity, and
volume, based upon their goals and assessment results. Exercise sessions varied
depending on the subject’s health and fitness status, but typically included a 5-minute
warm-up, 20 minutes of aerobic exercise, 25 minutes of resistance training, and 10
minutes of flexibility and balance training. Blood pressure and HR were measured at the
beginning and end of the exercise session, and HR, RPE, and SaO2 were monitored
throughout. Aerobic exercise intensity was based on the subjects’ initial VO2peak, and
was generally low to moderate intensity, ranging from 30% to 60% of heart rate reserve
(HRR). The Karvonen (percent heart rate reserve) method was used to determine target
exercise heart rate intensity using the formula
(220-age) − resting HR] × percent of exercise intensity + resting HR.
Subjects with poor overall health status health or low fitness were initially prescribed an
intensity level of 30%-45% HRR or a RPE of 1-3, whereas subjects with a moderate
health status or average fitness began their aerobic exercises at 50%-60% of HRR or an
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RPE of 4-5. The mode of aerobic exercise selected for each subject was based on the
mode offering the greatest anticipated benefit. Options included outdoor or treadmill
walking, stationary cycling, or recumbent stepping. Although rate of progression varied
significantly by subject, cancer exercise specialists aimed to increase increases speed or
resistance weekly, while keeping RPE values below 5 and HR values below 75% HRR.
At the beginning of the intervention, initial percent of 1-RM corresponded with
the percent of HRR values for aerobic exercise, based upon initial health and fitness
status (30%-45% 1-RM for low fitness, 50%-60% for average fitness). Cybex Eagle
Selectorized Strength Machines© (Cybex International Inc, Medway, MA, USA), free
weights, resistance bands and body weight exercises were all used for the exercise
intervention, depending upon fitness, mobility, and comfort of the cancer patient.
Muscular endurance was emphasized over hypertrophic training, as subjects performed 815 repetitions per set and typically ended each set at muscular fatigue rather than muscle
failure. Resistance was increased when 8-15 repetitions no longer resulted in muscular
fatigue.
All cancer patients were asked to avoid any substantial changes in their diet,
assuming a physician or nutritionist did not prescribe a change in eating habits. Subjects
in the standard care control group were asked to maintain their exercise habits during the
10-week study period. Although standard care cannot be “standardized” between
hospitals and patients, it did not involve routine, systematic exercises (van Waart et al.,
2010). Neither yoga nor stretching programs were utilized for the control group because
both interventions have the potential to alter markers of oxidative stress and antioxidant
capacity (Chambers et al., 2009; S. Singh et al., 2001). Control subjects were asked to
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complete an exit survey inquiring about any changes in physical activity, dietary habits,
medications, and medical procedures. Following the 10-week study period, control
subjects had the opportunity to exercise at RMCRI for three months at no cost.
Blood Handling and Analysis
A minimum of 4mL of blood was withdrawn into sterile tubes containing
potassium-EDTA and immediately put on ice. Samples were centrifuged at 3,000 rpm
for 10 minutes, and the plasma was separated and stored in multiple aliquots at -80°C
until analysis. All assays were performed in duplicate on the first thaw. Reactive
carbonyl derivatives were measured as a marker of oxidative protein damage. Protein
carbonyls were measured in plasma using an enzyme-linked immunosorbent assay
(ELISA) according to the procedures recommended by the manufacturer (Cell Biolabs,
Inc., San Diego, CA). Antioxidant capacity was measured in plasma using the Troloxequivalent antioxidant capacity (TEAC) assay using procedures outlined by the reagent
provider (Sigma Chemical, St. Louis, MO).
Statistical Analyses
Data are presented as means  SD.

Subjects’ baseline characteristics in the two

cancer groups (EX versus CON) and the NC group were compared using independent ttests. A repeated measures 2 (group) × 2 (pre- and post-intervention) analysis of
variance (ANOVA) with Bonferroni post hoc was used to determine differences within
(across time) and between the two groups related to markers of protein oxidation,
antioxidant capacity, VO2peak, and muscular strength. A Kolmogorov-Smirnov was
used to ensure that the normality assumption was met for this data set. Spearman
correlation coefficients were calculated to determine associations between baseline
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markers of oxidative stress and baseline CRF and muscular strength. Additionally,
Spearman correlation coefficients were calculated to determine associations between
post-intervention changes in markers of oxidative stress and post-intervention changes
CRF and muscular strength. A significance level of α = 0.05 was used for all statistical
analyses.
Results
Baseline subject characteristics for the EX, CON, and NC groups are summarized
in Table 18. The two cancer groups had statistically similar height, weight, body mass
index, and time out of treatment, and no significant differences in age were found
between the three groups. Although exit surveys in control subjects indicated no notable
changes in dietary habits, qualitative physical activity in this group increased from
baseline as, even in the absence of an exercise intervention, time out of treatment resulted
in greater vigor for activities of daily living and leisure time activity. Increases in
housework, light yard work, and walking were most commonly reported, but no control
subjects reported participation in a structured exercise program. One male control
subject failed to complete a reassessment of fitness despite completing both blood draws.
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Table 18
Subject Characteristics
Exercise

Control

Non-Cancer

8

7

7

64.0 ± 10.8

62.4 ± 9.7

55.1 ± 9.7

7

4

5

N
Age (years)
Females
Males

1

2

2

65.4 ± 2.5

66.8 ± 4.7

-

174.0 ± 32.3

179.5 ± 40.8

-

28.4 ± 4.3

28.1 ± 3.8

-

Radiation

4

4

-

Chemo

3

4

-

Days out of Treatment

29.9 ± 18.6

31.4 ± 21.7

-

Adherence rate (%)

83.9 ± 12.8

NA

-

Height (in)
Weight (lbs)
BMI
Primary treatment

Baseline oxidative stress parameters are found in Table 19. Plasma antioxidant
status, as determined by Trolox equivalent antioxidant status (TEAC), did not differ
between EX and CON, but was significantly reduced in cancer patients compared to NC
(p < 0.01). Similarly, plasma protein carbonyls did not differ between cancer groups, but
was significantly greater in cancer patients than NC (p < 0.05). Blood markers of
oxidative protein oxidation and antioxidant capacity at all time points are illustrated in
Figures 15 and 16, respectively.
Table 19
Baseline Oxidative Stress Parameters in Cancer and Non-Cancer Groups
TEAC (mM Trolox)

Protein Carbonyls (nmol/mg)

Cancer (N = 15)

0.27 ± 0.06 a

1.24 ± 0.27 b

NC (N=7)

0.37 ± 0.07

0.89 ± 0.25

a
b

Significantly lower than NC (p < 0.01)
Significantly greater than NC (p < 0.05)
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1.50

Protein Carbonyls
(nmol/mg)

1.25

#

*

1.00
0.75
0.50
0.25
0.00
EX Pre

EX Post

CON Pre

CON Post

NC

Figure 15. Plasma protein carbonyl concentration for all groups and time points.
*= significantly different than EX Pre (p < 0.01). # = significantly different than EX Pre,
CON Pre, and CON Post (p < 0.05).

0.45

*

#

Trolox Equivalent
Antioxidant Capacity
(mM)

0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
EX Pre

EX Post

CON Pre

CON Post

NC

Figure 16. Trolox Equivalent Antioxidant Capacity for all groups and time points.
*= significantly different than EX Pre (p < 0.01). # = significantly different than EX Pre
(p < 0.05) and CON Pre, (p < 0.01).
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Changes in antioxidant capacity and protein oxidation for EX and CON are
presented in Table 20. Protein oxidation was significantly diminished at follow-up, from
1.30 ± 0.44 to 0.84 ± 0.33 nmol/mg in EX (p < 0.05), whereas no such response was
apparent in CON (1.18 ± 0.42 to 1.12 ± 0.22 nmol/mg) Although no interaction effect
was present, this trend approached significance (p = 0.068). Increases in antioxidant
capacity were significant in EX (0.28 ± 0.07 mM to 0.39 ± 0.05 mM, p < 0.01), but not in
CON (0.26 ± 0.05 to 0.32 ± 0.08 mM p > 0.05). Following the 10-week study period, EX
no longer differed significantly from NC for protein oxidation, and neither cancer group
differed in antioxidant capacity from NC (p > 0.05, Figures 15 and 16).
Table 20
Changes in Oxidative Stress Parameters in Exercise and Control groups
TEAC (mM Trolox)
a

EX (N=8)

+ 0.11 ± 0.09

CON (N=7)

+ 0.06 ± 0.09

a
b

Protein Carbonyls (nmol/mg)
- 0.46 ± 0.30 b
- 0.06 ± 0.47

Significant increase from baseline (p < 0.01)
Significant decrease from baseline (p < 0.05)

Composite values for arm and leg strength were used for statistical analysis, and
these results are found in Table 21, in addition to isometric handgrip strength and
VO2peak. Both arm and leg strength improved significantly (p < 0.01) in EX, with 41%
and 34% increases, respectively. There were essentially no changes in arm (+ 2.5%) or
leg strength (-0.3%) strength in the control group. Accordingly, a significant time by
group interaction effect was present for both arm and leg strength (p < 0.01). Handgrip
strength gains in EX (+11.2%) were less compelling, but this change was significant
nonetheless (p < 0.05). Although CON exhibited a 5.5% mean increase in handgrip
strength, this result was not statistically significant. An analysis of indivudal strength
exercises reveald significant increases in all exercises other than the leg curl in the
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EX group, but no significant changes in the CON group. Furthermore, a significant
interaction effect between CON and EX was apparent in all exercises other than leg curl
and seated row. Detailed absolute and relative strength means and standard deviations
for individual exercises are found in Table 22, while handgrip and composite arm and leg
strength measurements at all time points are illustrated in Figures 17-19.
VO2peak, as determined by a graded exercise test to volitional fatigue, increased
16% following the exercise intervention in EX, representing a significant increase over
time (p < 0.05), whereas this parameter remained constant (+3.9%) in CON (p > 0.05).
There was no significant time by group interaction between these two groups. Similarly,
treadmill time improved significantly in the EX group (+2:05) but not in the CON group
(+0:20). VO2peak values and time to exhaustion on the treadmill at all time points are
found in Figures 20 and 21, respectively.
Table 21
Muscular Strength and Cardiorespiratory Fitness Changes
Pre

Post

EX (N=8)
Arm Strength (lbs)

230.4 ± 91.4

324.4 ± 125.2 a,c

Leg Strength (lbs)

332.3 ± 130.9

445.5 ± 157.2 a,c

Handgrip Strength (lbs)

25.8 ± 4.8

28.6 ± 6.0 b

VO2peak (ml·kg-1·min-1)

20.1 ± 9.7

23.4 ± 10.9 b

8:44 ± 3:18

10:49 ± 3:15 a

Arm Strength (lbs)

273.3 ± 148.1

280.1 ± 165.7

Leg Strength (lbs)

348.1 ± 166.3

346.9 ± 164.4

25.6 ± 9.7

26.8 ± 10.0

18.1 ± 4.4

18.8 ± 6.1

8:59 ± 2:42

9:19 ± 3:31

Treadmill Time (min)
CON (N=6)

Handgrip Strength (lbs)
-1

-1

VO2peak (ml·kg ·min )
Treadmill Time (min)
a

Significantly lower than baseline (p < 0.01)
Significantly lower than baseline (p < 0.05)
c
Significant time by group interaction with control group (p < 0.01)
b
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Table 22
Changes in Individual Muscular Strength Parameters
EX (N=8)

CON (N=6)

Pre

Post

Pre

Post

75.1 ± 13.4

102.6 ± 15.5 a,c

90.4 ± 39.4

89.9 ± 40.3

53.7 ± 18.6

a,c

34.0 ± 14.7

46.6 ± 29.2

48.3 ± 33.4

77.8 ± 31.4

a,c

62.5 ± 46.8

68.6 ± 50.6

b

73.2 ± 36.5

73.6 ± 44.4

82.3 ± 36.8

82.8 ± 40.4

113.8 ± 22.0

b,c

88.9 ± 48.1

73.3 ± 61.6

242.6 ± 33.5

a,c

177.0 ± 84.9

172.5 ± 69.9

Absolute Strength (lbs)
Lat Pulldown
Shoulder Press
Chest Press

51.3 ± 24.6

Seated Row

69.9 ± 8.5

90.2 ± 8.3

Leg Curl

74.1 ± 16.7

89.2 ± 10.1

Leg Extension

81.3 ± 26.5

Leg Press

176.9 ± 39.2

Relative strength (lbs / body weight)
Lat Pulldown
Shoulder Press
Chest Press

0.44 ± 0.09

0.61 ± 0.12 a,c

0.50 ± 0.18

0.51 ± 0.21

0.21 ± 0.10

0.32 ± 0.13

a,c

0.26 ± 0.15

0.26 ± 0.16

0.47 ± 0.21

a,c

0.34 ± 0.23

0.37 ± 0.25

0.53 ± 0.11

b

0.41 ± 0.18

0.41 ± 0.23

0.30 ± 0.14

Seated Row

0.41 ± 0.08

Leg Curl

0.43 ± 0.08

0.53 ± 0.12

0.45 ± 0.15

0.46 ± 0.20

Leg Extension

0.48 ± 0.16

0.68 ± 0.18 b,c

0.49 ± 0.22

0.43 ± 0.34

a,c

0.98 ± 0.40

0.95 ± 0.28

Leg Press
1.04 ± 0.27
1.45 ± 0.43
Significantly lower than baseline (p < 0.01)
b
Significantly lower than baseline (p < 0.05)
c
Significant time by group interaction with control group (p < 0.01)
a
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*

Handgrip Strength
(lbs)

30
25
20
15
10
5
0
EX Pre

EX Post

CON Pre

CON Post

Figure 17. Handgrip strength (average, both hands) for all groups and time points.
*= significantly different than EX Pre (p < 0.05).

147

Composite Arm Strength
(lbs)

400

†

*

300

200

100

0
EX Pre

EX Post

CON Pre

CON Post

Figure 18. Composite arm strength for all groups and time points.
*= significantly different than EX Pre (p < 0.01). † = significant group by time
interaction effect, compared to EX (p < 0.01).

*

Composite Leg Strength
(lbs)

500

†

400

300

200

100

0
EX Pre

EX Post

CON Pre

CON Post

Figure 19. Composite leg strength for all groups and time points.
*= significantly different than EX Pre (p < 0.01). † = significant group by time
interaction effect compared to EX (p < 0.01).
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*

27.5
25.0

(ml·kg-1·min-1)

VO2peak

22.5
20.0
17.5
15.0
12.5
10.0
7.5
5.0
2.5
0.0
EX Pre

EX Post

CON Pre

CON Post

Treadmill Time (min)

Figure 20. VO2peak values for all groups and time points.
*= significantly different than EX Pre (p < 0.05).

*

12
11
10
9
8
7
6
5
4
3
2
1
0
EX Pre

EX Post

CON Pre

CON Post

Figure 21. Time to exhaustion during treadmill test for all groups and time points.
*= significantly different than EX Pre (p < 0.01).
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Initial VO2peak exhibited a significant negative correlation (r = -0.71) with
baseline antioxidant capacity (p < 0.01), but not with baseline protein carbonyls.
Strength parameters did not significantly correlate with either protein oxidation or
antioxidant capacity at baseline. Spearman correlation analysis showed no significant
correlations between changes in VO2peak or muscular strength and changes in protein
carbonyls or antioxidant capacity. Correlations matrices are found in Tables 23 and 24.
Table 23
Correlations Between Oxidative Stress and Fitness Parameters at Baseline
Correlation
TEAC

Carbonyls
a

VO2 peak

Arm Strength

Leg Strength

Handgrip

-0.71

-0.23

0.1

-0.005

0.206

0.361

0.492

0.046

-0.06

-0.15

a

Significance

0.001

Correlation

-0.06

Significance
0.422
0.435
0.415
Significant correlation between blood parameter and VO2peak value (p < 0.05)

0.301

Table 24
Correlations Between Changes in Oxidative Stress and Fitness Parameters

TEAC

Carbonyls

VO2 peak

Arm Strength

Leg Strength

HG

Correlation

0.42

0.26

0.073

0.44

Significance

0.070

0.189

0.403

0.059

Correlation

-0.45

-0.4

-0.35

-0.21

Significance

0.053

0.078

0.114

0.236

Adverse Events and Exercise Adherence
Several of the EX patients exhibited chronic musculoskeletal limitations at
baseline, including osteoarthritis, rheumatoid arthritis, and complications associated with
previous surgery (including knee surgery, hip replacement, double mastectomy, wrist
surgery, lumbar fusion, and Whipple procedure for pancreatic cancer). Because of the
individualized nature of the exercise intervention, modification of the exercise program
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was sufficient to allow for continued exercise participation and completion of the
intervention in all EX subjects. Overall, exercise adherence was high, with subjects
attending 84 ± 13% of scheduled sessions. One patient missed three sessions during the
intervention due to hip pain associated with a previously failed hip replacement, and
another missed two sessions due to complications with a breast expander placed
following double mastectomy. Otherwise, scheduling conflicts and acute respiratory
infections accounted for most missed training sessions.
Conclusions
The present study demonstrated that an exercise intervention in cancer patients
following treatment simultaneously increased muscular strength, CRF and antioxidant
capacity, and reduced protein oxidation, whereas time out of treatment alone did not
significantly alter these variables. Few prior studies have investigated oxidative stress
changes in response to exercise in cancer patients, and results have varied. Our results
are most consistent with Allgayer et al., (2008) who found that 2 weeks of moderate
intensity exercise was capable of reducing oxidative stress, although a high intensity
exercise protocol resulted in non-significant increases in oxidative stress. More recently,
a 14-week exercise intervention resulted in increased urinary markers of oxidative stress
in lung cancer patients, but this also was a high-intensity exercise intervention, which
included 25-minute sessions at ventilatory threshold and 60-second interval bouts at peak
workload (L. W. Jones, Eves, et al., 2011). The positive outcomes in our current study
helps support the notion that an individualized, low to moderate intensity exercise
intervention may be preferential to high intensity exercise in the rehabilitation of cancer
patients.
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Despite concurrent changes in protein oxidation, antioxidant capacity, muscular
strength, and CRF, correlations between fitness and oxidative stress parameters were
largely absent. Although baseline CRF unexpectedly exhibited a negative correlation
with antioxidant capacity (r = -0.71), this relationship trended towards positive at followup (r = 0.35). Because muscular strength and CRF are strongly influenced by age,
gender, body composition and lifetime physical activity, it is difficult to quantify cancer
treatment-associated muscle damage and fitness decrements associated with cancer based
solely on post-treatment fitness assessment. Therefore it was not surprising that
oxidative stress was not correlated with baseline strength values within a population of
cancer survivors of this size. Because the pre-treatment muscular strength was not
known, we cannot exclude the possibility that protein carbonyls contributed to muscle
wasting, as has been suggested in the literature (Barreiro et al., 2005; Mantovani et al.,
2004; Moylan & Reid, 2007). Future studies may investigate decrements in muscular
strength and CRF prior to and following cancer treatment and compare these changes to
degree of oxidative damage.
Although it was anticipated that changes in oxidative stress and antioxidant
capacity would correlate with changes in fitness parameters, no significant Spearman
correlations were detected, but changes in VO2peak exhibited a strong trend towards
correlation with changes in antioxidant capacity (r = 0.42, p = 0.07) and protein carbonyls
(r = 0.45, p = 0.053). Due to musculoskeletal limitations in many of the patients,
including arthritis and history or surgery, muscular strength may have been strongly
limited by pain or limited range of motion, ultimately uncoupling a potential linear
relationship between protein oxidation and decrements in strength.
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Currently there is no good characterization of the time-course of chronic oxidative
stress status following the end of cancer chemotherapy or radiation. In mice,
extracellular malondialdehyde levels remained elevated one week after chemotherapy,
and oxidized glutathione was significantly higher than controls 6 weeks after treatment
(Abushamaa et al., 2002). Unfortunately, it is difficult to extrapolate these data to
humans due to varying lifespans. Our data presented here suggest that cancer patients
approximately one month out of treatment have persistent elevations in protein oxidation,
and furthermore, CON continued to exhibit elevated plasma protein carbonyls 10 weeks
later. It should be noted that, although the change in antioxidant capacity over was not
significant in CON, this variable no longer significantly differed from NC at follow-up,
suggesting some degree of redox normalization as time out of treatment progressed.
The 3.3 ml·kg-1·min-1 improvement in VO2peak in the exercise group compared
favorably with the 2.9 ml·kg-1·min-1 increase identified in a meta-analysis of 6
randomized controlled trials encompassing 344 cancer patients following various
exercise interventions (L. W. Jones, Liang, et al., 2011). Despite significant
improvements, CRF was poor in EX following the exercise intervention. Regardless, this
approximately 1-MET (3.5 ml·kg-1·min-1) mean improvement is clinically relevant.
Gulati et al. (2003) found that in apparently healthy individuals, for every 1-MET
increase in aerobic capacity, there was an associated reduction in mortality rate of 12% in
men and 17% in women. While such a relationship has yet to be elucidated in cancer
populations, a clinical lower limit of 15.4 ml·kg-1·min-1 has been proposed for full
independent living of cancer patients (L. W. Jones et al., 2012). In the same study,
patients with an absolute VO2peak greater than1.09 L·min-1 had an adjusted hazard ratio
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for death of 0.32 compared to patients with aerobic capacity values below 1.09 L·min-1.
Two EX subjects in the current study were below this threshold at baseline, but both
surpassed it during the course of the intervention, representing a meaningful clinical
outcome.
One control subject demonstrated an impressive 30% increase in VO2peak,
representing an outlier in this group. When excluding this subject, VO2peak in the
control group actually decreased by 2.3%. Despite increased time out of treatment and
improved familiarity with the treadmill protocol, CRF in 3 control subjects was
diminished at follow-up, which may have be associated with prolonged sedentary activity
or persistent oxidative stress, resulting in continued skeletal and cardiac muscle tissue
degradation (Powers, Smuder, & Criswell, 2011; Smuder et al., 2011b). Nishayama et al.
(1998) demonstrated that oxidative stress may be associated with exercise intolerance in
clinical populations, as a significant negative correlation between exercise-induced
malondialdehyde production and VO2peak was present in cardiac patients, whereas no
such relationship existed in healthy individuals. Our current investigation evaluated
chronic redox status rather than acute, exercise-associated oxidative stress, but future
studies investigating oxidative stress markers immediately following an exercise bout
may further elucidate the complex dynamic between exercise and oxidative stress in
cancer patients.
Summary
Cancer patients exhibited decrements in antioxidant capacity and increased
protein oxidation compared to healthy, age-matched individuals. Fortunately, a
prescribed, whole-body exercise intervention is capable of concurrently increasing
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muscular strength, CRF, and antioxidant capacity, while reducing markers of protein
oxidation. It therefore may be surmised that oxidative stress contributes to strength and
cardiorespiratory decrements in cancer patients following cancer treatment. Similarly,
improved antioxidant capacity may play a role in exercise-mediated cancer rehabilitation.
Limitations
Pseudo-randomization resulted in different gender characteristics between the EX
and CON groups. Although baseline strength variables were substantially greater in
males than females for this study, because this was a repeated measures experiment,
changes in muscular strength over time were not expected to be gender-dependent, and
this is unlikely to represent sampling bias. Because there were a variety of cancer types
and treatments among the subjects in this study, it is possible that undetected prolonged
physiological effects of treatment and cancer type may play a role in patient response to
exercise or time out of treatment. Although no substantial dietary alterations were
explicitly reported by either the EX or CON group at follow-up, diets were not controlled
and food logs were not utilized to evaluate subjects’ consumption of antioxidantcontaining foods. It is possible that whole foods containing variable antioxidant
compositions affected plasma antioxidant capacity or oxidative stress at either baseline or
follow-up. Finally, although exercise interventions were similar, individualization of
exercise regimens for each cancer patient based upon specific needs may have affected
the biochemical and fitness responses to exercise and could potentially limit the
generalizability of this study.
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PIPER FATIGUE SCALE
Directions: Many individuals can experience a sense of unusual or excessive tiredness whenever
they become ill, receive treatment, or recover from their illness/treatment. This unusual sense of
tiredness is not usually relieved by either a good night’s sleep or by rest. Some call this symptom
“fatigue” to distinguish it from the usual sense of tiredness.
For each of the following questions, please fill in the space provided for that response that best
describes the fatigue you are experiencing now or for today. Please make every effort to answer
each question to the best of your ability. If you are not experiencing fatigue now or for today, fill
in the circle indicating “0” for your response. Thank you very much!
1. How long have you been feeling fatigue? (Check one response only).
_ 1. not feeling fatigue
_ 2. minutes
_ 3. hours
_ 4. days
_ 5. weeks
_ 6. months
_ 7. other (Please describe) _______________________________________________
2. To what degree is the fatigue you are feeling now causing you distress?
No Distress
A Great Deal
1
2
3
4
5
6
7
8
9
10
3. To what degree is the fatigue you are feeling now interfering with your ability to complete your
work or school activities?
None
A Great Deal
1
2
3
4
5
6
7
8
9
10
4. To what degree is the fatigue you are feeling now interfering with your ability to socialize with
your friends?
None
A Great Deal
1
2
3
4
5
6
7
8
9
10
5. To what degree is the fatigue you are feeling now interfering with your ability to engage in
sexual activity?
None
A Great Deal
1
2
3
4
5
6
7
8
9
10
6. Overall, how much is the fatigue which you are now experiencing interfering with your ability
to engage in the kind of activities you enjoy doing?
None
A Great Deal
1
2
3
4
5
6
7
8
9
10
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7. How would you describe the degree of intensity or severity of the fatigue which you are
experiencing now?
Mild
Severe
1
2
3
4
5
6
7
8
9
10
8. To what degree would you describe the fatigue which you are experiencing now as being?
Pleasant
Unpleasant
1
2
3
4
5
6
7
8
9
10
9. To what degree would you describe the fatigue which you are experiencing now as being?
Agreeable
Disagreeable
1
2
3
4
5
6
7
8
9
10
10. To what degree would you describe the fatigue which you are experiencing now as being?
Protective
Destructive
1
2
3
4
5
6
7
8
9
10
11. To what degree would you describe the fatigue which you are experiencing now as being?
Positive
Negative
1
2
3
4
5
6
7
8
9
10
12. To what degree would you describe the fatigue which you are experiencing now as being:
Normal
Abnormal
1
2
3
4
5
6
7
8
9
10
13. To what degree are you now feeling:
Strong
1
2
3
4
5
6

7

8

9

14. To what degree are you now feeling:
Awake
1
2
3
4
5
6

7

8

Sleepy
9
10

7

8

9

Listless
10

7

8

9

Tired
10

17. To what degree are you now feeling:
Energetic
1
2
3
4
5
6

7

8

9

Unenergetic
10

18. To what degree are you now feeling:
Patient
1
2
3
4
5
6

7

8

Impatient
9
10

19. To what degree are you now feeling:
Relaxed
1
2
3
4
5
6

7

8

9

15. To what degree are you now feeling:
Lively
1
2
3
4
5
6
16. To what degree are you now feeling:
Refreshed
1
2
3
4
5
6

Weak
10

A Great Deal
10
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20. To what degree are you now feeling:
Exhilarated
1
2
3
4
5
6

7

8

9

Depressed
10

21. To what degree are you now feeling:
Able to Concentrate
1
2
3
4
5
6

7

8

9

Unable to Concentrate
10

22. To what degree are you now feeling:
Able to Remember
1
2
3
4
5
6

7

8

9

Unable to Remember
10

23. To what degree are you now feeling:
Able to Think Clearly
1
2
3
4
5
6

7

8

Unable to Think Clearly
9
10

24. Overall, what do you believe is most directly contributing to or causing your fatigue?
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
25. Overall, the best thing you have found to relieve your fatigue is: _____________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
26. Is there anything else you would like to add that would describe your fatigue better to us?
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
27. Are you experiencing any other symptoms right now? _____________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
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Informed Consent for Participation in Research
Project Title:
Oxidative Stress Alterations Following and Exercise
Intervention in Cancer Survivors
Rocky Mountain Cancer Rehabilitation Institute
Chris Repka, M.S., Research Associate
Phone Number: (908) 419-2767
crepka@skidmore.edu
Carole M. Schneider, Ph.D., Clinical Director
Phone Number: (970) 351-2676

You are being asked to participate in a research study collecting information to
assess the effect of an exercise program on oxidative stress following radiation and
chemotherapy. The Rocky Mountain Cancer Rehabilitation Institute (RMCRI) supports
the practice of protection of human subjects participating in research. The following
information is provided for you to decide whether you choose to participate in the present
study. You should be aware that even if you agree to participate, you are free to
withdraw at any time without affecting your opportunities in other projects offered by the
Institute.
This project involves the assessment of markers of oxidative stress, or free radical
damage, which may have been induced by cancer chemotherapy and radiation therapy.
Oxidative stress is known to play a role in the onset of numerous cancer treatment side
effects, including fatigue, neurological and psychological detriments, and damage to
cardiac and skeletal muscle. Blood samples will be obtained 2 times throughout the
study at RMCRI and will be analyzed for these markers of oxidative stress. The blood
samples will be obtained prior to initial assessment, and prior to reassessment, after 10
weeks of prescribed exercise.
In addition to blood draws, all subjects will be given the typical RMCRI fitness
assessment. Measurement of cardiorespiratory capacity will be conducted on a motordriven treadmill and will require you to run/walk at progressively increasing speed and
grade until exhaustion. A pulmonary function test requires maximum exhalation into a
sterile mouthpiece. Flexibility will be evaluated with a sit and reach test. A muscular
strength assessment includes 2-10 repetitions of leg press, leg extension, leg curl, seated
row, bench press, lat pulldown, and shoulder press. Heart rate, blood pressure, height,
weight, and circumference measurements are also recorded. Forms to be completed
include cancer history, medical history, cardiovascular risk profile, lifestyle/activity
questionnaire, and fatigue and depression scales. Assessments will take place at the
RMCRI and take approximately 2 hours to complete. Following the assessment of your
cardiovascular endurance and pulmonary function, the results will be analyzed, and an
exercise prescription written, by a cancer exercise specialist. During the course of the 10week exercise intervention, a cancer exercise specialist will be your trainer and will write
your daily, individualized exercise plan, which consists of 3, one-hour workouts per week
at low to moderate intensity.
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There is a possibility that you may be randomly selected for a control group. If
this is the case, following the 10 week period of the intervention, you will have the
opportunity to participate in the standard exercise intervention for the following 3 months
at no cost.
This study will run under the supervision of the RMCRI director and lead
investigator, but other persons will be associated with or assist in the data collection. The
obtained data may be used in reports or publications but your identity will not be
associated with such reports. A number will be used as your identification and your
medical and exercise information kept in a locked file cabinet available only to the lead
investigator. Confidentiality will only be broken if our assessment reveals that you are
severely depressed or if you indicate you are a threat to yourself or to others, at which
time you will be referred through our ancillary services for psychological counseling.
A great benefit for participating in this study is exercise training with trained
cancer exercise specialists. Additionally, each participant will be provided a summary of
his or her exercise data at the beginning and the end of the project period with a clear and
concise exercise intensity recommendation based upon the exercise assessment results.
There is no compensation for participating in this study.
Risks to you are minimal and may include the possibility of shortness of breath,
mild muscular fatigue and soreness, and moderately uncomfortable test situations (such
as during the pulmonary function test and the sit & reach test). Additionally, the
VO2peak fitness test used to assess your cardiorespiratory capacity can be uncomfortable.
The duration of the discomfort is short. Before all testing, an explanation of the
procedure will be given. Overall, the risks inherent in this study are no greater than
during a regular physical exercise session a participant may conduct on his or her own
time. All subjects will be cleared through the RMCRI Medical Director before the
physiological testing commences. When collecting blood samples for research, there is
no more risk than that which is encountered when one has blood drawn at a hospital or
clinic. Proper containment and disposal of blood will be implemented. If you are injured
as a result of this study, you will treated in the usual manner and charges billed to your
insurance/self. The study will not pay for health care costs.
Participation is voluntary. You may decide not to participate in this study and if
you begin participation you may still decide to stop and withdraw at any time. Your
decision will be respected and will not result in loss of benefits to which you are
otherwise entitled, including continued exercise training at RMCRI. Having read the
above and having had an opportunity to ask any questions, please sign below if you
would like to participate in this research. A copy of this form will be given to you to
retain for future reference. If you have any concerns about your selection or treatment as
a research participant, please contact the Office of Sponsored Programs, Kepner Hall,
University of Northern Colorado Greeley, CO 80639; 970-351-2161.
________________________________

___________________________________

Participant Name

Signature of Researcher

DATE

________________________________
Signature of Subject Agreeing to Participate.
By signing this consent you certify you are at
least 18 years of age.

DATE

__________________________________________
Signature of Medical Director
DATE
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Thursday, February 18, 2010 12:23 PM

Chris:
Thanks for your revised consent document and answers to my questions regarding your IRB
application. You now have UNC IRB approval. At the end of your consent document, please
make one minor change: the phone number for Sponsored Programs is 351-2161. I do not need
to see that change.
I wish you the best with your work.
Sincerely,
Gary Heise
Co-chair, IRB

Gary D. Heise, Ph.D.
School of Sport and Exercise Science
University of Northern Colorado
2760 Gunter Hall
Greeley, CO 80639
voice: 970-351-1738 fax: 970-351-1762

Thursday, January 14, 2010 9:40 AM

Chris;
I completed my review of your IRB application and have some comments that I would like you to
address. Comments on the informed consent document may be better addressed during a short
meeting. I will be at RMCRI later today (Thursday), but could also meet tomorrow (Friday).
Essentially, the consent document needs some details added (e.g., VO2peak procedures - as it is
written, the reader does not know that he/she will be wearing a mouthpiece, nose-clip and
walking until he/she can no longer continue). The discussion of risks and benefits need to be reworded - your narrative reads more clearly. I have a few other comments, but again can be
quickly addressed with a meeting.
The control group assignment worries me. People will be coming to RMCRI because they want to
exercise, so telling them that they are in a control group and cannot exercise is an issue that must
be addressed (delicately). In contrast to your comment to Dr. Weiler, I have heard some granting
agencies that do not allow non-exercising control groups for certain studies because it would be
unethical to withhold a treatment that is known to do good (can this be said for cancer patients?).
One other comment - "already approved by UNC IRB" should read "previously approved by UNC
IRB" IRB approval are for specific protocols. Dr. Schneider and I talked about a more "blanket"
IRB approval for RMCRI, but such approval is not currently in place.
Please let me know when you are available.
Thanks,
Dr. Heise
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Subject Update Questions
1. Did you have any problems as a result of your last training session?
(soreness, pain, etc.)
Yes No
If yes, identify the specific problem on the Client Update
Response Sheet
2. Are you having any specific problems today that would affect training?
(feeling ill, headache, pain, nausea, dizziness, extreme fatigue, etc.)
Yes No
If yes, identify the specific problem on the Client Update
Response Sheet
3. Are you taking any new medications? Has a medication been discontinued or the
prescribed amount changed? Has your health status changed?
Yes No
If yes, identify the change on the Client Update Response
Sheet and notify the Clinical Coordinator.
4. Since your last exercise session, have you been diagnosed with cancer recurrence?
Yes No
If yes, write an explanation and notify the Clinical Coordinator.
5. Since your last exercise session, have you begun chemotherapy treatment?
Yes No
If yes, immediately report the date and specific chemotherapy
drugs to the Clinical Coordinator.
6. Since your last exercise session, have you completed your chemotherapy
treatment?
Yes No
If yes, immediately report the date completed to the Clinical
Coordinator.
7. Since your last exercise session, have you begun your radiation treatment?
Yes No
If yes, immediately report the date of initiation and type of
radiation to the Clinical Coordinator.
8. Since your last exercise session, have you completed your radiation treatment?
Yes No
If yes, immediately report the date completed to the Clinical
Coordinator.
9. Since your last exercise session, did you perform any additional exercise?
Yes No
If yes, describe the type, duration, and intensity. If lengthy,
include on separate sheet in training log.
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Exit Survey for control subjects, Chris Repka’s Oxidative Stress Study
Name: _____________________

Date:________________________

1. Since your initial assessment, how many times per week did you engage in
physical activity?

2. Have you changed your dietary habits

3. Have you made any other lifestyle changes since we last met? (yoga, meditation,
support groups, changes in medication).

4. Have you had any further medical procedures?

5. How many days a week would you like to exercise at RMCRI?
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